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Abstract 
Preparations of the root bark of Gabonese plants, T. iboga and G. tessmannii have long been 
used in Central and West African traditional medicine for the treatment of diabetes. In this 
thesis phytochemical characterisation of T. iboga aqueous extract revealed the presence of 23 
unknown alkaloids and 7 already known alkaloids, including ibogaine, the main indole alkaloid 
found in T. iboga. For the first time, phenolic compounds have been identified in significant 
quantity in T. Iboga, the most prevalent being 3-O-CQA. The therapeutic potential of these 
constituents in diabetes remains to be determined. The aqueous extracts of these Gabonese 
plants for the potential to improve insulin release was examined. T. iboga (1 µg/ml) and G. 
tessmannii (70 µg/ml)  demonstrated insulinotropic effects in isolated rat pancreatic islets at 
non-stimulatory and stimulatory glucose concentrations (2.8 and 11.1 mM, for T. iboga and 
2.8 to 16.7 mM, for G. tessmannii), similar to the insulin secretagogue, tolbutamide (200 µM). 
An additive effect on glucose-induced insulin release was observed for both plant aqueous 
extracts in the presence of tolbutamide (200 µM). The mechanism of action of the 
insulinotropic effect of T. iboga (1 µg/ml) was explored through the use of a σ2 receptor 
antagonist, SM-21 (1 and 10 µM) which significantly blocked T. iboga (1 µg/ml) insulin 
potentiation at non-stimulatory and stimulatory glucose concentrations (2.8 and 11 mM) 
indicating these effects were seen to be partly through σ2 receptors. T. iboga (50, 100 and 200 
mg/kg) when administered daily over 28 days demonstrated no observable toxicity and exerted 
hypoglycaemic activity on glucose tolerance in healthy rats. Feeding a 10% fructose solution 
over 2 weeks combined with a low intraperitoneal dose of streptozotocin (STZ, 40 mg/kg) to 
rats led to the development of a T2D compared with T1D rats over 4 weeks. T. iboga at the 
lowest daily dose of 50 mg/kg significantly improved  hyperglycaemia after 3 and 4 weeks of 
treatment compared with glibenclamide. After 2 and 4 weeks daily administration of T. Iboga 
(50 and 200 mg/kg) glucose tolerance over a 2 hour fasted glucose load was improved 
compared with T2D rats treated with vehicle alone. Feeding a high fat diet (HFD) to mice for 
10 weeks produced manifestations of metabolic syndrome and T2D, as compared to mice fed 
a low-fat diet (LFD). Supplementation of HFD with T. iboga aqueous extract at ibogaine doses 
of 0.83 (low) and 2.07 (high) mg/kg/day did not improve these HFD-induced metabolic effects 
except for a reduction of plasma MCP-1 in the low dose group, indicative of an anti-
inflammatory effect. Overall, T. iboga and G. tessmannii aqueous extracts have demonstrated 
insulin potentiation, hypoglycaemic and anti-hyperglycaemic activities. However, further 
investigations are needed to validate their safe use for the management of DM in Gabon. 
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C h a p t e r  1 :  G e n e r a l  i n t r o d u c t i o n   
 
 1.1. Diabetes Mellitus and Metabolic syndrome definition 
Diabetes mellitus (DM) is a complex metabolic disorder characterised by constant elevated 
blood glucose levels (hyperglycaemia), caused by an insufficient or blunted insulin secretion 
and / or reduced tissue sensitivity to insulin. The disease has become a global issue and can 
now be considered a pandemic (Motala and Ramaiya, 2010).  
Depending on the form of the insulin insufficiency, the disease can be categorised into two 
main types. Type 1 diabetes mellitus (T1DM) is caused by a profound reduction in the 
number of functional pancreatic b-cells, destroyed in many by autoimmune mechanisms 
leading to hyperinsulinemia and hyperglycaemia; while Type 2 diabetes mellitus (T2DM) 
results in impaired insulin secretion and its subsequent action, often referred to as insulin 
resistance, leading to hyperglycaemia. T2DM is the most prevalent form with over 85 % of 
the total DM prevalence (Forouhi and Wareham, 2018). Other types such as Gestational 
Diabetes Mellitus (GDM) also exist (Motala and Ramaiya, 2010). The cause of diabetes are 
multifactorial and certain conditions including metabolic syndrome, increase diabetes 
development especially T2DM.  
Metabolic syndrome (MetS), is a group of different metabolic abnormalities which represents 
a clinical challenge, especially in developed countries. MetS has been considered as a 
concept rather than a diagnostic and is now defined by the association of physiological, 
biochemical, clinical and metabolic factors that are directly involved in the risk for 
developing atherosclerotic cardiovascular disease (ASCVD) and T2DM (Grundy et al., 2004; 
Kaur, 2014). The international Diabetes Federation (IDF) estimates that more than 25% of 
world’s adult population has MetS, although this estimate varies with age, ethnicity, and 
gender of the population studied (Nolan et al., 2017). Unfortunately, no specific data are 
available for Southern countries including Sub-Saharan Africans, eastern Mediterranean and 
Middle East population (Kaur, 2014). MetS pathophysiology is defined by a state of low 
grade inflammation as a result of complex inter-related genetic and environmental factors 
(Jeppesen et al., 2006; Kaur, 2014). Insulin resistance and/or impaired glucose tolerance, 
abdominal obesity (or visceral adiposity), atherogenic dyslipidemia, endothelial dysfunction, 
elevated blood pressure, pro-inflammatory state, and prothombotic state are components that 
constitute the syndrome. Adults having MetS are at increased risk for developing T2DM and 
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cardiovascular disease independently from other common risk factors including age, sex, 
serum cholesterol levels, and smoking (Grundy et al., 2004; Kaur, 2014). 
 
 1.2. Prevalence and incidence of diabetes  
More than 415 million people worldwide have been diagnosed with diabetes in 2015 and the 
International Diabetes Federation (IDF) has forecasted an increase up to 642 million by 2040 
(Khanam et al., 2017), mainly because of the increase in obesity. In African communities, 
more than 19 million people have diabetes and these figures are estimated to rise up to 41 
million by 2035 (Peer et al., 2014). 
Commonly, diabetes is caused by a defected pancreas which fails to produce insulin, or to 
supply enough efficient insulin to allow glucose from the blood to be used by body cells 
(Motala and Ramaiya, 2010). T1DM is an auto-immune disease and occurs when the body 
immune system recognises pancreatic b-cells that produce insulin and destroys them. The 
destruction of the b-cells leads to an absolute insulin deficiency. This type of diabetes 
accounts for 5-10% of diabetics and people diagnosed with it needs insulin therapy for 
survival. T2DM, however, is the most common type of diabetes (90-95% of diabetics) and is 
defined by insulin resistance and/ or altered insulin secretion and the rise of glucose 
production (Motala and Ramaiya, 2010; Tripathi and Srivasta, 2006). This form is largely 
responsible for the high mortality and morbidity rates caused by diabetes due to its related 
complications (Levitt, 2008; Sobngwi et al, 2002).  
 
1.3. Complications associated with diabetes 
As a metabolic disease, diabetes mellitus with the hyperglycaemia state, triggers alterations 
of the metabolism of carbohydrates, fat, proteins within the body, leading to major chronic 
complications (Adeghate et al., 2006). These complications are mostly the cause of diabetes 
high morbidity and mortality rates. Diabetes complications are subdivided into vascular and 
non-vascular complications. The vascular complications concern microvascular 
complications (small blood vessels damaged) such as nephropathy, neuropathy and 
retinopathy, and macrovascular complications (large blood vessels damaged) such as 
coronary artery disease, peripheral vascular disease and cerebrovascular disease (Laddha and 
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Kulkarni, 2019). In arteries, at early stage of the disease, intracellular hyperglycaemia 
induces alterations in blood flow and vasodilator availability such as nitric oxide (NO), 
leading to endothelial dysfunction and cellular damage (Alexandru et al., 2016). The non-
vascular complications include disorders such as gastroparesis, sexual dysfunction and skin 
troubles (Tripathi and Srivasta, 2006; Alexandru et al., 2016). These complications combined 
with high blood glucose concentrations (> 11.1 mM or > 200 mg/dl) were for many years the 
main features of diabetes diagnosis. Furthermore, diabetes complications including chronic 
kidney disease, coronary artery disease (CAD), foot and leg ulcers or eye damage 
(Trikkalinou et al., 2017), dramatically alter diabetics quality of life and contribute to the 
heavy economic burden of this disease. The association of increasing diabetes prevalence and 
the rise of diabetes complication rates is leading to a huge rise of financial and societal 
burden on healthcare systems, especially for southern countries which sanitary structures are 
not well developed (Sobngwi et al, 2002; Saleh et al., 2014). 
 Nowadays, because of the steady rise of diabetes-related complications and the economic 
and social impact of diabetes, extensive investigations have been done in order to understand 
the pathogenesis of this disease. Now, it is fairly understood that diabetes is the result of an 
impairment of insulin function, and the permanent hyperglycaemia state is a major cause of 
the related complications (Brownlee, 2005; Llorente and Malphurs, 2007).  
The causative mechanisms of diabetes complications are complex and not fully understood. 
Thus, the pathophysiology of diabetes, the hyperglycaemia role in the genesis of diabetes 
complications, insulin secretion, insulin signalling and roles are important notions to 
understand.  
In addition, elevated levels of the highly reactive glucose and fructose metabolites, 
methylglyoxal (MGO) in diabetes (plasma levels > 800 nM) increases oxidative stress 
accelerating advanced glycation end (AGE) products resulting in pancreatic cell cytotoxicity 
exacerbating hyperglycaemia, further MGO production and complications. A recent review 
of the literature demonstrates a clear correlation between MGO and the diabetes 
complications of insulin resistance, neuropathies, vascular and gastrointestinal dysfunction 
and neuropathic pain (Shamsaldeen et al., 2016). Monitoring changes in metabolic 
biomarkers, understanding the actions of MGO and other markers (e.g. adropin, oxidised 
LDL, Shamsaldeen et al., 2018) should highlight new therapeutic targets for treating diabetes 
complications. 
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 1.4. Insulin secretion (Insulin signalling and action)  
The major role of insulin is to manage glucose homeostasis by stimulating glucose uptake 
into muscle and adipocyte cells while decreasing glucose generated from the liver via 
glucogenesis and glycogenolysis (Rains and Jain, 2011). The secretion of insulin is a 
complex process occurring in pancreatic ß-cells and involving Ca2+ outflow and inflow as 
reviewed by Herchuelz and Pachera, 2018. As shown in Figure 1.1, under physiological 
conditions, rise of blood sugar levels triggers glucose rapid metabolism via glucose 
transporter GLUT-1 into pancreatic ß-cells, causing a fall in ADP/ATP ratio (which generates 
ATP) and the closure of K+-ATP dependent channels. This closure induces subsequent opening 
of the voltage-gated Ca2+ channels (T type) and the rise of intracellular Ca2+ which triggers 
the exocytosis of insulin-containing granules (Gustavsson et al., 2008; Ashcroft and 
Rorsman, 2012). Moreover, other pathways can control Ca2+ intracellular concentrations such 
as plasma membrane NA+/Ca2+ exchanger and Ca2+ channels (P Type) (Herchuelz and 
Pachera, 2018). In parallel, a Ca2+ independent pathway is also capable to induce insulin 
granules exocytosis via the protein kinase A (PKA)-dependent and Epac2-dependent 
mechanisms involving glucagon-like peptide-1 (GLP-1) (Ashcroft and Rorsman, 2012).  
 
	 29	
 
 
 
PKA Epac2 
+ 
+ 
Secretory  
 granules 
MITOCHONDRIA 
Ca
2+ Ca2+ Ca2+ 
ATP 
cAMP 
Glucose 
Glucose 
GCK 
Glucose-6-P 
ADP 
ATP 
Glut1 
GLP-1 
Insulin 
SUR1 
SUs 
K
+ K+ 
T type 
  Ca
2+ 
Na+ 
Na+ P/Q and L type 
        Ca2+ 
Figure 1.1. Insulin release pathways in pancreatic ß-cell, via transporter GLUT-1 as glucose 
uptake triggers K
+ 
channels closure thus, Ca
2+ 
influx and insulin secretion, while glucagon-like 
peptide-1 (GLP-1) triggers PKA and Epac2 which stimulate insulin release (Adapted from 
Ashcroft and Rorsman, 2012).  
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Similarly, the action of insulin in muscle cells and adipocytes involves a succession of 
complex signalling events as shown in Figure 1.2. As soon as the hormone binds to its 
receptor, insulin receptor (IR), which is a tyrosine kinase-coupled receptor, it promotes IR 
auto phosphorylation at certain tyrosine residues which induces the phosphorylation of 
multiple tyrosine residues of insulin-receptor-substrates (IRS-1 to 4) and other intracellular 
protein substrates. The phosphorylated IRS binds to phosphatidylinositol 3’-kinase 
(PI3k)/protein kinase B (PKB) at its Src-Homology-2 (SH2) domain, which phosphorylates 
membrane phospholipids and phosphatidylinositol 4,5-biphosphate (PIP2) on the third 
position to generate phosphatidylinositol 4,5-triphosphate (PIP3). PIP3 recruits’ protein 
kinase B/ Akt (PKB/ Akt) leading to its domain AS160 phosphorylation which stimulates 
GLUT-4 translocation to the membrane, glycogen synthesis by phosphorylation of GSK-3, 
and lipogenesis by up-regulating synthesis of the fatty acid synthase gene (Choi and Kim, 
2010; Rains and Jain, 2011). In parallel, IRs expressed in the endothelial cells are also 
involved in the release of nitric oxide (NO) and the regulation of vascular tone via 
vasodilation. The phosphorylation of PKB/ Akt protein after IRS-1 binding by insulin also 
activate endothelial nitric oxide synthase (eNOS) which induces NO synthesis, an important 
vasodilator (Tripathi and Srivasta, 2006), as shown in Figure 1.2 below. Decrease of NO 
levels may lead to insulin resistance seen in T2D and diabetes complications including 
endothelial dysfunction (Alexandru et al., 2016). 
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Figure 1.2. Insulin signalling cascades in muscle cells and adipocytes, after binding of insulin 
receptor (IR), insulin triggers IR auto phosphorylation, then phosphorylation of insulin receptor 
substrate which induces phosphorylation of phosphatidylinositol 3-kinase (PI3K) which 
phosphorylates membrane phosphatidylinositol 4,5-biphosphate (PIP2) at 3
rd
 position (PIP3). PIP3 
phosphorylates protein kinase B/ Akt which phosphorylates its AS160 domain, these triggers GLUT-4 
translocation to the plasma membrane. Also, PKB/Akt phosphorylation induces endothelial nitric 
oxide synthase (eNOS) phosphorylation which leads to NO synthesis in smooth muscle cells (SMCs)  
(Adapted from Choi and Kim 2010). 
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The secretion and action of insulin are part of integrated mechanisms, responsible for 
carbohydrate uptake, from nutrient consumption, and storage at key sites after its conversion 
into lipids. However, this ingenious ability to avoid caloric scarcity has been altered 
drastically recently. Evidences strongly suggest that ectopic lipid metabolites accumulation 
such as diacylglycerols and/or ceramides, maybe one major cause of liver and muscle insulin 
resistance, pathology that has been previously associated with diabetes complications 
(Samuel and Shulman, 2012). Indeed, insulin resistance which is characterized by lowered 
tissues sensitivity to the hormone, induce higher insulin quantity production to overcome 
insulin reduced sensitivity and to achieve insulin-mediated biological activity (Kahn et al., 
2006). This impairment is well compensated for in healthy individuals but plays an important 
part in the development of T2D. Moreover, in T2D patients it contributes largely to the 
development of diabetes-related complications as mentioned previously (Giacco and 
Brownlee, 2010). 
 
1.5. Diabetes management (conventional treatments) 
DM is characterized by constant high blood glucose, thus, the control of blood sugars levels 
and diabetes-related complication risks such as high blood pressure and cardiovascular 
diseases, are the first targeted lines to improve diabetes outcomes. T1D patients who have an 
absolute insulin deficiency require insulin therapy to survive thus insulin or its analogs is 
administered daily to replace the endogenous hormone (Tripathi and Srivasta, 2006). While, 
T2D patients are generally prescribed oral anti-diabetic agents and/or exogenous insulin to 
help in the management of hyperglycaemia when lifestyle modifications are not sufficient 
(Packer and Castro, 2015; Tahrani et al., 2011). Several pharmacological drugs with different 
mechanisms of action are available to complement lifestyle changes outcomes in the 
treatment of T2DM. However, most of these drugs have several limitations (Table 1.1) and 
cannot maintain initial glycaemia improvements as b-cells continue to degenerate during the 
course of the disease. Furthermore, several side-effects (Table 1.1) such as hypoglycemia, 
weight gain, potential cardiovascular risks and gastrointestinal disturbances, have been 
reported for these treatments (Tahrani et al., 2011; Li et al., 2018; Hsia et al., 2017).  
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Table 1.1. Summary of anti-diabetic drugs and action 
  Examples Mechanism (s) of 
action  
Route Dosing Advantages  Disadvantages 
Insulin  
(1922) 
Rapid acting (lispro, 
aspart), Short acting 
(actrapid, humulin S), 
intermediate acting 
(insulatard, humulin I), 
long acting (glargine, 
detemir) 
Activate insulin 
receptor, diminution 
hepatic glucose 
production, increase 
peripheral glucose 
utilisation and decrease 
lipolysis 
Subcutaneous 
injection 
Once to four 
times a day 
Sustained glycemic 
improvements  
Weight gain, 
hypoglycemia, 
fluid retention 
and self-
monitoring of 
blood glucose 
needed 
Sulphonylureas (1946) Glibenclamide, 
Glipizide, 
Tolbutamide 
Increase insulin 
secretion by binding to 
SUR1, leading to 
membrane 
depolarization and Ca2+ 
influx which triggers 
insulin secretion 
Oral Once or twice 
a day 
Long-term effects, 
low cost 
Hypoglycemia, 
weight gain, 
self-monitoring 
of blood 
glucose needed 
and careful 
dose titration 
Biguanide (1957) Metformin Inhibits hepatic glucose 
release, rises insulin 
sensitivity in muscle and 
interferes with lactate 
and glucose metabolism 
in the gut 
Oral Once or twice 
a day 
Long-term effects, 
low risk of 
hypoglycemia, 
decrease 
myocardial 
infarction risk in 
Possible link to 
lactic acidosis, 
gastrointestinal 
disorders, renal 
function altered 
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experimental 
study, low cost 
a-glucosidase inhibitors 
(1995) 
Acarbose, miglitol Decrease carbohydrate 
digestion in the gut 
Oral Three times a 
day  
Long-term effects, 
low cost 
Gastrointestinal 
side-effects 
Meglitinides (1997) Nateglinide, 
Repaglinide 
Bind to SUR1 on a 
different site than 
sulfonylureas leading to 
a more rapid insulin 
response 
Oral With each 
meal 
Short acting  Few data for 
long-term 
safety, weight 
gain, 
hypoglycemia, 
blood glucose 
self-monitoring 
Thiazolidine-diones 
(1997) 
Pioglitazone, 
rosiglitazone 
Peroxisome-proliferator-
activated-receptor-g 
agonists act in adipose 
tissue to increase 
adipogenesis and 
decrease free fatty acid 
release, also increase 
insulin sensitivity in 
muscle and liver 
Oral Once a day   Oedema and 
potential risks 
of heart failure, 
long-term 
safety not 
established, 
weight gain 
and fractures 
Glucagon like-peptide-1 
(2005) 
Exenatide, liraglutide Bind to GLP-1 receptor 
resulting in increased 
glucose-dependent 
insulin release and 
glucagon inhibition, 
delayed gastric 
emptying and appetite. 
Subcutaneous 
injection 
Once or twice 
a day 
Low risk of 
hypoglycemia, 
weight loss, 
possible effect on 
b-cell decline 
Long-term 
safety not 
known, 
gastrointestinal 
side-effects, 
might stimulate 
renal failure 
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Amylin analogue (2005) Pramlintide S Soluble analogue of 
human amylin which 
lowers postprandial 
sugar by inducing 
satiety sensation, 
suppressing postprandial 
glucagon secretion and 
delaying gastric 
emptying 
Subcutaneous 
injection 
Three times a 
day 
Weight loss Long term 
safety 
unknown, 
hypoglycemia, 
used associated 
with insulin 
only 
Dipeptidyl-peptidase-4 
inhibitors (DDP-4) 
(2006) 
Saxagliptin, Sitagliptin Rise of endogenous 
incretin levels (GLP1 
and GIP) by inhibiting 
incretins degradation 
Oral Once a day Low risk of 
hypoglycemia, 
possible effect on 
b-cell survival 
Unknown long-
term safety, 
association 
with 
pancreatitis 
Sodium Glucose 
cotransporter 2 
inhibitors (SGLT2) 
(2013) 
Chapagliflozin, 
Empagliflozin 
Reduced renal tubular 
glucose reabsorption, 
producing a reduction in 
blood glucose 
independently of insulin 
Oral Once/ twice a 
day 
Low risk of 
hypoglycaemia, 
possible 
improvement of 
blood pressure 
Genital 
infections, 
increase 
urinary 
frequency, 
rarely ortho 
static 
hypotension, 
pancreatitis 
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Metformin remains the first-line glucose-lowering treatment prescribed to newly diagnosed 
T2D patients. Indeed, this biguanide acts through enhancement of hepatic insulin sensitivity, 
increases glucose uptake by peripheral cells, reduces hepatic gluconeogenesis and contributes 
to weigh loss (Refuerzo et al., 2015).  
 
 
 
Figure 1.3. Understanding of how current anti-diabetic drugs increase insulin sensitivity and 
insulin secretion- Metformin case). Metformin uptake through OCT1 (organic cation 
transporter 1) in hepatocyte exerts mild and specific inhibition of the respiratory chain 
complex 1, resulting in decreased ATP levels and increase of AMP. ATP drop blocks the 
gluconeogenesis and AMP accumulation inhibits gluconeogenesis through allosteric 
regulation of fructose-1,6- biphosphatase and the reduction of glucagon-stimulated adenylate 
cyclase activity. Chronic high glucose is avoided and insulin secretion increased (Adapted 
from Ashcroft and Rorsman, 2012; Viollet and Foretz, 2013; Yang et al., 2017). 
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All these processes would improve insulin resistance, which contributes to diabetes 
complications. However, metformin can also promote gastrointestinal adverse effects such as 
cramps, abdominal bloating, nausea, vomiting and diarrhea (Sharrat et al., 2015; Mahmood et 
al., 2013). Furthermore, for patients considered being “at risk”, metformin can be harmful 
and may cause acute heart failure, shock and lactic acidosis (Packer and Castro, 2015; Scheen 
and Paquot, 2013). In addition, recent toxicity studies, have exhibited potential genotoxicity 
of chronic treatment of metformin (114.4 µg/ml or 572 µg/ml in CHO-K1 cells for 24 hr), 
while others suggested that metformin may act as a mild embryo-toxic agent since it 
exhibited cytotoxicity at 800 µg/ml in embryonic stem cells (D3 cells), drawing cautious to 
pregnant women that need metformin for treatment (Zhou et al., 2018). 
Sulfonylureas such as tolbutamide are generally prescribed as a second-line therapy in 
patients with T2D. Although, these drugs can be used as alternative treatment to metformin 
for patients facing intolerance to biguanides or who are overweight. Sulfonylureas can also 
be prescribed in combination with metformin for more efficient glycemic control. 
Sulfonylureas act by binding specific ß-cells K+ channels receptors (SUR 1), inducing insulin 
secretion using glucose similar pathway (Tripathi and Srivasta, 2006). The major adverse 
effects of sulfonylureas are hypoglycaemia and weight gain (Packer and Castro, 2015; 
Tripathi and Srivasta, 2006). 
Another class of drugs named thiazolidinedione have been prescribed as alternative second-
line or third-line treatment for T2D patients. Although these drugs improve insulin resistance 
(detrimental for diabetic complications) by targeting specific receptor gamma and have great 
efficacy in combination with other anti-diabetic agents, the side effects reported, such as 
heart failure, oedema, anaemia and weight gain, have decreased their popularity (Packer and 
Castro, 2015; Tripathi and Srivasta, 2006). 
Recently, newer therapies have been developed to improve glycemic control such as sodium 
glucose co-transporter 2 (SGLT2) inhibitors and incretin hormones such as GLP-1 receptor 
agonists, for example exenatide, liraglutide, lixisenatide, dulaglutide which increase insulin 
secretion (Table 1.1), reduce glucagon release and slow gastric emptying. 
Dipeptidylpeptidase-4 (DDP4) inhibitors such as sitagliptin, linagliptin, saxagliptin, and 
vildagliptin, have been reported to have a lower risk of hypoglycemia and do not lead to 
weight gain, although long-term safety is unknown. Newer, long lasting insulin formulations 
have also been developed to allow a better flexibility to patients but not avoiding the daily 
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injection disagreement. Moreover, novel insulin delivery routes are tested such as inhaled 
insulin with hypoglycemia and throat pain as major side effects reported (Packer and Castro, 
2015).  
Unfortunately, despite the presence and abundance of these well investigated anti-diabetic 
agents, diabetes and its devastating complications including sight loss, foot complications, 
infections and amputations, remain an important health problem in industrialized and 
economically developing countries (Kim et al., 2006). Chronic hyperglycaemia in itself 
certainly plays a major precipitating and directly causative role in diabetes complications, but 
additional factors are likely to contribute because even with good glucose homeostasis in 
well-controlled diabetic, complications still occur and are resistant to resolution 
(Shamsaldeen et al., 2016). These oral anti diabetic drugs decrease only relatively the risk of 
complications but cannot prevent them, and mostly increase the risk of hypoglycemia (King 
et al., 1999). The expense of drugs and recommended diets in cities and rural regions, along 
with the social burden imposed by everyday treatment practices and culture pressures are the 
main factors of biomedical diabetes management failure in Africa (Levitt, 2008). Hence, a 
large number of African communities are still relying on traditional remedies as first line 
treatment for the management of diabetes mellitus and its related complications.  
 
 1.6. Medicinal plants widely used for diabetes 
The efficacy and safety limitations of currently available conventional oral anti-diabetic 
drugs combined with the rise of the disease incidence and its related complications globally, 
have promoted alternative therapeutic research with the aim of managing diabetes more 
safely and efficiently (Pandey et al., 2011). Indeed, the World Health Organisation (WHO) 
have listed more than 21, 000 plants used for medicinal purposes, supporting extensive 
investigations to find potential therapeutic agents among anti-diabetic-claimed plants 
(Jayaprasad et al., 2011). Moreover, medicinal plants are ready, available and show few side 
effects which represent great advantages and prospect for the discovery of new anti-diabetic 
drugs (Arumugam et al., 2013; Patel et al., 2012). Besides, a large number of medicinal 
plants are accessible as there are domesticated in garden or are wild plants in forests near 
habitations, especially in African communities (Bading Taika et al., 2018). In Africa, plant 
based medicine is widely used to treat numerous of ailments including diabetes without any 
scientific supportive data on the mechanism of action and the safe range of doses for long 
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term use. In countries such as Gabon where traditional medicine is used and relied on by 
more than half of population due to reduced cost of traditional medicines and the easy access 
of plants (Bading Taika et al., 2018).  
Numerous medicinal plants have been studied for their potential ability to restore pancreatic 
tissue functions by either increasing insulin release, inhibiting glucose intestinal absorption, 
or insulin-dependent metabolism processes (Kuete and Efferth, 2010). The most studied 
plants with hypoglycemic activity include Momordica charantia (bitter melon), Trigonella 
foenum graecum (fenugreek), Gymnema sylvestre (gurmar), Panax quinquefolius (ginseng), 
Opuntia streptacanthia (nopal cactus), Aloe barbadenis (Aloe), Vaccinium mytillus 
(bilberry), Silybum marianum (milk thistle), Allium sativum (garlic), Allium cepa (onions) 
and Pterocarpus marsupium (Vijayasar) (Upendra Rao et al., 2010). Common culinary herbs 
and spices based extracts from cinnamon, cloves and bay leaf have also demonstrated insulin-
like or insulin-potentiating in vitro action by improving glucose metabolism. Now, more than 
200 isolated phytochemicals are known to be hypoglycemic, although caution has been made 
that it can be due to metabolic or hepatic toxicity (Broadhurst et al., 2000). 
Nowadays, it is well accepted that people around the world have used medicinal plants to 
treat diabetes safely and with good success for long time. Indeed, botanical products can 
improve glucose metabolism and the overall condition of persons with diabetes not only by 
direct hypoglycaemic effects but also by improving lipid metabolism, antioxidant status, and 
capillary function (Patel et al., 2012). According to several phytochemical analyses, most of 
cited medicinal plants contain natural bioactive substances exhibiting anti-diabetic effects 
such as glycosides, alkaloids, terpenoids, flavonoids, carotenoids (Patel et al., 2012). 
However, few of these lead compounds have been further developed into clinically useful 
phytomedicines which would have direct benefits on patients. In this context, it is important 
to mention that metformin, a biguanide, is a derivate of an active natural product, galegine a 
guanidine isolated from the plant Galega officinalis L. used in ancient times to relieve the 
intense urination in diabetic people (Andrade-Cetto and Heinrich, 2005).  
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	1.7. Plants used in Gabon to treat diabetes 
Gabon is a little country with 1.8 million population covered by 80% of forest. The national 
prevalence of diabetes is more than 9%. Thus, it is the third country in sub-Saharan Africa 
the most affected by diabetes mellitus (Bading Taika et al., 2018). 
There is a rise of diabetes features in Gabon that is caused by many factors including 
urbanisation, changes in lifestyle with fewer physical activities and more high fat food 
consumed, obesity and recently, more diagnosed diabetics. Commonly in Gabon, diabetes is 
fairly well managed in urban regions. However, in rural areas the poor availability of 
treatments and difficult access to medicines as well as their expensive cost, helped with the 
culture and religious beliefs, diabetic patients tend to relying more on traditional practitioners 
and medicinal plants for the management of this disease (Bading Taika et al., 2018).  
Indeed, plant based traditional medicine is widespread in Gabon and it is used to treat 
numerous ailments including renal insufficiency, HIV and diabetes. In Gabon, more than 
1600 medicinal plants have been reported with beneficial biological activities including anti-
diabetic property such as Irvingia gabonensis (Odika or wild mango), Pseudospondias 
longifolia, Antrocaryon klaineanum and Tabernanthe iboga (Bading Taika et al., 2018). We 
recently published an ethnobotanical literature review identifying 69 medicinal plants, 
currently used in Gabon, that have been reported to have in vivo or in vitro hypoglycaemic 
activities, reducing blood glucose or stimulating insulin secretion in human or animal models 
(Bading Taika et al., 2018). Active substances were defined in only 12 out of 69 plants, 
which included Anacardium occidentale, Sclerocarya birrea, Ageratum conyzoides, Ceiba 
pentandra, Kalanchoe crenata, Bridelia ndellensis, Tabernanthe iboga (T. iboga), Irvingia 
gabonensis, Bersama engleriana and Morinda lucida (Bading Taika et al., 2018). These 
plants have revealed natural compounds that have shown anti-diabetic potential such as 
alkaloids, terpenoids, flavonoids, phenolics (Jung et al., 2006). Also, other constituents 
frequently involved in anti-diabetic activities have been mentioned including carotenoids, 
peptidoglycan, and steroids (Akinmoladun et al., 2014). These compounds can justify the use 
of these plants in traditional medicine for the management of diabetes (Bading Taika et al., 
2018). For example, the root bark of T. iboga and its preparations are used in Gabonese 
traditional medicine combating diabetes in Central and West Africa, but their active anti-
diabetic constituents are not fully identified or characterised. 
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Since ancient time, treatments for numerous diseases including diabetes have been provided 
by African traditional healers through plants such as T.  iboga in Cameroon and Gabon 
(Eyong, 2007). Traditional “doctors” use the air-dried root barks, stem barks or other plant 
parts in different recipes obtained usually via maceration (plants macerated in water) or 
decoction (boiled plants) to form the remedy given to patients (Bading Taika et al., 2018). 
However, as mentioned above, only 69 plants have been investigated to date, while more 
plants are claimed to be anti-diabetic and are currently used by population but have limited or 
no available scientific evidence on their anti-diabetic mechanism of action such as T.  iboga 
and G. tessmannii. 
T. iboga also called “iboga” or the “sacred wood” has been investigated for several biological 
activities such as anti-addiction, anti- cancer and anti-diabetic (Souza et al., 2011). T. iboga 
belongs to the Apocynaceae family and grows in tropical forest of central Africa, including in 
Cameroon and Gabon (Eyong, 2007; Souza et al, 2011). T. iboga is a shrub of about 5 to 10 
m height with white flowers and orange-yellow fruit as shown in Figure 1.4 below (Sanner, 
2007).  
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Figure 1.4. T. iboga in natural environment (a), flower (b) and fruit (c) (Bayissi Bading-
Taïka, February 2014, Arboretum of Sibang, Libreville/Gabon) 
 In vitro experiments have shown potentiation of insulin secretion from isolated pancreatic rat 
ß-cells, at very low concentrations of T. iboga aqueous extract (1ug/ml) and in presence of 
stimulatory glucose concentration (11.1 mM), involving K+-ATP channels (evidenced by 
diazoxide which prevented the closure of K+-ATP channels and suppressed T. iboga effect) 
and extracellular Ca2+ (evidenced in presence of cobalt, an inorganic Ca2+ channel blocker, 
which strongly inhibited the insulinotropic effect of T. iboga) (Souza et al., 2011). In this 
study, σ2 receptors were hypothesized to be involved in the insulin-secretion action of the 
plant (Souza et al., 2011).  
Previous phytochemical analysis of T. iboga aqueous extract of the roots has shown an 
association of indole alkaloids ibogaine (80 %), ibogaline (15 %) and up to 5 % of ibogamine 
(Mačiulaitis et al., 2008) but whether any of these exhibit active anti-diabetic constituents has 
not been determined to date. 
Similarly, G. tessmannii Harms Leonard, also known as ‘Bilinga’, has been investigated for 
its antioxidant activity (Nyangono et al., 2013), and anti-hypertensive property (Madingou et 
al., 2012). It has also been reported as medicinal plant used for the treatment of diabetes 
complications (Bading-Taika et al., 2018), cardiovascular diseases such as arterial 
hypertension (Madingou et al., 2012), cancer, and sexual troubles (Watcho et al., 2013), 
supporting the use of this plant by Gabonese population for the treatment of diabetes 
complications, although no studies on its anti-diabetic effect were reported up to now. G. 
tessmannii is one of the largest tree occurring in forests in Cameroon and Gabon (growing up 
(a) Shrub   (b) Flower  (c) Fruit  
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to 30-280 meters) as shown in Figure 1.5. It belongs to the Leguminoseae family, and is 
mainly found in tropical Africa and tropical America (Madingou et al, 2012; Mbaveng et al, 
2011). 
 
   
(a) Trunk                                      (b) Foliage 
Figure 1.5. G. tessmannii in natural environment (Bayissi Bading-Taïka, February 2014, 
Arboretum of Sibang, Libreville/Gabon) 
Phytochemical analyses of G. tessmannii aqueous extracts have revealed the presence of 
sterols, alkaloids, polyphenols, reductor compounds, saponosides and terpenes which are 
bioactive compounds also cited for anti-diabetic activity (Madingou et al., 2012). Numerous 
studies of aqueous and hydro-ethanolic extracts of G. tessmannii at 200 mg/kg have revealed 
antioxidant and anti-hyperlipidemic activities in tritonised hyperlipidemic rats (Nyangono 
Beyegue et al., 2012). Moreover, in vitro antioxidant activity of aqueous and hydro-ethanolic 
extracts of G. tessmannii was also demonstrated, which supports previous in vivo findings 
(Nyangono Beyegue et al., 2013). It has been shown that alkaloids and flavonoids have 
antioxidant activity, which is beneficial on human nutrition and health care. Alkaloids may 
act through peroxidation inhibition and flavonoids are responsible of lipid peroxidation 
inhibition (avoid cell injury) by scavenging free radical, linking metal ions and/or inhibiting 
enzymes involved in oxidation systems (Nyangono Beyegue et al., 2013). Recently, the study 
of biosafety of G. tessmannii aqueous extract has determined acute and sub-acute toxicities 
values. Large safety range of doses have been determined with an oral LD50 (lethal dose 
killing 50% of treated population) above 5000 mg/kg which place this plant in a Class 5 drug, 
recognised as a low toxic product (Koumba Madingou et al., 2016). This result was 
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supported by intraperitoneal administration to Swiss mice, LD50 estimated at 328.78 mg/kg 
which is considered as low toxicity. The weak bioavailability of the active compounds that 
cause toxicity, a poor gastrointestinal absorption, or rapid metabolism to non-toxic 
metabolites might explain this low toxicity (Koumba Madingou et al., 2016). Furthermore, 
sub-chronic exposition of aqueous extract of G. tessmannii (150-3000 mg/kg b.w.) to Wistar 
rats for 28 days, did not alter animal behaviour, food and water intake, nor vital organs and 
body weights, which could indicate side effects of the administered plant extract (Koumba 
Madingou et al., 2016). 
However, the lack of scientific evidence of anti-diabetic effects of Gabonese medicinal plants 
claimed to be anti-diabetic, endangers the health care systems already weakened by the heavy 
burden of this life time disease in this community. Indeed, as a large number of Gabonese 
population rely on traditional medicine for the management of diabetes, there is a warrant 
need of evidence either to prevent or promote the use of certain Gabonese medicinal plants as 
alternative treatment for the management of diabetes in this country.   
 
 1.8. Animal models of diabetes  
Although medicinal plants have been long used for the treatment of diabetes around the 
world, few of them have received scientific validation and been tested in humans. (Bading 
Taika et al., 2018; Fröde and Medeiros, 2008). Thus, the effectiveness of anti-diabetic 
medicinal plants is largely not supported by applied medical research (Fröde and Medeiros, 
2008). In order to be able to evaluate in vitro and in vivo anti-diabetic efficacy, their side 
effects and mechanism of action of plants and plant-derived extracts, animal models have 
been used (Eddouks et al., 2012). Diabetes is a complex metabolic disorder and is hard to 
model in vitro. Animal models of diabetes are therefore very important for the study of the 
disease pathogenesis and can be used for the study of diabetic complications that are seen 
clinically, including glucose homeostasis, insulin sensitivity, vascular, gastrointestinal and/ or 
urogenital dysfunction and neuropathic pain.  
Over 130 years ago, the surgical removal of the pancreas in a dog and the consequent 
polyuria, polydipsia and diabetes, highlighted the role that the pancreas plays in diabetes 
(Von Mering and Minkowski, 1889). Due to the complexity of diabetes features in human, 
not one single animal model can be representative to a precise type of diabetes in man. Thus, 
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many different animal models have been used for T1D and T2D (Eddouks et al., 2012). The 
majority of published experiments in ethno-pharmacology have used T1D or T2D models as 
presented on Table 1.2. 
The most frequently used animal models are rodents, which are cheaper to maintain than 
larger animals and generally exhibit more rapidly the onset of their diabetic condition 
(Eddouks et al., 2012; Fröde and Medeiros, 2008).  
The induction of diabetes in animal models can be done by pharmacologic, surgical or 
genetic manipulations in a large number of animal species. Although, most experiments are 
carried out on small rodents, few studies are still conducted in larger animal such as dogs 
(Eddouks et al., 2012; Fröde and Medeiros, 2008). To date, there is no evidence that a plant 
material can be use as substitute for insulin, though, a large number of plant products have 
been reported to mimic or improve endogenous insulin effects.  
Streptozotocin (STZ) and alloxan are the most frequently used chemicals to induce diabetes 
that are selectively toxic to the ß-cells in the islet of pancreatic islets (Lenzen, 2008). Both 
drugs show their diabetogenic action when they are administered intravenously, 
intraperitoneally or subcutaneously. The dose required of these drugs for inducing diabetes 
mainly depends on the animal species and route of administration. According to the dose 
administered of these agents, features similar to either T1DM, T2DM or glucose intolerance 
can be induced (Eddouks et al., 2012). In rodents, systemic administration of chemicals that 
are selectively toxic to the ß-cells of pancreatic islets such as STZ (Schein et al., 1974) and 
ALX (Lenzen, 2008) induce a rapid and sustained diabetic state of hyperglycaemia and 
insulin deficiency. For many researchers, STZ is the agent of choice due to its more 
reproducible induction of diabetes through greater stability than ALX at physiological pH 
(Lenzen, 2008). 
There are a wide variety of genetic models of T2D but these are expensive and not easy to 
maintain. Non-genetic models are widely available, such as nicotinamide-STZ model and 
high fat fed-STZ models but these can lead to permanent ß-cell damage (akin to T1D) and 
require special dietary formulations. Back in the 1950s it was recognised that diets high in 
fructose can rapidly induce hyperglycaemia, hyperinsulinemia and impaired glucose 
tolerance (Sleder et al., 1980). Recent studies have combined fructose feeding in drinking 
water (10%) over 2 weeks with a lower dose (40 mg/kg i.p.) of STZ and demonstrated a 
stable hyperglycaemia, polydypsia, oral glucose tolerance, insulin resistance, hyperlipidaemia 
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and sensitivity to anti-diabetic drugs metformin and glibenclamide (Wilson and Islam, 2012).  
These STZ-induced rat models of diabetes are well-established at the University of 
Hertfordshire and are highly reproducible and lead to moderate severity. Within hours 
following STZ injection, animals show typical symptoms of diabetes, such as polydipsia, 
polyuria, glycosuria, dyslipidaemia and hyperglycaemia.  
Transgenic or highly inbred animal strains have also been developed that spontaneously or 
conditionally develop diabetes (eg. ob/ob, Zucker), although the use of these can be restricted 
by their cost and the fact that diabetes is highly genetically determined unlike heterogeneity 
seen in humans (Rees and Alcolado, 2005). The most commonly used inbred models in 
research are the non-obese diabetic mouse (NOD) and the bio breeding (BB) rat (Rees and 
Acolado, 2005). Both of these models spontaneously develop diabetes but there are 
drawbacks in that the NOD model demonstrates a large gender difference with females 
showing an increased propensity of developing diabetes and the BB rat requires 
administration of exogenous insulin to survive (Rees and Alcolado, 2005). There are 
numerous models of T2D due to the complexity and heterogeneity of the human disease. 
They include ob/ob and db/db mice, which have been shown to be leptin deficient and leptin 
resistant respectively (Rees and Acolado, 2005) and the Zucker (fa/fa) rat (also leptin 
resistant). Transgenic models have been developed for the study of specific elements of the 
disease but the use of these is economically restrictive and has other drawbacks especially 
when wanting to look at a disease from a non-biased viewpoint. Advantages and 
disadvantages of different categories of T2 diabetic animal models are listed on Table 1.3. 
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Table 1.2: Classification of type 2 and type 1 diabetes models in animals (Rees and Alcolado, 2005) 
Type 1 Spontaneous syndromes Experimentally induced 
  
  - BB rat   
- NOD mouse 
- LEW.1AR1/Ztm-iddm rat                                                     
- Chemically with ALX or STZ or surgically by near-total 
pancreatectomy                                                                
Type 2 Obese Non Obese 
1. Spontaneous or 
genetically derived diabetic 
animals 
  
  
  
  
  
  
  
      -     ob/ob mouse, db/db  
            mouse   
      - KK mouse, KK/Ay mouse  
       -  NZO mouse                                              
       -  NONcNZO10 mouse    
       -  TSOD mouse, M16 mouse 
       -  Zucker fatty rat, ZDF rat 
       -  SHR/N-cp rat, JCR/LA-cp  
          rat 
  -  Cohen diabetic rat, GK rat; Torri rat  
      Non-obese C57BL/6; (Akita) mutant  
      mouse, ALS/Lt mouse 
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2. Diet-induced diabetic 
animals 
  
3. Chemically induced 
diabetic animals 
  
  
  
  
  
4. Surgically diabetic 
animals 
       -  OLETF rat 
       - Obese rhesus monkey 
       -  Sand rat, C57/BL 6J  
          mouse, Spiny mouse 
      -  GTG-treated obese mice 
  
  
  
      -  VMH lesioned dietary obese  
         diabetic rat 
      -  ß3 receptor knockout mouse 
     -  Uncoupling protein (UCP1)   
        knock-out mouse 
  
  
  
  
- Low-dose ALX or STZ adult rats,    
      mice; Neonatal STZ rat; Non- 
    genetic rat models (Fructose- 
   induced-STZ model type 2 model) 
 
 
 
 
 
 
 
- Partial pancreatectomized animals   
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5. Transgenic/knock-out 
diabetic animals 
   (dog, primate, pig, and rat) 
 
 
- Transgenic or knockout mice     
   involving genes of insulin, insulin  
   receptor, and its components of  
   downstream; Insulin signalling (IRS- 
   1, IRS-2, GLUT-4, PTP-1B …);   
   PPAR-g tissue-specific knockout  
   mouse; Glucokinase or GLUT-2  
   knockout mice; Human islet amyloid  
   polypeptide (HIP) over expressed rat 
DIO: Diet-induced obesity; KK: Kuo Kondo; KK/Ay : yellow KK obese; VMH: ventromedial hypothalamus; ZDF: Zucker diabetic fatty; NZO: 
New Zealand obese; TSOD: Tsumara Suzuki obese diabetes; SHR/N-cp: spontaneously hypertensive rat/NIH-corpulent; JCR: James C Russel; 
OLETF: Otuska Long Evans Tokushima fatty; GTG: gold thioglucose; ALX: alloxan; STZ: streptozotocin; GLUT: glucose transporter; IRS: 
insulin receptor substrate; GK: Goto-Kakizaki; PPAR: peroxisome proliferator activated receptor; PTP: phosphotyrosine phosphatase; ALS: 
alloxan sensitive.
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Table 1.3: Advantages and disadvantages of various categories of type 2 diabetic animal models (adapted from Eddooks et al., 2012) 
Model category Advantages Disadvantages 
  
  
 Spontaneous diabetic animals 
- T2D development is spontaneous involving 
genetic factors, and features resembling human 
T2D 
- Most inbred animal models are homogenous 
and in controlled environment, that allows 
easy genetic dissection 
- Variability of results is low and require small 
sample size 
- Highly inbred, homogenous and in majority 
monogenic. Inheritance and development is 
genetically determined, unlike heterogeneity of 
humans 
- Limited availability and very expensive. 
High mortality due to ketosis in animals with 
brittle pancreas (db/db, ZDF rat P. obeus, and 
more), and it requires insulin in later stage for 
survival 
- Require sophisticated maintenance 
  
 Diet/nutrition induced diabetics 
- Develop diabetes with obesity due to over 
nutrition like diabesity syndrome in humans 
- Toxicity of chemicals on other vital organs 
can be avoided 
- Most of them require long dietary treatment 
- No direct hyperglycaemia develops upon 
dietary treatment in normal animals and hence 
unsuitable for screening antidiabetic agents on 
circulating glucose parameters 
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 Chemical induced diabetic animals 
- Selective loss of pancreatic ß-cells 
(ALX/STZ) leaving alpha and delta cells 
undamaged 
-Residual insulin secretion help animals to live 
long without insulin treatment 
- Cheaper, easier to develop and maintain 
comparing to other models 
- Hyperglycaemia develops by cytotoxicity 
action on the ß-cells, leading to insulin 
deficiency rather than insulin resistance 
- Diabetes induced by chemicals is less stable 
and reversible due to spontaneous regeneration 
of ß-cells. Care is thus required to assess ß-cell 
function in log-term experiments 
- Chemically induced toxicity on other organs 
along with its action on ß-cells 
- High variability on hyperglycaemia 
development  
  
  
  
Surgical diabetic animals 
- Avoid cytotoxicity effects of chemicals 
inducing diabetes on other organs 
- Due to reduced ß-cell mass, resembles to 
human T2D 
- Requires technical skills and post-operative 
procedure 
- Some digestive problem may occur due to 
excision of exocrine portion leading to the 
deficiency of amylase  
- Dissection of alpha cells (secreting glucagon) 
along with ß-cells leading to the counter 
regulatory response to hypoglycaemia  
- High mortality 
Transgenic/ knock out diabetic animals - In vivo effect of single gene or mutation on 
diabetes can be investigated 
- Study of complex genetics of T2D is easier 
- Highly sophisticated and costly for 
maintenance and production 
- Expensive for regular screening experiments 
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 1.9. Pharmacological approaches 
In vitro experiments are usually designed using known drugs mechanism of action already 
used for the management of diabetes including inhibitory effects against activity on PPAR 
gamma receptors which activation increases glucose metabolism (thiazolidinediones-like 
effect), insulin release from pancreatic ß-cells (sulfonylureas), glucose uptake increase in 
muscle or liver, increase expression of glucose transporter GLUT4, which enhance glucose 
uptake into muscles and adipose tissues, DPP-IV inhibitors, or aldose reductase inhibitors 
like the drug epalrestat (Ezuruike and Prieto, 2014). This methodology supports an easier 
identification of potential medicinal plants with therapeutic value having identified natural 
compounds (chapter 2). Although, this experimental approach excludes extracts that might 
act on unknown targets with unknown mechanisms. The investigation of mixture of plants 
would not be appropriate using this approach only as numerous active metabolites and targets 
may be involved (chapter 2).  
In vivo experiments need safe and effective drug dosing. The common perception of scaling 
of dose based on the body weight (mg/kg) is not the right approach on its own. Therefore, 
extrapolation of dose from animals to humans or vice versa needs consideration of body 
surface area, pharmacokinetics, and physiological time to increase experiments or preclinical 
trial safety (Nair and Jacob, 2016). Four different methods to assess the initial dose have been 
reported in the literature, including dose by factor, similar drug, pharmacokinetically guided, 
and comparative approaches (Nair and Jacob, 2016). In chapter 4 and 5, the dose by factor 
approach was used, using the same guideline values to back calculate the human dose to 
animal dose for preclinical toxicological studies. This empirical method use the No 
Observable Adverse Effect Level (NOAEL) of drug from preclinical toxicological studies to 
estimates human equivalent dose (HED). The dose selection is based on minimum risk of 
toxicity (Nair and Jacob, 2016). 
 
1.10. Aims and objectives 
The use of specific plants for the treatment of diabetes is very common in Gabon. However, 
the lack of scientific evidence on claimed anti-diabetic plants has raised safety and health 
concerns in the country. Only 69 plants used for the treatment of diabetes in Gabon have been 
documented in the literature, with little preliminary data. Most of these plants investigations 
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to date revealed poor general design and unrealistic doses unveiling the huge work to be done 
before obtaining plant-based medicines from the Gabon plants used (Bading Taika et al., 
2018). 
To date, there is insufficient scientific information regarding the appropriate range of doses for 
T. iboga and G. tessmannii extracts as remedy for diabetes. Scientific Research is therefore 
needed to provide an insight into acute and long-term effects of aqueous extracts of T. iboga 
and G. tessmannii for the development of standardized extracts of these plant species for 
preventing or ameliorating diabetes in humans.  
Overall aims of this study: 
1. Perform a phytochemical characterization of T. iboga root bark to identify known and 
unknown novel compounds and determine if any (based upon literature) are insulinotropic 
agents.  
2. Investigate the aqueous extracts from T. iboga and G. tessmannii plant material and to 
determine the effects on glucose stimulated insulin release from isolated rat pancreatic islets 
and the involvement of σ2 receptors. These experiments would determine whether 
concentrations of T. iboga and G. tessmannii aqueous extracts can potentiate insulin release 
from rat pancreatic islets in vitro before evaluating in vivo efficacy in diabetes disease 
models.  
3. Investigate effects of the aqueous extract of T. iboga on animal models of diabetes. 
Specifically, the in vivo effects of the extract on naïve rats, as well as rat and mouse T2D. 
Effects on glucose tolerance, insulin tolerance and metabolic syndrome (including disease 
tissue biomarkers) were determined. 
Phytochemical isolation and characterization of active T. iboga antidiabetic constituent 
compound(s) could lead to a patent and investment to designing and synthesising analogues 
that could be used in the controlled medical treatment of diabetes in Gabon in the future. 
Further this project will be the first to determine the in vitro and in vivo activity of T. iboga in 
models of diabetes and whether aqueous extract from widely used G. tessmannii plant stem 
bark has anti-diabetic potential.  
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The objectives of this study were investigated as the following: 
1. To identify the Phytochemical characterization of T. iboga plant root bark using LC-
MS/MS and metabolomics (Chapter 2) 
2. To develop a methodology for isolation of rat pancreatic islets (Chapter 3) 
3. To investigate the effects of low and high glucose concentrations on insulin secretion 
from isolated rat pancreatic islets (Chapter 3) 
4. To investigate the concentration dependent effects of T. iboga and G. tessmannii 
aqueous extracts on low and high glucose induced insulin secretion from the isolated 
rat pancreatic islets (Chapter 3) 
5. To investigate the effect of T. iboga and G. tessmannii on insulin release from 
isolated rat pancreatic islets in the presence of Tolbutamide (Chapter 3) 
6. To investigate the effect of T. iboga on insulin release from isolated rat pancreatic 
islets in the presence of σ2 receptor antagonist SM-21 (Chapter 3).  
7. To evaluate T. iboga toxicity and optimal dose regimen in vivo in rats (Chapter 4) 
8. To investigate the in vivo anti-hyperglycemic and hypoglycemic effect of T. iboga in 
naïve control rats (Chapter 4) 
9. To investigate the in vivo anti-diabetic effect of T. iboga in Fructose-induced STZ 
type diabetic animal model (Chapter 4) 
10. To investigate T. iboga for the improvement of dysfunctional metabolism in mouse 
DIO models of metabolic disease (Chapter 5) 
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C h a p t e r  2 :  P h y t ochemica l  charac ter i sa t i on  o f  T.  i boga  p l a n t  r o o t    
                 b a r k s  b y  L C- MS/MS  and  metabo lomics  
	
2.1. Introduction 
Plants and plant-derived substances have become of great interest due to their wide range of 
pharmacological activities. Phytochemicals as referred to the biologically active compounds 
found in plants are great resource of drugs for traditional medicine, alternative modern 
medicine, food supplements, folk medicines and chemical patterns for synthetic drugs (Ncube 
et al., 2008; Ingle et al., 2017). It has been estimated that more than 74% of 
pharmacologically active plant-derived compounds were identified following ethno 
medicinal reports of the plants’ use. A large number of interesting outcomes have been 
reported with the use of mixtures of natural products for the treatment of many diseases 
especially the synergistic effects and poly-pharmacological use of plant extracts (Ncube et 
al., 2008; Panchal and Tiwari, 2017). Phytochemistry describes the abundance of secondary 
metabolites occurring in the plants. Nowadays, it is well known that plants are the reservoirs 
of natural chemical compounds with structurally diverse bioactive molecules (Ingle et al., 
2017). 
The first step to the development of pharmaceuticals commences with the sample 
preparation, separation and then detection (Moein et al., 2017). Sample preparation involves 
suitable extraction methods which can allow a better identification of bioactive principles, 
followed by in-depth biological assays, dosage formulations and clinical studies to evaluate 
safety, efficacy, and pharmacokinetic profile of the new drugs derived from plant extracts 
(Ncube et al., 2008; Moein et al., 2017). Numerous analytical techniques have been 
developed to identify unknown compounds involving extraction, isolation of compounds and 
qualitative determination of elements with spectrometry, MS (mass spectrometry), IR* 
(infrared spectroscopy), NMR (nuclear magnetic resonance spectroscopy), UV (ultra-violet 
spectrophotometry), chromatography, HPLC (high performance liquid chromatography), GC 
(gas chromatography), TLC (thin-layer chromatography), electrophoresis and fluorescence 
for the most cited in the literature (Milman, 2011; Ingle et al., 2017). 
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Extraction 
Extraction is the critical first step in the analysis of medicinal plants, as it is essential to 
extract the wanted chemicals from the plant materials for further separation and 
characterisation. Extraction is a technique of separation of compounds, usually solid, based 
on their solubility. Depending on the phases involved, it can be either liquid-solid or liquid-
liquid, the latter being the most commonly used in organic laboratory (Hoffman and 
Stroobant, 2007). The common procedures include pre-washing, drying of whole plant or 
plant parts or freeze drying, grinding to obtain uniform sample and then reconstitution for 
further analysis. Precautious actions are required to avoid loss, destruction or deterioration of 
potential active principles during extraction process. Usually, when the plant was selected on 
the basis of traditional uses, the extract is prepared according to the traditional practitioner 
method in order to obtain a product as close as possible to the one used traditionally 
(Sasidharan et al., 2011). The solvents for the extraction are selected according to the nature 
of potential bioactive compounds being targeted. Different solvents are available to extract 
the bioactive compounds from natural products. Hydrophilic compounds are usually 
extracted using polar solvents such as methanol, ethanol or ethyl acetate. Lipophilic 
components are usually extracted using less polar solvents such as DMSO 
(dimethylsulfoxide), hexane or heptane. The targeted compounds may be non-polar to polar 
and even thermally sensitive, thus the appropriate method of extraction must be assessed. 
Besides, since the final product obtained will contain traces of residual solvent, the solvent 
chosen should be non-toxic for bioassay. Generally, traditional practitioners use water 
extracts to prepare their remedies although organic plant extracts have been reported to carry 
more active molecules than water extracts (Ncube et al., 2008).  
Numerous methods of extraction are available such as sonication, heating under reflux and 
Soxhlet extraction. Alternatively, plant extracts are also obtained by maceration, decoction, 
infusion (Bading Taika et al., 2018) or percolation of fresh green plants or dried powdered 
plant materials in water or organic solvents (Sasidharan et al., 2011). Modern extraction 
techniques are also available including solid-phase micro-extraction, supercritical-fluid 
extraction, pressurised-liquid extraction, microwave-assisted extraction, solid-phase 
extraction, and surfactant-mediated methods, which present many advantages including 
automation of these methods with gain of time, less organic solvent use and sample 
degradation, fewer steps before chromatographic analysis with the elimination of additional 
sample clean-up and concentration, improvement in extraction efficiency, selectivity, kinetics 
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of extraction (Gupta et al., 2012). Plant extracts usually appear as a mixture of various type 
of phytochemicals, which represent a real challenge for their separation, identification and 
characterisation processes. As mentioned previously, multiple separation and identification 
techniques of bioactive compounds in a sample are available (Sasidharan et al., 2011), 
although in this project we will focus on mass spectrometry technique.  
  
Mass spectrometry (MS) 
Among the numerous methods of detection, mass spectrometry (MS) is one of the most 
powerful analytical techniques for the identification of unknown compounds, quantification 
of known compounds and to elucidate structure and chemical properties of molecules. Using 
MS spectrum, the molecular weight of sample can be determined (Ingle et al., 2017). This 
method is used for the structural elucidation of organic compounds, for peptide identification 
and for monitoring the presence of previously characterised compounds in mixtures with high 
specificity by defining, at the same time, both molecular weight and a diagnostic fragment of 
the molecule.  
MS has been referred to as the smallest scale in the world as this is a micro-analytical method 
used to selectively detect and determine the amount (~200 Da or less), the elemental 
composition and aspects of the molecular structure of a given component. MS has the 
capacity for direct determination of the nominal mass of an analyte, to produce and detect 
fragments of the molecule that match with distinct groups of atoms of various elements that 
disclose structure characteristics (Grebe and Singh, 2011; Kang, 2012). Mass spectrometers 
provide mass spectra which allow the exploitation of information about the analyte. A mass 
spectrometer produces ions from a specimen, screen the resulting mixture of ions according 
to their mass-to-charge (m/z) ratios, and delivers signals which are measures of relative 
abundance of each occurring ionic species. The principle of MS is to obtain ions from a 
specimen, to separate them according to their m/z ratios (it can be assimilated to the mass as 
most of the ion has usually a single charge), and to detect ions depending on their abundance. 
A mass spectrum of the molecule is then produced as a plot of ion abundance versus mass-to-
charge (m/z) ratio. In mass spectra, the most intense peak or base peak is arbitrarily assigned 
the highest relative abundance of 100% and abundances of all other peaks are given as 
percentage of the base peak abundance ions obtained in MS provide information on the 
nature and structure of their precursor/ formal molecule (Hoffmann and Stroobant, 2007). A 
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typical mass spectrometry apparatus has four components as shown in Figure 2.1, which are 
all under vacuum (low pressure) to allow ions produced to reach the detector without 
unwanted collisions. 
 
 
                                                                 Vacuum System   
                                                              
 
 
 
Figure 2.1. Basic diagram for a mass spectrometer comprising an ion source, an analyser, a detector 
and a data processor.  
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Figure 2.2. Simplified scheme of mass spectrometry (MS) (a) and tandem mass spectrometry (MS-
MS) (b). In MS-MS, after first analyser, analytes are fragmented and fragments analysed in second 
analyser 
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Sample inlet may be coupled to a liquid chromatography system (LC-MS), gas 
chromatography system (GC-MS) or capillary electrophoresis system (Hoffmann and 
Stroobant, 2007). Samples are ionised prior to analysis in the mass spectrometer. Only ions 
can be detected in MS and any particles that are not ionic can move freely from one point to 
another without being detected (Kang, 2012).  
Ionisation is a process whereby an electrically neutral atom or molecule becomes electrically 
charged either by losing or gaining one or more of its extra nuclear electrons. All ions 
(positively or negatively charged atoms, group of atoms or molecules) can be analysed by 
mass spectrometer, although most of apparatus are used to investigate positive ions as there 
are more abundant in most ions sources than negative ions (Kang, 2012).  
Multiple ionisation techniques are described in the literature for mass spectrometry, with 
some very energetic, causing extensive fragmentations and others softer, producing ions of 
the molecular species. Electron ionisation (EI), chemical ionisation (CI) and field ionisation 
(FI) are the most cited for gas-phase ionisation of volatile and thermally stable compounds. 
However, numerous compounds are not thermally stable and non-volatile and must be 
directly extracted from the condensed to the gas phase (Hoffmann and Stroobant, 2007). 
Matrix-assisted laser desorption/ ionisation (MALDI) is the most cited for non-volatile and 
thermally labile compounds, while, electrospray ionisation (ESI) is the preferred strategy of 
ionisation for sample in liquid form. Two types of ions sources exist: liquid-phase ion source 
and solid-state ion sources. In the first one, the analyte is in a solution which is introduced by 
nebulisation, as droplets into the mass spectrometer through vacuum pumping stages. Sources 
including electrospray, atmospheric pressure chemical ionisation and atmospheric pressure 
photoionisation correspond to this type. While, in solid-state sources, the analyte is in a non-
volatile deposit. Sources are obtained through methods involving the introduction of a matrix 
(solid or viscous fluid) which is irradiated by energetic particles or photons that absorb ions 
close to the deposit surface. The resulted ions can then be extracted by an electric field and 
focus towards the analyser. Sources such as matrix-assisted laser desorption, secondary ion 
mass spectrometry, plasma desorption and field desorption use this system to produce ions 
(Hoffmann and Stroobant, 2007).  
EI source is widely used in organic MS as it induces extensive fragmentations, however, the 
molecular ion is not always observed. Although, these fragmentations are useful as it 
provides structural information necessary to elucidate unknown analyte molecules. In this 
	 61	
technique, electron beam is produced by a heated filament of rhenium or tungsten wire at a 
temperature over 1000 k for electrons (e-) emission. The generated e- are accelerated to 70 
eV resulting in an e- beam. Volatile sample or sample in a gaseous phase containing neutral 
molecules is introduced to the ion source in a perpendicular direction to the e- beam. The 
impact of e- on the analyte leads to loss of e-, producing cation M+ or gain of e-, producing 
anion M-.  
CI, in another hand, produces ions with little excess energy which yield to a spectrum with 
less fragmentations and the molecular ions are generally observed. In this technique, the 
reagent gas is ionised due to e- impact. When analyte molecules are injected, they undergo 
many collisions with the reagent gas. In the cloud formed by reagent gas ions, there is a 
reaction leading to adduct ions formation, which are excellent proton donors for analyte. Both 
EI and CI sources are complementary (Hoffmann and Stroobant, 2007).  
MALDI and ESI are soft ionisation techniques which lead to minimum fragmentation of the 
sample. The first one uses matrix (a metal plate where sample is spotted on and dried) which 
absorbs the laser light energy causing a small part of the target substrate to vaporise. As the 
process of forming analyte ions is not clear, it is believed that matrix protonates neutral 
analyte molecules after absorbing laser light energy. The second one, the analyte solution is 
introduced from a syringe pump or as an eluent flow from LC, through the electrospray 
needle that has a high potential difference applied to it, which forces the spraying of charged 
droplets. Solvent evaporation occurs as droplet moves towards counter electrode cone with 
droplets shrinking until it reaches the point that surface tension can no longer sustain the 
charge (the Rayleigh limit) causing droplets break which leads to smaller droplets. This 
process is repeated until all solvent is evaporated and charge passed on to analyte. The 
charged analyte molecules can have single or multiple charges (Hoffmann and Stroobant, 
2007). 
Among the wide variety of possible ionisation, proton transfer is the most common one. 
Usually, when analyte molecules M are introduced in the ionisation plasma, the reagent gas 
ions GH+ can easily transfer a proton to the molecules M and produce protonated molecular 
ions MH+. Almost all neutral substances are able to yield positive ions, whereas negative 
ions require the presence of acidic groups or electronegative elements to produce them. This 
specificity allows some selectivity for their detection in mixtures. Negative ions can be 
produced by capture of thermal electrons by the analyte molecule or by ion-molecule 
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reactions between analyte and ions present in the reagent plasma. Additionally, ion pair 
production is observed with a large variety of electron energies above 15 eV, process which 
principally leads to negative ion production under conventional EI conditions (Hoffmann and 
Stroobant, 2007) 
 
Mass analyser 
Once ions have been produced, they need to be separated according to their mass-to-charge 
ratio (m/z) by a mass analyser. Several types of mass analysers have been developed related 
to the sources and the principle of separation such as Quadrupole (Q) using m/z (trajectory 
stability), Ion trap (IT), Fourier transform ion cyclotron resonance (FTICR) and Fourier 
transform orbitrap (FT-OT), the three using m/z (resonance frequency) and Time-of-flight 
(TOF) using velocity (flight time). They all use static or dynamic electric and magnetic fields 
alone or combined and can be divided into two main classes. The first includes scanning 
analysers which transmit the ions of different masses successively along a time scale. They 
can be magnetic sector apparatus with a flight tube in the magnetic field, allowing only the 
ions of a given mass-to-charge ratio to go through at a given time, or quadrupole instruments. 
The second includes the dispersive magnetic analyser, the TOF mass analyser and the 
trapped-ion mass analyser which allow the simultaneous transmission of all ions. Mass 
analysers can be combined in sequence in order to enhance the strengths of the apparatus and 
allow a large number of experiments to be performed. For instance, triple quadrupole and 
hybrid apparatus including quadrupole TOF instruments or the ion-trap triple quadrupole 
instruments allow the decomposition of an ion selected in the first analyser and generate 
multiple fragments (Hoffmann and Stroobant, 2007). Once ions pass through the mass 
analyser, there are detected and transformed into a signal by a detector capable to generate an 
electric current that is proportional to their abundance. A computer registers the data given by 
mass spectrometer and stores spectra in the library (Hoffmann and Stroobant, 2007). 
In this study, we used Liquid Chromatography combined with tandem Mass spectrometry 
(LC-MS/MS) with reference to known compound libraries and computer matching. This 
method is rapid, simple and sensitive and has several advantages including small sample 
volume, simple sample preparation, good chromatographic resolution, specific and sensitive 
mass spectrometric conditions. LC-MS/MS consists on the fragmentation of charged ions and 
the detection of the resulting fragments. It has thus, much higher selectivity and sensitivity 
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than LC-MS and makes it possible to elucidate metabolite structures. LC-MS is a hyphenated 
technique, combining the physicochemical separation power of liquid chromatography 
HPLC, and the mass analysis with the detection power of mass spectrometry. HPLC is very 
useful in this technique as it allows to remove the interferences from the sample that would 
impact the ionisation (Maheswari et al., 2013). Usually, the sample is ionised in the source of 
ionisation- electrospray ionisation or atmospheric pressure chemical ionisation (ESI or 
APCI), passes into the first mass filter, then into the collision cell, followed by a 2nd mass 
filter, finally to reach the detector (Figure 2.2). In ESI, the solvent-analyte flow from the LC 
passes into the source through a positively charged, very narrow capillary, and gets nebulised 
as microscopic, positively charged solvent-analyte droplets. These droplets fly towards the 
negatively-charged faceplate, with solvent evaporating on the way, until they disintegrate in a 
Coulomb explosion, when the repulsive charge of their ionised components exceeds their 
surface tension. The individual ionised analyte molecules then pass through the faceplate 
entry hole into the mass spectrometer. In APCI, the solvent-analyte stream from the LC is 
vaporised by heated nebuliser gas and the polar components of the solvent (s) vapour are 
ionised by a high-current discharge of a Corona needle. The solvent molecules subsequently 
transfer their charge to ionisable analyte molecules, which pass through the faceplate entry 
hole into the mass spectrometer (Grebe and Singh, 2011). This apparatus allows the user to 
perform, within the instrument’s sensitivity and mass resolution multiple reaction monitoring 
(MRM) (mode of separation) which allows highly specific detection of an analyte with m/Q 
selected in Q1 (first mass filter) that is known to fragment specifically into the product ion 
selected in Q3 (2nd mass filter before detection) (Kang, 2012).  
The raw data processing was enabled by use of Progenesis QI software (NonLinear 
Dynamics, UK). Progenesis QI is a new generation of bioinformatics vehicle targeting small 
molecule discovery analysis for metabolomics. This novel software platform enable to 
perform chromatographic alignment, peak-picking, and mining of metabolomics data to 
quantify and then identify subsequent molecular interactions between groups of samples. The 
software utilises a MetaScope search engine for metabolite identification, search parameters 
to be defined by user to probe both home and open-accessed available databases. The 
interface is easy to use with the possibility to combine information for metabolite 
identification such as accurate mass, retention time, collision cross section and the 
experimental or theoretical fragment ions (Arapitsas and Mattivi, 2018). These properties can 
improve the confidence of metabolites identification while decreasing the number of false 
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positives. This expensive tool is the fastest, more powerful and the most stable on the market 
to date, giving consistent high quality results, and were provided by Mass spectrometry 
centre of Oregon State University. 
We report outcomes of analytical methodologies applied on T. iboga extracts in order to 
measure ibogaine concentrations from the plant extract for further experiments and also for 
the identification of other known or unknown compounds, never reported before for this 
plant. 
 
2.2. Materials and Methods 
 
2.2.1. Plant material and preparation of T. iboga extract for quantitative and qualitative 
analysis 
Root bark of T. iboga was provided by the Institute of Pharmacopoeia and Traditional 
Medicine (IPHAMETRA) in Libreville, Gabon voucher no 20358 deposited at the National 
Herbarium of Gabon.  The barks of T. iboga were collected in Gabonese forest (at Libreville) 
during harvest time by botanists from IPHAMETRA and brought to Oregon (USA) in air-free 
plastic bags to avoid humidification. T. iboga extract for analytical chemistry study was 
prepared according to the method of Sadoon et al., (2014) for optimal extraction result as 
traditional method do use analytical methods. Briefly, root barks chips were ground using a 
coffee grinder to obtain a fine powder. The powder obtained (50 g) was macerated in distilled 
water with magnetic stirring for 24h at room temperature. The slurry was filtered and the 
residue rinsed twice with distilled water. The water extract was adjusted to pH 9 with 
ammonium hydroxide and then extracted five times with 25 mL of chloroform in the fume 
hood. Anhydrous sodium sulphate (50 mg) was added to the combined chloroform extracts 
and the chloroform layer was filtered before drying under vacuum using a rotary evaporator. 
4 g of dry residue was obtained and the different steps are shown in Figure 2.3 below. The 
residue (T. iboga organic extract) was characterised by LC-MS/MS, using the facilities of the 
Mass Spectrometry Centre at Oregon State University, and used for preparing the iboga-
fortified diet for experiments of chapter 5.  
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Figure 2.3. Steps of the preparation of T. iboga extract for chemical characterisation (a) T. 
iboga dried stem barks, (b) Ground powder, (c) Maceration in distilled water, (d) Filtration, 
(e) Chloroform extraction, (f) Chloroform layer separation, (g) Drying by rotavapor (Linus 
Pauling Centre, February 2017, Bayissi Bading-Taïka) 
 
2.2.2. Measurement of ibogaine concentration in T. iboga extract by liquid  
          chromatography tandem mass spectrometry (LC-MS/MS) 
A Shimadzu Prominence HPLC system (Shimadzu, Colombia, MD USA) was used for 
chromatography of the T. iboga extract. Chromatographic separation of ibogaine was 
achieved on an Agilent Poroshell 120 EC-C8 column (2.1 x 50 mm, 2.7 µm) eluted with 
solvent A (water with 0.1% formic acid) and B (acetonitrile with 0.1% formic acid). The 
column effluent was introduced into the electrospray ionisation source of an applied 
Biosystems 4000 QTRAP (Figure 2.4) hybrid linear ion trap-triple quadrupole instrument 
(Sciex, Concord, ON, Canada) operated at a source temperature of 400oC with a needle 
(a) T. iboga dried stem 
barks  
(b) Grounded 
powder  
(c) Maceration in 
distilled water  
(d) Filtration  
(e) Chloroform 
extraction  
(f) Chloroform layer  
     separation  
(g) Drying by 
rotavapor 
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voltage of 5 kV in the positive ion mode. Ibogaine was detected using multiple reaction 
monitoring (MRM), using mass to charge ratio (m/z) 311.4 > 174.1 as the qualifier transition 
and m/z 311.4 > 122.1 as the quantifier transition. The concentration of ibogaine in the bark 
extract was determined by external calibration method using a standard of ibogaine obtained 
from Cambridge Chemicals (Woburn, Massachussetts, USA). 
 
  
 
Figure 2.4.  4000 Q Trap hybrid (linear ion-trap triple quadrupole instrument (Mass 
Spectrometry Center, Oregon, April 2017, Bayissi Bading-Taïka) 
 
 
	 67	
 
 
Figure 2.5. Standard curve of pure ibogaine 
 
2.2.3. LC-MS detection of other phytochemicals in T. iboga root bark. 
Pieces of iboga root bark were ground to a fine powder by using a coffee grinder. Ten 
milligrams of bark powder were extracted with 10 mL of 70 % aqueous methanol (v/v) by 
sonication for 30 min at 25 ºC. After sonication, the extract was centrifuged at 15,000 rpm for 
10 min. Other phytochemicals from T. iboga were investigated by chromatographic 
separation, conducted using a Shimadzu Nexera UPLC system equipped with an Inertsil 
Phenyl-3 column (150 × 4.6 mm, 5 µm). The injection volume was 10 µl. Mobile phase A 
was water with 0.1 % formic acid, and mobile phase B was methanol with 0.1% formic acid. 
The gradient started with 5% B and was held for 1 min at 5% B, followed by a 10-min linear 
gradient from 5% to 30 % B. The gradient was increased linearly to 100% B at 20 min, held 
for 10 min at 100% B and, finally, stepped back to 5% B to equilibrate the column. The flow 
rate was 0.4 mL min-1, with the auto-sampler set at 10 ºC, and the column temperature was 
maintained at 50 ºC. The column effluent was introduced into a QToF mass spectrometer 
(AB Sciex Triple TOF 5600) equipped with a TurboSpray electrospray ionization source 
operated in the negative and positive ionization modes. The instrument was operated in the 
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information-dependent acquisition (IDA) mode using a collision energy of 35 V. For analysis 
of phenolic compounds, compound identification was based on accurate mass, isotopic 
similarity, retention time and MS/MS spectral comparison with authentic compounds. A 
targeted analysis was performed for 1,3-di-O-caffeoylquinic acid, 1,5-di-O-caffeoylquinic 
acid, 3,4-di-O-caffeoylquinic acid, 3,5-di-O-caffeoylquinic acid, 3-O-caffeoylquinic acid, 
4,5-di-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, caffeic acid, 
catechin, dihydrocaffeic acid, dihydroferulic acid, dihydroisoferulic acid, epicatechin, 
epigallocatechin, ferulic acid, isoferulic acid, kaempferol, naringin, quercetin and rutin. An 
external calibration curve was prepared for all precursor ions (Calibration points: 0.05, 0.1, 
0.5, 1.0, 5.0 mg L-1, R values > 0. 995). 
 
2.2.4. Qualitative analysis of T. iboga extract (untargeted compounds) 
For qualitative (untargeted) analysis, LC-MS/MS data were acquired on the AB Sciex Triple 
TOF 5600 system using the same chromatographic separation. In order to detect alkaloids as 
protonated molecular species, MS acquisition was performed in the positive ionisation mode. 
Raw data were processed by using Progenesis QI software (NonLinear Dynamics, Newcastle 
upon Tyne, UK). Progenesis QI is a bioinformatics tool for small molecule discovery and 
analysis. Over 6,300 raw mass spectra were collected. Molecules were assigned by extensive 
querying and comparison of molecular features, namely accurate mass-to-charge ration (m/z), 
MS/MS fragmentation patter, and isotopic similarity, against MetlinTM MS/MS, HMDB 
(Wishart et al., 2018), KEGG and KnapSack data bases. In the Progenesis QI workflow, we 
considered a confidence score higher than 50 sufficient for assignment of constituents in T. 
iboga extract. A score higher than 50 for a putative compound is reached when the deviation 
of the accurate mass from the extract mass is lower than 5 ppm combined with an isotopic 
pattern similarly > 90%. 
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2.3. Results 
 
2.3.1. Estimation of ibogaine and total alkaloid concentration in T. iboga extract 
Figure 2.6 below, shows the LC-MS/MS chromatograms of the ibogaine standard and 
ibogaine content in the bark aqueous extract of T. iboga. Different solvents (acid, alcohol and 
water) were used for extraction (Table 2.1 and 2.3) and allowed the determination of ibogaine 
concentration in the samples (Table 2.2). The analyte peaks of ibogaine detection from 
samples of acid/water extract diluted 105 and 104 times with acetonitrile are recorded on 
Table 2.1.  
 
 
Figure 2.6. LC-MS/MS chromatograms of ibogaine. (A) 10 nM ibogaine standard. (B) 
ibogaine in root bark extracts. (C) Multiple reaction monitoring (MRM) transitions: m/z 
311.4 > 174.1 (qualifier MRM), m/z 311.4 > 122.1 (quantifier MRM) 
 
Plant extract was dissolved in 1ml of chloroform and then diluted 105 times with acetonitrile: 
water ratio 1:1. 
- Sample 1 (S1) contained 21 x 105 (nM) of ibogaine in 1 ml solution, thus 21 µmol of 
ibogaine in 100 mg of plant powder.  
This 2.1 µmol x 310 µg/ µmol (MW of pure ibogaine) gave 651 µg of ibogaine in S1. 
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- Sample 2 (S2) contained 20.5 x 105 (nM) of ibogaine in 1 ml solution, thus 2 µmol of 
ibogaine in 100 mg of plant powder. 
This 2 µmol x 310 µg/ µmol gave 620 µg of ibogaine 
- Sample 3 (S3) contained 26.5 x 105 (nM) in 1 ml, thus 2.6 µmol of ibogaine in 100 mg of 
plant powder. 
This 2.6 µmol x 310 µg/ µmol gave 806 µg of ibogaine. 
Ibogaine detection from ethanol and water extracts is reported in table 5. Dilution factor was 
x105 (with acetonitrile: water = 1:1, v/v). Plant extract was dissolved in 1ml chloroform and 
then diluted 105 times. We did not consider extraction efficiency thus, 312 x 105 (nM) in 1 ml 
solution gave 31.2 µmol of ibogaine in 500 mg of plant powder. Then, 31.2 µmol x 310 µg / 
µmol (MW of ibogaine) gave 9.67 mg of ibogaine in 500 mg of plant powder extracted with 
H2O. 
 
Table 2.1. Ibogaine content in T. iboga extracts (HCL/H2O extracts) (m/z 311.4 >174.1 and 
m/z 311.4 >122.1) 
Samples Name Analyte Peak Area (counts) Analyte Peak Height (cps) 
std 100 pM 3.17 x 102  1.46 x 102 
std 100 pM 1.81 x 102 1.02 x 102 
std 1nM 1.83 x 103 5.41 x 102 
std 1nM 1.15 x 103 3.74 x 102 
std 10 nM 1.87 x 104 5.51 x 103 
std 10 nM 9.89 x 103 2.84 x 103 
std 100 nM 1.77 x 105 4.74 x 104 
std 100 nM 9.70 x 104 2.68 x 104 
std 200 nM 3.54 x 105 9.01 x 104 
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std 200 nM 1.94 x 105 4.82 x 104 
std 500 nM 7.66 x 105 1.84 x 105 
std 500 nM 4.20 x 105 1.02 x 105 
std 1 µM 1.39 x 106 3.21 x 105 
std 1 µM 7.43 x 105 1.67 x 105 
HCL/H2O (diluted 
x105) 
5.67 x 105 1.31 x 105 
HCL/H2O (diluted 
x105) 
3.01 x 105 7.09 x 104 
s1 105 2.99 x 104 8.05 x 103 
s1 105 1.61 x 104 4.28 x 103 
s2 105 2.93 x 104 8.33 x 103 
s2 105 1.55 x 104 4.02 x 103 
s3 105 3.79 x 104 9.73 x 103 
s3 105 2.00 x 104 5.10 x 103 
s1 104 2.84 x 105 7.05 x 104 
s1 104 1.52 x 105 3.72 x 104 
s2 104 2.79 x 105 7.02 x 104 
s2 104 1.50 x 105 3.55 x 104 
s3 104 3.43 x 105 8.63 x 104 
s3 104 1.90 x 105 4.59 x 104 
 
Extraction of 500 mg of iboga powder using acid/water solvent lead a better yield of ibogaine 
content (9.67 mg/ml for 500 mg of iboga powder) than extraction with ethanol/water (2.20 
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mg/ml for 500 mg of iboga powder) or with water only (0.7 mg/ml for 100 mg of iboga 
powder, which would take to 3.5 mg/ml for 500 mg of iboga powder considering optimal 
yield). The powdered root bark of iboga (100 mg) contained 1.93 % ibogaine (w:w). 
 
Table 2.2. Ibogaine concentrations in T. iboga extracts (HCL/H2O extracts) 
Samples (diluted x105)  Area (cps)  Concentration (nM) 
s1  2.99 x 104 20.9 
s2  2.93 x 104 20.5 
s3 3.79 x 104 26.5 
 
 
Table 2.3. Ibogaine content in T. iboga extracts (EtOH/ H2O, H2O extracts) (m/z 311.4>174.1 
and m/z 311.4>122.1) 
Sample Name Analyte Peak Area 
(counts) 
Analyte Peak Height (cps) 
std 100 pM 1.49 x 103 3.82 x 102 
std 1 nM 3.09 x 103 9.36 x 102 
std 10 nM 1.83 x 104 5.05 x 103 
std 100 nM 1.94 x 105 4.73 x 104 
std 200 nM 4.31 x 105 9.12 x 104 
std 500 nM 9.90 x 105 2.19 x 105 
std 1 µM 1.61 x 106 3.40 x 105 
EtOH H2O (diluted x105) 1.46 x 105 3.22 x 104 
EtOH H2O (diluted x104) 1.10 x 106 2.36 x 105 
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H2O (diluted x105) 6.25 x 105 1.37 x 105 
H2O (diluted x104) 3.83 x 106 7.55 x 105 
 
Table 2.4. Ibogaine concentrations from different extracts 
Samples Ibogaine concentration (mg/mL) 
EtOH/H2O (diluted x 105 - 500 mg of 
plant) 
2.20 
HCL/H2O (diluted x 105 - 500 mg of 
plant) 
9.67 
H2O (diluted x 105 - 100 mg of plant) 0.7 
H2O (diluted x 106 - 50 g of plant) 8.39 
 
2.3.2 Analysis of T. iboga extract by mass spectrometry (MS) 
Analysis of over 6,300 mass spectra recorded in the positive ionisation mode revealed 38 
compound identifications with high confidence using Progenesis QI software (score > 50, 
Table 2.5). Among them,30 compounds are alkaloids previously reported in plants (Afendi et 
al., 2012; Kanehisa et al., 2017; Smith et al., 2005) (MetlinTM, HMDB, KEGG or 
KnapSack, table), with ibogaine as the major alkaloid (Figure 2.6 A-C). 
Further analysis of 70 % aqueous methanol extract by negative ion mass spectrometry using 
several standards, showed the presence of five phenolic compounds, including 3-O-
caffeoylquinic acid (Table 2.5, Figure 2.8). 
The calculated amount of the 3-O-caffeoylquinic acid was 0.97 mg/g in 100 mg of plant root 
barks.  
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Table 2.5. Phytochemicals detected in T. iboga root barks. Compounds detected in the 
positive electrospray ionization (ESI) mode were assigned using Progenesis QI (score>50). 
For compounds detected by negative ESI-MS, identity was assigned based on comparison of 
m/z, retention time and MS/MS spectra comparison with authentic standards (1Afendi et al., 
2012; 2Bartlett et al., 1957; 3Harborne and Baxter, 1999; 4Taylor, 1968). 
Alkaloid m/z R.T 
(min) 
Detected 
Adducts 
Formula Composition %a 
Alkaloids, positive ESI 
Ibogaine1-3 311.2115 21.63 [M+H]+ C20H26N2O 24.60 
Iboxygaine4 327.2063 21.46 [M+H]+ C20H26N2O2 11.00 
Ibogaline4 341.2220 21.39 [M+H]+ C21H28N2O2 10.77 
Alloibogaine 325.1908 22.01 [M+H]+ C20H24N2O2 8.21 
Catharanthine4 337.1912 22.77 [M+H]+ C21H24N2O2 5.69 
Ibogamine1-3 281.2010 21.58 [M+H]+ C19H24N2 3.37 
Noribogaine 297.1958 20.66 [M+H]+ C19H24N2O 2.76 
Voacangine1-3 369.2167 21.82 [M+H]+ C22H28N2O3 1.87 
Yohimbine 355.2013 19.89 [M+H]+ C21H26N2O3 1.81 
Hydroxy-ibogamine 
(isomer of noribogaine) 
297.1958 21.41 [M+H]+ C19H24N2O 1.79 
Quinidine 325.1912 18.64 [M+H]+ C20H24N2O2 1.01 
Coronaridine1-3 339.2054 22.86 [M+H]+ C21H26N2O2 0.97 
11-O-demethyl-17-O-
deacetylvindoline 
383.1965 18.18 [M+H-
H2O]+ 
C22H28N2O5 0.86 
Affinisine 309.1959 20.47 [M+H]+ C20H24N2O 0.84 
17-O-
acetylnorajmaline 
355.2015 23.68 [M+H]+ C21H26N2O3 0.55 
Affinine 325.1908 23.55 [M+H]+ C20H24N2O2 0.43 
Rhazidigenine N-oxide 315.2063 19.49 [M+H]+ C19H26N2O2 0.40 
1,2-Dihydrovomilenine 353.1858 23.95 [M+H]+ C21H24N2O3 0.23 
11-Hydroxyyohimbine 371.1958 20.03 [M+H]+ C21H26N2O4 0.20 
16-Methoxytabersonine 367.2010 22.43 [M+H]+ C22H26N2O3 0.19 
N4-demethylechitamine 371.1959 21.72 [M+H]+ C21H26N2O4 0.19 
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Quinine-N-Oxide 341.1855 19.42 [M+H]+ C20H24N2O3 0.18 
Iboluteine 327.2052 23.21 [M+H]+ C20H26N2O2 0.08 
Strictosidine aglycone 369.1808 22.68 [M+H]+ C21H24N2O4 0.08 
Aspidodasycarpine 353.1859 23.54 [M+H-
H2O]+ 
C21H26N2O4 0.05 
Reserpic acid 401.2069 20.48 [M+H]+ C22H28N2O5 0.03 
Ajmaline 327.2061 29.40 [M+H]+ C20H26N2O2 0.02 
Jerantinine B 399.1909 19.11 [M+H]+ C22H26N2O5 0.02 
Vinervine 321.1596 24.46 [M+H-
H2O]+ 
C20H22N2O3 0.01 
Ellipticine 247.1222 25.46 [M+H]+ C17H14N2 0.01 
Unknown alkaloids 
(48)b 
N/A N/A [M+H]+ N/A 21.77 
 
Polyphenols and other compounds, positive ESI 
4-Guanidinobutanoic 
acid 
146.0918 6.13 [M+H]+ C5H11N3O2 N/A 
Betaine 118.0859 4.52 [M+H]+ C5H11NO2 N/A 
Catechin 291.0859 13.76 [M+H]+, 
M+Na]+ 
C15H14O6 N/A 
Choline 104.1071 6.48 [M+H]+ C5H13NO N/A 
Epicatechin 291.0861 15.97 [M+H]+, 
[M+Na]+ 
C15H14O6 N/A 
Glutamate 148.0599 4.59 [M+H]+ C5H9NO4 N/A 
Indoleacetaldehyde 177.1015 10.27 [M+H] C10H9NO N/A 
Phosphocholine 184.0728 5.29 [M+H]+ C5H14NO4P N/A 
 
Phenolic compounds, negative ESI 
5-O-Caffeoylquinic 
acid 
353.0461         11.86 [M-H]- C16H18O9 <LOQc 
1,3-Di-O-caffeoylquinic 
acid 
515.1217 N/A [M-H]- C25H24O12 <LODd 
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1,5-Di-O-caffeoylquinic 
acid 
515.1210 N/A [M-H]- C25H24O12 <LOD 
3,4-Di-O-caffeoylquinic 
acid 
515.1207 N/A [M-H]- C25H24O12 <LOD 
3,5-Di-O-caffeoylquinic 
acid 
515.1208 N/A [M-H]- C25H24O12 <LOD 
3-O-Caffeoylquinic 
acid 
353.0409 15.28 [M-H]- C16H18O9 0.97±.015 
mg/g bark 
4,5-Di-O-caffeoylquinic 
acid 
515.1210 N/A [M-H]- C25H24O12 <LOD 
4-O-Caffeoylquinic 
acid 
353.0508 N/A [M-H]- C16H18O9 <LOD 
Caffeic acid 179.0346 N/A [M-H]- C9H8O4 <LOD 
Catechin 289.0729 N/A [M-H]- C15H14O6 <LOD 
Dihydrocaffeic acid 181.0497 N/A [M-H]- C9H10O4 <LOD 
Dihydroferulic acid 195.0651 N/A [M-H]- C27H30O16 <LOD 
Epicatechin 289.0707 N/A [M-H]- C15H14O6 <LOD 
Epigallocatechin 305.0668 N/A [M-H]- C15H14O7 <LOD 
Ferulic acid 193.0497 19.6 [M-H]- C10H10O4 <LOQ 
Iso Ferulic acid 193.0499 N/A [M-H]- C10H10O4 <LOD 
Kaempferol 285.0405 21.95 [M-H]- C15H10O6 <LOQ 
Naringin 579.1718 N/A [M-H]- C27H32O14 <LOD 
Quercetin 301.0345 21.08 [M-H]- C15H10O7 <LOQ 
Rutin 609.1502 19.01 [M-H]- C27H30O16 <LOQ 
 
a Assuming comparable detector responses for detected alkaloids, all which contain two 
nitrogen atoms indicative of indole alkaloids. 
b Compounds with a mass defect ranging from 0.1939 to 0.2100. 
c LOQ Calibration quantification limit evaluated as S/N ratio 10:1; LOQ > 3.3 µg L-1 
d LOD- Calibration detection limit evaluated as S/N ratio 3:1; LOD > 1.0 µg L-1 
<LOD not detected; <LOQ detected below LOQ 
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2.3.3 Mass defect analysis 
Alkaloids are suitable for LC-MS analysis in positive ionisation due to nitrogen presence in 
their structure. Filtering of data based on mass defect is a useful post-acquisition data 
processing technique for distinguishing metabolites and chemical components in traditional 
medicines (Xie et al., 2012), and allowing the classification of chromatographic peaks in 
chemical families on the mass acquired in high resolution. To screen T. iboga alkaloids, we 
used as reference the mass defect range obtained from the monoisotopic neutral mass of 
previously reported alkaloids in T. iboga (Afendi et al., 2012; Barlett et al., 1958; Harborne 
et al., 1999). The absolute mass defect or mass excess of alkaloids varied from 0.1939 to 
0.2100. Major alkaloids reported in KnapSack database (Afendi et al., 2012) for T. iboga 
possess a mass defect in the range of 0.201 to 0.212 (Harborne, 1999). In this experiment, we 
achieved 5 ppm or better as accurate mass, thus, we used a screening range from 0.1900 to 
0.2190 (Figure 2.7).  
 
 
	 78	
 
Figure 2.7. LC-HRMS/MS analysis of T. iboga extract in positive ionisation mode (1 mgmL-
1 of dry mass re-suspended in 70% aqueous ethanol). A. Molecular features detected in T. 
iboga extract with a mass defect in a range from 0.1900 to 0.2190. The size of the circles 
corresponds to the magnitude of the chromatographic peak area of a particular feature; the 
largest circle represents ibogaine. B. [M+H+] extracted ion chromatograms (XIC) of indole 
alkaloids. C. Fragmentation spectrum and proposed dissociation of ibogaine.  
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Figure 2.8. LC-HRMS/MS analysis of T. iboga root bark extract. A. extracted ion 
chromatogram [M-H]+ m/z 353.09, 10 µL injection. Black line- 1 mg L-1 of standards 3-O-
caffeyolquinic acid (3-O-CQA) and 4-O-caffeylquinic acid (4-O-CQA). Blue line- 1 mg mL-1 
of bark extract, both re-suspended in 70% aqueous methanol. B. Fragmentation spectrum of 
3-O-CQA detected in T. iboga extract. C. Fragmentation spectrum of 3-O-CQA standard 
(1mg L-1). 
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2.4. Discussion 
T. iboga is a plant belonging to the Apocynaceae family (Bading-Taika et al., 2018), rich in 
indole alkaloids which are low molecular weight compounds containing nitrogen (Dewick, 
2009). We extracted alkaloids from the powdered T. iboga root barks using extraction 
method as close as possible to the method used by traditional practitioners in Gabon. 
Therefore, water extraction which was not the most efficient method (ibogaine content of 
1.93% vs 7.2% reported by Mazoyer et al., 2013) was selected for further experiments in our 
project. We estimated the total alkaloid content of the bark to be 7.8% (Table 2.2). This 
number is higher than the 5-6% indole alkaloids in the root barks previously reported by 
Delourne-Houdé, 1948; Marion, 1952 and Dewick, 2002. However, this number is lower than 
the alkaloid content of powdered T. iboga root (7.2% ibogaine, 0.6% ibogamine) previously 
reported by Mazoyer et al. (2013). This discrepancy may be related to the techniques used for 
the extraction. Organic extraction was performed in that study, and it is the more used for 
complex molecules such as ibogaine (Mazoyer et al., 2013; Dewick, 2009). 
The chromatographic peak area of ibogaine comprised 24.6% of the total area of 
chromatographic peaks assigned to known and unknown alkaloids based on their common 
mass defect. Data are in accord with those reported by Kontrimaviciute et al., 2006.  Only 
seven alkaloids have been previously reported for T. iboga (Table 2.5) which are ibogaine, 
iboxygaine, ibogaline, alloibogaine, catharanthine, ibogamine and noribogaine (and its 
isomer hydroxy-ibogamine (Taylor, 1968; Alper, 2001; Gaignault and Delourme-Houdé, 
1977; Bowen, 2001), all of which we identified by the plant metabolomics approach at the 
Mass Spectrometry Centre of Oregon State University (OSU, Table 2.5). Moreover, we 
tentatively (fingerprinting using libraries and data comparison) assigned 23 other alkaloids 
not previously reported for T. iboga but reported for other plants species including plants 
belonging to Apocynaceae family (Table 2.5), such as Voacanga africana, Ervatamia 
coronaria Stapf, and Vinca roseus Linn (Taylor, 1968). Unfortunately, as plant metabolome 
constitute heterogeneous group of molecules with complex physicochemical properties and 
wide fluctuation in concentration ranges, it is currently impossible to extract and analyse all 
metabolites of plant in single analysis. The currently characterised plant metabolites represent 
only a small fraction of the whole metabolome (Tugizimana et al., 2013).   
To the best of our knowledge, numerous of these ibogaine congeners possess biological 
properties such as voacangine, that is a small molecule largely occurring in Voacanga 
africana was reported to inhibits angiogenesis in vitro and in vivo (Kim et al., 2012).  
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Yohimbine from Rauwolfia root bark may induce impulsivity and reinstate seeking of various 
drugs through κ opioids receptors (Funk et al., 2019; Stavrinides et al., 2015). Hydroxyl-
ibogamine and coronaridine showed anti-addictive and anti-tumour properties (Arias et al., 
2011; Arias et al., 2017). Quinidine has been identified as an effective agent for both atrial 
and ventricular arrhythmias in patient with Brugada syndrome (Halperin et al., 2018; Yang et 
al., 2009; Stavrinides et al., 2015). Affine and affinisine might be chemotherapeutic for 
melanoma cells (Rosales et al., 2019; Yang et al., 2010). The 1,2-hihydrovomilenine, 
ajmaline, reserpic acid and strictosidine aglycone from Rauwolfia species might also be anti-
arrhythmic (Von Schumann et al., 2002; Stavrinides et al., 2015). Ellipticine quinone has 
shown anti-proliferative activity in cell lines (Nishiyama et al., 2017). Aspidocarpine from 
Aspidosperma cuspa (Kunth) Blake has shown anti-nociceptive activity that may be mediated 
through opioid receptors (Pérez et al., 2012). Jerantinine B isolated from Tabernaemontana 
corymbosa has shown potential as chemotherapeutic agent (Qazzaz et al., 2016), and 
ellipticine exhibited anticancer properties due to its size, shape and planarity (Zsila and 
Samsonov, 2018). Anti-addictive, anticancer and anti-HIV properties have been widely 
reported for T. iboga (Bading Taika et al., 2018; Souza et al., 2011). 
For the first time, phenolic compounds are cited for T. iboga in chemistry analytical reports. 
The amount of 3-O-caffeoylquinic acid (3-CQA) in T. iboga root bark, extracted with 70% of 
aqueous methanol, was 0.97 mg/g of powdered root barks. 3-O-CQA, also called chlorogenic 
acid (CGA) is a bioactive natural phenolic compound found in food. CGA is formed by 
esterification of trans-cinnamic acids such as caffeic, coumaric and feluric acid, with (-)- 
quinic acid. It contains a group major of isomers including 3-CQA, 4-O-caffeoylquinic acid 
(4-CQA), and 5-O-caffeoylquinic acid (5-CQA) (Bagdas et al., 2015). Several 
pharmacological properties of CGA have been reported including antioxidant, free radical 
scavenging, anti-inflammatory, radio protective, anti-tumour, anti ulcerogenic, and analgesic 
activities (Bagdas et al., 2015; Jabeur et al., 2016).  
Thus here, we revealed known and unknown compounds of T. iboga aqueous extract 
including alkaloids and chlorogenic acid that may support anti-diabetic potential activity 
investigated in rat pancreatic islets in the next chapter. 
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C h a p t e r  3 :  I n  v i t r o  i nve s t i g a t i o n s  i n t o  t h e  e f f e c t s  o f  a q u e o u s   
                ex t rac t s  f rom T.  i boga  and  G .  t e s s m a n n i i  on  g lucose -  
                s t i m u l a t e d  i n s u l i n  r e l e a s e  f r o m  i s o la t ed  ra t  pancrea t i c   
                i s l e t s   
 
3.1. Introduction 
T. iboga or “iboga” belonging the Apocynaceae family is one of the most widely used 
medicinal plants in Gabon due to religious beliefs. It is believed to help contact with 
ancestors and develop mind in Gabonese religious ritual such as ‘Bwiti’, when large amounts 
are chewed and consumed as doses from 100 mg to 1g of ibogaine cause trance-like visual 
and auditory hallucinations (Mazoyer et al., 2013). However, small amounts are ingested to 
offset hunger and fatigue (Souza et al., 2011; Chèze et al., 2008). T. iboga is used 
traditionally for numerous medicinal purposes including drugs addiction, HIV1, 
psychological troubles, and as spasmolytic (Bading-Taika et al., 2018). Ethnobotanical 
surveys conducted in the province of Estuaire (Gabon) show that many healers use T. iboga 
for the treatment of many diseases, including diabetes (Tjeck et al., 2017). 
Previous in vitro studies of T. iboga aqueous extract have demonstrated its sulfonylureas-like 
action on insulin release. Indeed, T. iboga aqueous extracts (1 µg/mL) potentiated the 
stimulation of insulin secretion at glucose stimulatory concentrations (11.1 and 16.7 mM) in 
vitro via the closure of K+-ATP channels and the increase of Ca2+ influx in rat pancreatic ß-
cells which triggered glucose-induced insulin release, in the same way of tolbutamide (Souza 
et al., 2011). 
G. tessmannii is another widely used medicinal plant for the treatment of diabetes 
complications in Gabon and has been largely linked to antioxidant activity (Bading Taïka et 
al., 2018; Nyangono Beyegue et al., 2012). Several phytochemical bioactive compounds 
have been identified, sterols, alkaloids, flavonoids, tannins, polyphenols, sugars and 
saponides (Koumba Madingou et al., 2012; Nyangono Beyegue et al., 2012) and G. 
tessmannii has been shown to restore functional status of liver (hepatic AST and ALT levels) 
and decrease glucose levels supporting its anti-diabetic potential (hypoglycaemic effect) of 
the plant extract (Koumba Madingou et al., 2016). Few studies on pharmacological activities 
of G. tessmannii have been carried out, except for antioxidant activity (Nyangono Beyegue et 
al., 2012). 
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In chapter 2, we identified novel phytochemical constituents with anti-diabetic potential in T. 
iboga. The main constituent is ibogaine which pharmacological activity is mediated by 
numerous classes of neurological receptors and transporters, including the σ2, κ and µ opioid 
receptors, 5HT2 and 5HT3 receptors, α, ß4 nicotinic receptors, and N-methyl-D-aspartic acid 
(NMDA) ion channel (Paškulin et al., 2006). However, few studies of in vitro anti-diabetic 
property and mechanism of action have been reported for T. iboga and ibogaine. Despite the 
in vitro anti-diabetic efficacy data with T. iboga and ibogaine no in vivo efficacy in animal 
models or patients have yet been reported. Moreover, numerous safety studies raised 
concerns including neurotoxicity and cardiotoxicity which have been observed in animal and 
human studies using ibogaine (Mačiulatis et al., 2008). 
 
σ2 receptors and insulin release 
 
Two major subclasses of σ receptors have been documented, σ 1 and σ 2 receptors are 
different on their pharmacological profile, function and molecular size; σ1 receptors are 25 
kDa whereas σ2 receptors are 18-21.5 kDa in size (Bowen, 2001). 
σ receptors are widely distributed throughout the brain, endocrine, immune and reproductive 
tissues, including ß pancreatic islets, kidney and liver organs (Bowen, 2001). Furthermore, 
both subtypes of σ receptors are found to be highly expressed in tumour cell lines derived 
from numerous tissues including neuroblastomas, glioma, melanoma, carcinoma cell lines of 
breast, prostate, lungs, and pancreas (Bowen, 2001; Kashiwagi et al., 2009). No endogenous 
functional ligand for σ receptors has been convincingly identified, however, certain steroids 
may be endogenous ligands for σ receptors such as progesterone (Rybczynska et al., 2009). 
The functions of σ1 receptors in the brain have been involved in the modulation of the 
synthesis and release of dopamine and acetylcholine (Sambo et al., 2018) as well as the 
modulation of NMDA-type glutamatergic receptor electrophysiology (Gonzalez-Alvear and 
Werling, 1995) and modulation of NMDA-stimulated neurotransmitter release (Zamanillo et 
al., 2013). There is no evidence supporting T. iboga constituents as σ1 ligands, although σ1 
modulation could explain, in part, some of the central actions of T. iboga (addiction, fatigue). 
However, less is known about the function of σ2 receptors in the brain. Chronic activation of 
σ2 receptors leads to morphological changes and cell death by apoptosis (Bowen, 2001). It is 
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well established that Ca2+ plays a role in cytotoxicity and that alterations in cell Ca2+ levels 
induce apoptosis in various cell types (Bowen, 2001). σ receptors ligands such as CB-64D, 
produce two types of increases in cell (cytosolic) Ca2+ concentration ([Ca2+]i). Mediation of 
the effect on [Ca2+]i by σ2 receptors was demonstrated by the high activity of the selective σ2 
receptors against CB-64D (Bowen, 2001), which induced an immediate, dose-dependent, and 
transient rise in [Ca2+]i (reversible action). As this transient rise in [Ca2+]i occurred in the 
absence of extracellular Ca2+ (pre-treatment by thapsigargin), it has been shown that σ2 
receptors stimulate a transient release of Ca2+ from endoplasmic reticulum stores. However, 
prolonged exposure of cells to σ2 receptors ligands lead to a latent and sustainable rise in 
[Ca2+]i, not altered by removal of extracellular Ca2+ or thapsigargin treatment, indicating the 
release of Ca2+ from mitochondrial stores or from other Ca2+ stores as Golgi apparatus 
(Bowen, 2001). Moreover, recent study has shown that under diabetes conditions, high blood 
glucose levels and decreased insulin levels (STZ-induced T1D in mouse), Ca2+ homeostasis 
was disrupted and intracellular Ca2+ levels altered, which may induce cell death through 
depletion of Ca2+ from endoplasmic reticulum (ER) and ER stress (Ahn et al., 2015).    
Ibogaine alkaloids have been found to induce a rise in [Ca2+]i by selective interaction with σ2 
receptors and induced morphological changes and apoptosis in neuroblastoma and glioma 
cells (Bowen, 2001). Ibogaine and related iboga alkaloids including 10-t-Butoxy-ibogamine 
act as σ2 receptor agonists to gate Ca2+ ions from cytoplasmic reticulum towards cytosol 
(Bowen, 2001). However, it has been shown that in the absence of extracellular Ca2+, iboga 
alkaloids failed to induce intracellular Ca2+ release (Souza et al., 2011), in contrast with 
previous findings and expectations (Bowen, 2001). Although numerous σ2 receptor agonists 
have been documented, there are few selective pharmacological antagonists for this subtype. 
SM-21 (3 alpha-tropanyl-2-(4-chorophenoxy)-butyrate has been reported to possess high 
preferential affinity in mice and rat brain (nearly 10-fold preferential affinity compared to σ1 
receptor) for σ2 receptors, and acts as a potent and selective σ2 receptor antagonist 
(Ghelardini and Bartoloni, 2000; Matsumoto and Mack, 2001; Matsumoto et al., 2007). 
In this chapter, we have investigated the effects of two plants aqueous extracts, T. iboga and 
G. tessmannii, on glucose stimulated insulin secretion from isolated rat pancreatic islets, in 
order to assess their potential therapeutic actions and elucidate the anti-diabetic mechanism 
of action in vitro via σ2 receptors prior to further investigations in vivo (chapters 4 and 5). 
Furthermore, we aimed to develop an assay which will provide viable islets, as pancreatic 
cells are extremely vulnerable to oxidative stress even in healthy conditions due to their lack 
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of strong antioxidant system (Miceli et al., 2018). Hyperglycaemia (exposure to high 
glucose > 16.7 mM) and other metabolic or mechanical alterations of pancreatic cells may 
lead to increase of oxidative stress, thus enhanced NO production, leading to cellular damage 
and ultimately resulting to cell death and its associated complications (Adela et al., 2015; 
Miceli et al., 2018). We investigated whether the insulin potentiating concentrations of 
aqueous extracts of T. iboga and G. tessmannii and low and high glucose exposure induces 
changes in NO production in isolated rat pancreatic islets. 
 
3.2. Materials and methods  
 
3.2.1. Plant material and preparation of T. iboga and G. tessmannii aqueous extracts 
The plants were prepared according to the traditionally recommended method for oral 
administration, in chemistry laboratory at the University of Hertfordshire. The barks of T. 
iboga and G. tessmannii were collected in Gabonese forest (at Libreville) during harvest time 
by botanists from IPHAMETRA, authenticated, a voucher specimens have been identified 
and deposited at the National Herbarium of Gabon and brought to London in air-free plastic 
bags to avoid humidification.  
In short, G. tessmannii stem barks were collected from Mandji forest by botanists, 
authenticated at the National Herbarium of Gabon (voucher no 16067), grounded into fine 
pounder using a traditional grounder at IPHAMETRA institute. The aqueous extract was 
obtained after maceration of the dried barks fine powder (100 g) in distilled water (500 mL) 
for 96 hours and under magnetic stirrer (500 rpm) and at room temperature at the University 
of Hertfordshire chemistry laboratory. The aqueous extract was filtered with Whatman paper 
number 1 and freeze-dried in a lyophilisator.  
Similarly, T. iboga root barks were collected by botanist from IPHAMETRA at Lambaréné 
forest where the plant grows near the sand and have bigger roots. The plant was authenticated 
at the National Herbarium of Gabon (voucher no 20358), the root barks were grounded in a 
traditional big grounder to obtain a fine powder. The powder of the root barks (75 g) was 
macerated for 24 hours first in n-hexane (500 mL), under magnetic stirrer and at room 
temperature at the University of Hertfordshire chemistry laboratory. The solid material 
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obtained was then macerated with distilled water (500 mL) at room temperature and under 
magnetic stirrer for another 24 hours. The macerate obtained was filtered using cotton and 
Whatman number 1 filter paper placed in a Buchner funnel, and freeze-dried in a 
lyophilisator. Both powders were stored at room temperature in a desiccator to avoid 
humidity as shown in Figure 3.1 below.  
                       
 
Figure 3.1. T. iboga: from the root barks to the aqueous extract powder  
                 (a) air-dried root barks; (b) grounded fine powder; (c) maceration under magnetic   
                 stirrer; (d) filtration; (e) freeze-drying; (f) aqueous extract stored in desiccator. Iphone 7+       
                 camera (Bayissi Bading-Taïka, 2014)   
(a) air-dried root barks (b) grounded fine powder (c) maceration under magnetic stirrer 
(d) filtration (e) freeze-drying (f) aqueous extract in dessicator 
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3.2.2. Animals and environment 
Male Wistar rats were used in this chapter (source Charles River) with baseline body weights 
350 g (10 weeks of age). Animals were housed in the University of Hertfordshire Biological 
Services Unit in pairs in standard cages (Techniplast 2000P) with sawdust (Datesand grade 7 
substrate) and shredded paper wool bedding with water and food (5LF2 10% protein 
LabDiet) freely available. The housing room was maintained at a constant temperature of 22 
± 2 oC, under a 12h light dark cycle (lights on: 07:00 to 19:00 h). All studies were approved 
by the Institutional Animal Welfare and Ethnics review committee and conducted in 
accordance with guidelines established by the Animals (Scientific Procedures) Act, 1986 and 
European directive 2010/63/EU. 
 
3.2.3. Isolation and preparation of rat pancreatic islets 
Two methods were tested for the isolation of rat pancreatic islets. The first method was using 
histopaque gradient for pancreatic islets separation according to Carter et al., 2009 method 
and the second was using Ficoll gradient to separate islets according to the method of Szot et 
al., 2007.  
Carter et al., 2009 have given a well detailed protocol for pancreatic islets isolation from rats. 
Briefly, after opening the rat abdomen cavity in a V-shape, the common bile duct (CBD) was 
clamped off near the small intestine. At the junction of the cystic duct and the gall bladder, 
the CBD was cannulated with 10 mL syringe filled with 8 mL of collagenase, and a 27-30-
gauge needle (an insulin needle can be used as well), 1.4 mg/mL of collagenase solution was 
injected into the CBD as shown in Figure 3.2 below. 
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Pancreas was removed from rodent and placed in a beaker containing 2 mL of collagenase. 
The separated pancreas was incubated for 20 min in a 37o C water bath to digest the 
pancreatic cells. After digestion in the water bath, the tube was shaken by hand for few 
seconds to complete tissue separation. After this step, the tube containing the digested 
pancreas was rapidly placed in ice to slow the digestive process. The isolated islets were 
obtained from extracted pancreas following six centrifugations. First four centrifugations for 
  
Figure 3.2. Islets isolation procedure (a) Common Bile Duct (CBD) clamped off; (b) Cannulation;  
                 (c) Inflated pancreas; (d) Extracted pancreas in collagenase, Bayissi Bading- 
                   Taïka, February 2015 
(a) CBD (b) Cannulation 
(c) Inflated pancreas (d) Extracted pancreas 
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2 min at 1,200 rpm followed by a centrifugation at 1,500 rpm for 4 min to spin down the 
islets and a last one at 1,200 rpm for 3 min to obtain isolated islets. This step allows the 
separation of islets according to their density with a mix of histopaque 1077 solution and 
histopaque 1119 solution to have the histopaque 1100 solution (1.100 g/mL) which enhance 
islets purity. Islets were transferred to a Petri dish containing culture medium composed of 
RPMI 1640 + L-Glutamide, 10% FBS and Penicillin/ Streptomicin for cell culture 
possibilities or incubation. The cells were picked up under light microscope (Letz laborlux 
11) at 10X magnitude using low-retention pipette and placed in a 6 wells plate for insulin 
secretion studies. For counting purposes the cells were frozen. 
The second method followed Szot et al., 2007 protocol with Ficoll gradient. The distension of 
pancreas followed the same procedure as in Carter et al., 2009 protocol. However, there is 
only 3 steps of centrifugation at 1,300 rpm to spin down the cells. The pancreatic cells 
separation was performed quickly with 7 mL of Ficoll density 1.108, and 3 layers of 2 mL of 
Ficoll density 1.096, 1.069 then 1.037 in a 15-mL conical. After a centrifugation at 1,800 rpm 
for 15 min, islets were picked up from the second layer using an eye dropper as shown in 
Figure 3.3 below. 
 
  
The collected islets were re-suspended in 20 mL RPMI-1640 (containing 10% FCS and 
penicillin and streptomycin, HEPES, MEM-NEAA) and mix gently. A 100 µL was 
transferred for counting to a 35 mm Grid-plate containing 1 mL of media and 1 mL dithizone. 
Another method of counting was under light microscope with a Petri dish divided into four 
Figure 3.3. Islet layer with Ficoll gradient (Szot et al., 2007) 
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parts. Cells were counted in the first section and an extrapolation was done for the three other 
sections. The number of islets counted is mean ± SEM (standard error of the mean) of 30 
experiments (cells counting). 
 
3.2.4. Insulin secretion experiments 
The insulin secretion experiments followed the modified protocol of Bardy et al., 2013 and 
Souza et al., 2011. In brief, isolated islets were counted under light microscope 10 X 
magnification or with inverted microscope, separated and placed in glass tubes (10 islets per 
tube) containing a bicarbonate buffer solution containing (in mM): 115 Nacl, 5 Kcl, 24 
NaHCo3, 2.56 CaCl2, 1.3 MgCl2, 2.8 glucose, gassed with 95 % O2 and 5% CO2 and 
supplemented with 1 g/L BSA and kept at room temperature.  
First, the islets were pre-incubated in 1 mL of continuously gassed (95% O2 and 5% CO2) 
bicarbonate buffer solution for 45 to 60 min at 37oC. Following the pre-incubation time, the 
medium bicarbonate buffer solution was removed from each tube and replaced by fresh 
bicarbonate buffer without glucose (0 mM) or with increasing glucose concentrations (2.8 
mM, 11.1 mM, 16.7 mM and 25 mM), various drugs or aqueous extracts for 90 minutes, 
gassed with 95 % O2 and 5% CO2 at 37oC. At the end of incubation periods, aliquots of 
supernatant were collected and stored at -20oC until the insulin experiments performed, to 
evaluate the possible mechanisms of action underlying the action of the plant extracts, the 
effects of the extracts were studied in the presence of insulin secretagogue, as tolbutamide (an 
inhibitor of ß-cell K+-ATP channels) and SM-21 (a σ2 receptor antagonist). 
  
Measurement of insulin 
 
ELISA or enzyme-linked immunosorbent assay, is a technique used to detect the presence of 
an antibody or antigen in samples. Sandwich ELISA measures the amount of antigen between 
two layers of antibodies (capture and detection antibody). The antigen to be measured must 
contain at least two antigen sites of binding to antibody, since at least two antibodies act in 
sandwich. Either monoclonal or polyclonal antibodies can be use as the capture and detection 
antibodies in Sandwich ELISA systems. A polyclonal is often used as the capture antibody to 
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pull down as much as of the antigen possible. In Sandwich ELISA, the sample does not need 
to be purified before analysis and the assay can be very sensitive (Büyükköroglu et al., 2018). 
 
3.2.5. Measurement of the effects of T. iboga (0.001 to 100 µg/ml) on glucose-induced 
insulin secretion from isolated rat pancreatic islets 
Following insulin secretion experiments in presence of no glucose (0 mM) or with increasing 
glucose concentrations (2.8 mM, 11.1 mM, 16.7 mM and 25 mM), the effect of T. iboga 
aqueous extracts on glucose-induced insulin release was evaluated. As described above, after 
the pre-incubation period, the medium bicarbonate buffer solution was replaced by fresh 
bicarbonate buffer containing glucose at 0 mM, 2.8 mM, 11.1 mM, 16.7 mM and 25 mM 
without or with T. iboga extracts (0.001, 0.01, 0.1, 1, 10 and 100 µg/mL), for 90 minutes 
gassed with 95% O2 and 5% CO2 at 37oC. At the end of incubation periods, aliquots of 
supernatant were collected and stored at -20oC until the insulin ELISA was performed.  
 
3.2.6. Measurement of the effect of T. iboga (1 µg/mL) on glucose-induced insulin 
secretion in presence of Tolbutamide (200 µM) from isolated rat pancreatic islets 
As described above, after the pre-incubation period, the medium bicarbonate buffer solution 
was replaced by fresh bicarbonate buffer containing glucose at 0 mM, 2.8 mM, 1.11 mM, 
16.7 mM or 25 mM without or with T. iboga extracts (1 µg/mL) and with or without 
tolbutamide (200 µM) for 90 minutes gassed with 95% O2 and 5% CO2 at 37oC. At the end of 
incubation periods, aliquots of supernatant were collected and stored at -20oC until the insulin 
ELISA was performed. 
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3.2.7. Measurement of the effects of T. iboga (1 µg/mL) on glucose-induced insulin 
secretion in presence of SM-21 concentrations (1, 10 µM) from isolated rat pancreatic 
islets 
As described above, after the pre-incubation period, the medium bicarbonate buffer solution 
was replaced by fresh bicarbonate buffer containing glucose at 0 mM, 2.8 mM, 11.1 mM, 
16.7 mM or 25 mM without or with T. iboga extracts (1 µg/mL) and with or without the σ 
receptor antagonist, SM-21 (1, 10 µM) for 90 minutes gassed with 95% O2 and 5% CO2 at 
37oC. At the end of incubation periods, aliquots of supernatant were collected and stored at -
20oC until the insulin ELISA was performed. 
 
3.2.8. Measurement of the effects of G. tessmannii (1 µg/mL to 10 mg/mL) 
concentrations on glucose-induced insulin secretion from isolated rat pancreatic islets 
The effects of G. tessmannii aqueous extracts at 1, 10, 30, 50, 70 100 µg/mL and 1, 10 
mg/mL on glucose-induced insulin release was evaluated following the same protocol as 
described above. Concentrations were selected according to previous results by Madingou et 
al., 2011. As described above, after the pre-incubation period, the medium bicarbonate buffer 
solution was replaced by fresh bicarbonate buffer containing glucose at 0 mM, 2.8 mM, 11.1 
mM, 16.7 mM or 25 mM without or with G. tessmannii extracts (1, 10, 30, 50, 70, 100 
µg/mL and 1, 10 mg/mL), for 90 minutes gassed with 95% O2 and 5% CO2 at 37oC. At the 
end of incubation periods, aliquots of supernatant were collected and stored at -20oC until the 
insulin ELISA was performed.  
 
3.2.9. Measurement of the effects of G. tessmannii (70 µg/mL) on glucose-induced insulin 
secretion in presence of Tolbutamide (200 µM) from isolated rat pancreatic islets 
As described above, after the pre-incubation period, the medium bicarbonate buffer solution 
was replaced by fresh bicarbonate buffer containing glucose at 0 mM, 2.8 mM, 11.1 mM, 
16.7 mM or 25 mM without or with G. tessmannii extracts (70 µg/mL) and with or without 
tolbutamide (200 µM) for 90 minutes gassed with 95% O2 and 5% CO2 at 37oC. At the end of 
incubation periods, aliquots of supernatant were collected and stored at -20oC until the insulin 
ELISA was performed. 
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3.2.10. Measurement of the effects of T. iboga (1 µg/mL) and G. tessmannii (70 µg/mL) 
on NO production at low and high glucose concentrations from rat pancreatic islets. 
Since ibogaine has shown neurologic cytotoxic effects (Bowen et al., 2001), and is the major 
constituent of T. iboga, a Griess assay was performed to determine levels of nitrates as a 
marker of oxidative stress following exposure of isolated rat pancreatic islets to low and high 
glucose concentrations and 1 µg/mL of T. iboga and 70 µg/mL of G. tessmannii. After 
incubation of isolated rat pancreatic islets with fresh bicarbonate buffer containing glucose at 
0 mM, 2.8 mM, 11.1 mM, 16.7 mM or 25 mM with/without G. tessmannii extract (70 
µg/mL) and with/without T. iboga (1 µg/mL) for 90 minutes gassed with 95% O2 and 5% 
CO2 at 37oC. Aliquots of 100 µL of supernatant were removed for Griess reaction assay. 
Griess assay reaction is a colorimetric assay that has been extensively used because of its 
simplicity since it was first described in 1879, to measure the levels of Nitrite (NO2-) in 
biological samples. Nitric oxide (NO), a gaseous free radical secreted by endothelium, is a 
major modulator of endothelial function (Adela et al., 2015). NO is a highly reactive 
molecule with a short half-life in vivo (few seconds), thus, levels of more stable metabolites, 
nitrite (NO2-) and nitrate (NO3-) have been used to indirectly measure NO in samples. NO 
concentrations are based on the enzymatic conversion of NO3- to NO2- by nitrate reductase. 
The reaction is followed by colorimetric detection of NO2- as an azo dye product of the 
Griess reaction. The Griess reaction is based on the two-step diazotisation reaction in which 
acidified NO2- produces a nitrosating agent, which reacts with sulfanilic acid to produce the 
diazonium ion. This ion is then coupled to N-(1-naphthyl) ethylenediamine to form the 
chromophoric azo-derivative which absorbs light at 540-570 nm (ParameterT).  
Briefly, a series of nitrite concentrations as standards were prepared from 65 µM to 1.01 µM 
to stay within the working range of the Griess reagent modified (0.43-65 µM nitrite). In a 96 
wells plate, 100 µL of the standards and aliquot samples were added into their respective 
wells followed by 100 µL Griess reagent modified into each well. After 15 min incubation at 
room temperature, the absorbance at 540 nm was measured using a plate reader, and 
absorbance of each sample was recorded to assess the amount of NO produced. 
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3.2.11. Data analysis 
Data were analysed using GraphPad Prism 7.0 software to determine the level of 
significance. All data are expressed as means ± standard error mean (SEM). The level of 
probability (p) was considered statistically significant when values were less than 0.05 (*), 
0.01 (**), 0.001 (***) or 0.0001 (****). One- way analysis of variance (ANOVA) was 
performed to examine the effect of a single variable on more than two groups (effect of 
increasing glucose concentrations on insulin release) followed by Tukey’s tests. Two-way 
ANOVA were performed to examine the effect of two independent variables with Dunnett or 
Tukey’s post-hoc tests. 
 
3.3. Results 
 
3.3.1. T. iboga and G. tessmannii aqueous extracts yield 
The aqueous extraction of G. tessmannii (100 g) and T. iboga (75 g) gave a yield of 12.49 g 
(12.5 %) and 2.11 g (3 %), respectively of aqueous extract. 
 
3.3.2. Isolation of rat pancreatic islets 
The pancreatic islets were separated by gradient (graduation 9) from other acinar and 
pancreatic tissues (graduation 13).  
 
	 95	
 
 
Islets were mainly found as clusters Figure 3.5 a, e, however, some isolated ones were 
localised Figure 3.5 b, c, d, f with variable sizes. Cells have a normal appearance with ß 
granules inside and some were surrounded with contaminating exocrine tissue Figure 3.5 a, c, 
e. 
 
(a) Islets layer by Ficoll gradient  (b) Islets layer by Ficoll gradient  
Figure 3.4. Islets layer (graduation 9) by Ficoll gradient, other pancreatic and acinar tissues at  
                  graduation 13, UH Laboratory, Bayissi Bading-Taïka, 2015 
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(a) Digested pancreas  (b) Islets and other tissues 
  spin down 
(c) Islets cells separation  
(d) Islets further separation  (e) Islets isolated  (f) Collected isolated islets  
 
Figure 3.5. Rat pancreatic islets centrifugation steps using Histopaque gradient, University of Herfordshire 
Bayissi Bading-Taïka, 2015 
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The number of islets per pancreas was approximately SEM 1887 ± 428 (n=30) and a visual 
inspection under a light microscope shown spherical and golden-brown cells with varying 
diameter from 50 µm to 600 µm. 
 
 
 
 
(a) Isolated islets 
600µm 
400µm 
200X 200X 200X 
200X 500X 500X 
(b) Cluster of islets (c) Isolated islets  
(d) Isolated islets (e) Isolated islets (f) Isolated islets 
Figure 3.6. Isolated rat pancreatic islets (200X). Light microscope (a-b), Inverted microscope (c-d),     
                   Isolated islets diameter (X500) (e-f) 
	 98	
3.3.3. Effect of increasing glucose concentration on insulin release from isolated rat 
pancreatic islets 
Before each experiment, the effect of glucose was tested on rat isolated islets. The Figure 3.7 
below shows the effect of glucose concentrations on insulin release after a static incubation 
of 90 min. Increasing glucose concentrations (0 mM, 2.8 mM, 11.1 mM, 16.7 mM and 25 
mM) were added to the medium of each tube containing isolated pancreatic rat islets (~10) 
and insulin secretion was measured. The data shows a concentration dependent increase of 
insulin release from 11.1 mM of glucose. Insulin secretion was not induced in medium with 
no glucose (0 mM) (0.406 ng/mL/10 islets), however, a slight increase, non-significant, was 
shown at glucose concentration of 2.8 mM (0.928 ng/mL/10 islets). There is a significant 
concentration-dependent increase of insulin release from 11.1 mM glucose (3 ng/mL/10 
islets) to 25 mM glucose (7 ng/mL/10 islets) compared to non-stimulatory glucose 
concentrations (0 mM and 2.8 mM). The isolated pancreatic cells were secreting insulin in a 
concentration-dependent manner in the presence of increasing glucose concentrations, which 
confirmed that freshly isolated rat pancreatic islets were insulin secreting cells.
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Figure 3.7. The effect of increasing glucose concentrations (0, 2.8, 11.1, 16.7 and 25 mM) on insulin release from isolated rat pancreatic islets. 
Data is presented as mean ± SEM of 21 independent experiments. Data was analysed by one-way ANOVA and Tukey’s post-hoc test. 
Statistical significance is presented as **** p < 0.001 compared 0 mM (no glucose) group. 
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3.3.4. Concentration dependent effects of T. iboga (0.001 to 100 µg/mL) aqueous extract 
on low and high glucose (0 to 25 mM) induced insulin secretion from isolated rat 
pancreatic islets 
To screen the effect of T. iboga aqueous extract on insulin secretion, the freshly isolated islets 
were tested with various concentrations (0.001, 0.01, 0.1, 1, 10, 100 µg/mL) of the plant 
extract, in the presence of increasing glucose concentrations (0, 2.8, 11.1, 16.7 and 25 mM), 
over a 90-min static incubation. The data shows that in the absence of glucose (0 mM) T. 
iboga did not influence insulin release. The stimulatory effect of the extract was then 
compared in presence of non-stimulatory (Figure 3.8 a) and stimulatory glucose 
concentrations (Figure 3.8 b, c, and d). Glucose-induced insulin secretion was significantly 
increased in the presence of T. iboga extract (1 µg/mL) at 2.8 mM (Figure 3.8 a) compared to 
control (no extract, no glucose) by more than 9-fold (0.39 vs 3.63 ng/mL/10 islets, p < 0.001) 
and more than 3-fold compared to control at same concentration (0.92 vs 3.63 ng/mL/10 
islets, p < 0.001). At 11.1 mM glucose (Figure 3.8 b), a substantial increase of insulin 
secretion was observed at 1 µg/mL of T. iboga (7.31 ng/mL/10 islets, p < 0.0001) compared 
to the control (no extract, no glucose) and at the same glucose concentration (no extract) (3 
ng/mL/10 islets, p < 0.001). However, an inhibition on insulin potentiation at 1 µg/mL of T. 
iboga was observed at 16.7 mM glucose compared to control at same glucose concentration 
(no extract) (3.51 ng/mL/10 islets vs 4.67 ng/mL/10 islets) (Figure 3.8 c), which was more 
marked at 25 mM glucose (4.81 ng/mL/10 islets vs 6.99 ng/mL/10 islets, p < 0.001) (Figure 
3.8 d). Interestingly, at concentrations below and above 1 µg/mL of T. iboga, there is no 
significant potentiation of insulin secretion levels, at 0.001 µg/mL (0.11 ng/mL/10 islets), 
0.01 µg/mL (0.75 ng/mL/10 islets), 0.1 µg/mL (1.60 ng/mL/10 islets) and at 10 µg/mL (1.28 
ng/mL/10 islets) and 100 µg/mL (0.84 ng/mL/10 islets) compared to control (no extract) 
(0.90 ng/mL/10 islets) at 2.8 mM glucose. Similarly, at 11.1 mM of glucose (Figure 3.8 b), 
there is a no significant potentiation of insulin release at 0.1 µg/mL (2.83 ng/mL/10 islets) 
and 10 µg/mL (2.29 ng/mL/10 islets) compared to control (no extract) (3 ng/mL/10 islets). 
However, there is a significant inhibition of insulin release at 0.001 µg/mL (0.21 ng/mL/10 
islets), 0.01 µg/mL (1.28 ng/mL/10 islets) and 100 µg/mL of T. iboga (1.23 ng/mL/10 islets) 
compared to control at same glucose concentration (no extract) (3 ng/mL/10 islets, p < 0.01). 
At 16.7 mM of glucose, low (0.001 to 1 µg/mL) and high (10 and 100 µg/mL) T. iboga 
extract concentrations inhibited significantly insulin release compared to control at same 
glucose concentration (no extract) which was more marked at 25 mM of glucose. Indeed, at 
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16.7 mM of glucose (Figure 3.8 c), T. iboga extract at 0.001 µg/mL (0.31 ng/mL/10 islets), 
0.01 µg/mL (1.16 ng/mL/10 islets), 0.1 µg/mL (2.50 ng/mL/10 islets), 1 µg/mL (3.52 
ng/mL/10 islets), 10 µg/mL (2.11 ng/mL/10 islets) and 100 µg/mL (0.94 ng/mL/10 islets) 
inhibited significantly insulin release compared to control at the same concentration (no 
extract) (4.67 ng/mL/10 islets, p < 0.05). Similarly, at 25 mM of glucose T. iboga extract 
concentrations (0.001 to 100 µg/mL) inhibited significantly insulin release compared to 
control at the same glucose concentration (no extract) (6.99 ng/mL/10 islets, p < 0.001). At 
low (2.8 mM) and high (11.1, 16.7 and 25 mM) glucose concentrations, T. iboga extract at 1 
µg/mL was the concentration optimal compared to control (no extract, no glucose).
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Figure 3.8. Effects of the aqueous extract of T. iboga (0.001 to 100 µg/mL) on insulin release from rat pancreatic islets. Dose-response effect of 
T. iboga on insulin release in the presence of both non-stimulatory (0, 2.8 mM) and stimulatory concentrations (>11.1 mM) of glucose. Values 
are means of 21 observations. Data were analysed by two-way ANOVA followed by Dunnett’s test, effect of T. iboga and effect of panel a) 2.8 
mM b) 11.1 mM c) 16.7 mM d) 25 mM * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 relative to respective glucose (no extract). † 
p < 0.05, †† p < 0.01 and †††† p < 0.001, compared with incubations at 0 mM glucose (control) and at same concentrations of T. iboga extract
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3.3.5. Effects of T. iboga optimal concentration (1 µg/mL) on insulin release from 
isolated rat pancreatic islets in the presence of increasing glucose concentrations 
Figure 3.9 below shows the dose-response effect of increasing glucose concentrations (0, 2.8, 
11.1, 16.7, 25 mM) upon insulin release in the presence or absence of T. iboga at 1 µg/mL. 
At 2.8 and 11.1mM of glucose, T. iboga induced a significant increase of insulin secretion by 
4-fold and 2-fold compared to the respective controls (3.63 vs 0.92 ng/mL/10 islets and 7.31 
vs 3 ng/mL/10 islets, at 2.8 and 11.1 mM glucose respectively, p < 0.0001). However, at 25 
mM of glucose, T. iboga potentiation of insulin release decreased from 6.99 to 4.81 
ng/mL/10 islets, this inhibition of the extract potentiation was significant p < 0.05. At 16.7 
mM glucose, there is a decrease from 4.67 to 3.52 ng/mL/10 islets. Although, this variation 
was not significant. The optimal effect of T. iboga at 1 µg/mL on glucose induced insulin 
release compared to the control was seen at glucose concentration of 11.1 mM.  
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Figure 3.9. Dose-response effect of glucose upon insulin release in the presence and absence of T. iboga extract (1 µg/mL). Values are means ± 
SEM for groups of 15 observations and were analysed by two-way ANOVA followed by Tukey’s test. * p < 0.05, **** p < 0.0001, compared 
with incubations at the same glucose concentration without T. iboga extract (control).
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3.3.6. Effects of T. iboga (1 µg/mL) on insulin release from isolated rat pancreatic islets 
in the presence of Tolbutamide 
The Figure 3.10 below shows the effect of optimal T. iboga (1µg/ml) concentration in the 
presence of tolbutamide (200 µM), an insulin secretagogue, on glucose-induced insulin 
secretion. Both tolbutamide and T. iboga aqueous extract stimulated insulin secretion at 
glucose stimulatory and non-stimulatory concentrations, however, the magnitude of their 
effects was totally different. Tolbutamide enhanced significantly glucose-induced insulin 
secretion at concentrations greater than 2 mM glucose in a glucose concentration-dependent 
manner. Whereas T. iboga aqueous extract potentiated glucose-induced insulin secretion on a 
bell shape manner. Indeed, at 2.8 and 11.1 mM glucose T. iboga aqueous extract induced 
more potentiation of glucose-induced insulin release compared to tolbutamide at the same 
glucose concentrations (3.63 vs 2.73 and 7.31 vs 6.07 ng/ml/10 islets, respectively), although 
this potentiation is not significant. However, at 16.7 and 25 mM glucose there is a significant 
inhibition of T. iboga potentiation of glucose-induced insulin secretion while, the effects of 
tolbutamide were steadily increased (3.51 vs 7.02 ng/ml/10 islets, p < 0.0001 and 4.81 vs 
8.79 ng/ml/10 islets, p < 0.0001 respectively). Also, glucose-induced insulin secretion was 
significantly increased in presence of both T. iboga and the secretagogue, tolbutamide at 
stimulatory glucose concentrations 2.8 and 11.1 mM compared to their solely effects (5.56 vs 
2.73 ng/ml/10 islets for tolbutamide alone and vs 3.63 ng/ml/10 islets for T. iboga alone at 
2.8 mM glucose, and 9.03 vs 6.07 for tolbutamide alone and vs 7.31 ng/ml/10 islets for T. 
iboga alone at 11.1 mM glucose). This suggests a combination effect of the plant extract and 
the anti-diabetic drug and more potentiation of glucose insulin release compared to the 
secretagogue alone. However, there is a decrease on glucose-induced insulin release levels at 
16.7 mM when islets are incubated with both T. iboga aqueous extract and tolbutamide 
comparing to the effect of tolbutamide alone (5.25 vs 7.02 ng/ml/10 islets, p < 0.0001). The 
effect of tolbutamide remained unchanged at 25 mM glucose.  
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Figure 3.10. Effect of T. iboga (1 µg/mL) on insulin release from rat pancreatic islets in the presence of Tolbutamide (200 µM) in the presence 
of 2.8 mM, 11.1 mM, 16.7 mM and 25 mM glucose. Data is presented as ± SEM of 10-22 independent experiments and were analysed by one-
way ANOVA followed by Tukey’s test. ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to control no extract, no drug, † p < 0.05,  
 † † † † p < 0.0001 compared with T. iboga (1 µg/ml), #### p < 0.05 compared with Tolbutamide (200 µM) 
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3.3.7. Effects of T. iboga (1 µg/mL) on insulin release from isolated rat pancreatic islets 
in the presence of σ receptor antagonist, SM-21 
To investigate mechanism of action of T. iboga aqueous extract on insulin secretion, we 
examined its effect in presence of selective σ2 receptor antagonist SM-21. Firstly, SM-21 
effects were assessed on glucose-induced insulin release. The data below (Figure 3.11) shows 
that SM-21 significantly inhibited insulin secretion at 11.1, 16.7 and 25 mM glucose (p < 
0.001). At low concentration of SM-21 (1 µM), insulin release decreased from 3 vs 1.31, 4.67 
vs 1.52 ng/ml/10 islets and 6.99 vs 0.61 ng/ml/10 islets at 11.1, 16.7 and 25 mM glucose, 
respectively p < 0.001 (Figure 3.11 c). However, there is little or no effect of SM (1 µM) at 0 
mM and 2.8 mM glucose (Figure 3.11 c). Similarly, at high concentration, SM-21 (10 µM) 
significantly inhibited glucose-induced insulin release at 11.1, 16.7 and 25 mM glucose (p < 
0.0001). SM-21 at 10 µM divided by 6-fold the insulin levels compared to control at 11.1 
mM and 25 mM glucose, and by 4 at 16.7 mM (p < 0.0001) glucose compared to control 
(Figure 3.11 d).  
The effect of optimal T. iboga concentration (1 ug/ml) was then assessed in presence of low 
and high concentrations of SM-21 (Figure 3.11 e, f). Data in Figure 3.11 e, f shows that at 
low and high glucose concentrations 2.8, 11.1 and 25 mM, there is a significant decrease in T. 
iboga potentiation of insulin release at both low and high SM-21 concentrations. Indeed, 
insulin levels in presence of T. iboga (1 µg/ml) at 2.8 mM glucose decreased from 3.63 to 
1.65 ng/ml/10 islets in presence of SM-21 at 1 µM (Figure 3.11 e) and to 0.97 ng/ml/10 islets 
in presence of SM-21 at 10 µM (Figure 3.11 f). At 11.1 mM, T. iboga insulin secretion 
potentiation decreased by 65% in presence of low and high SM-21 concentrations (1 and 10 
µM) and by more than 20% at 25 mM glucose in presence of both SM-21 concentrations. 
However, T. iboga aqueous extract effect was not altered in presence of the antagonist SM-21 
at 16.7 mM glucose.
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Figure 3.11. Effect of T. iboga (1 µg/mL) on insulin release from rat pancreatic islets in the presence of SM-21 (1 and 10 µM) at increasing 2.8 
mM, 11.1 mM, 16.7 mM and 25 mM glucose. Data is presented as ± SEM of 10-21 independent experiments and were analysed by two-way 
ANOVA followed by Tukey’s test * p < 0.05, *** p < 0.001, **** p < 0.0001 compared with control (no extract, no drug). †† p < 0.01, †††† p 
< 0.0001 compared with T. iboga (1µg/ml).
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3.3.8. Effects of T. iboga (1 µg/mL) optimal concentration and increasing glucose 
concentrations on nitrite production from rat isolated pancreatic islets 
Griess assay was performed on cells that were treated with T. iboga optimal concentration (1 
µg/mL) at increasing glucose concentrations (0, 2.8, 11.1, 16.7 and 25 mM). Levels of total 
nitrite are shown on Figure 3.12 below, which reflects the amount of nitric oxide (NO), one 
major marker of oxidative stress. Total nitrite productions are low in cells treated with 0, 2.8 
and 11.1 mM glucose (0.01, 0.01 and 0.02 µM respectively, p > 0.05 versus 0 mM) and 
increased significantly at 16.7 and 25 mM glucose (0.14 and 0.27 µM, p < 0.05 and p < 
0.0001, respectively, compared with 0 mM and 11.1 mM). Similarly, total nitrite productions 
in presence of T. iboga (1 µg/ml) are low at 0, 2.8 and 11.1 mM glucose (0.03, 0.04 and 0.05 
µM respectively, p > 0.05 versus 0 mM) and significantly increased at 16.7 and 25 mM 
glucose (0.163 and 0.29 µM, p < 0.05 and p < 0.0001, respectively compared with 0 mM and 
11.1 mM). Nitrite levels in the presence of T. iboga were not significantly altered compared 
to respective controls (no extract). 
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Figure 3.12. Effect of the aqueous extract of T. iboga (1 µg/mL) optimal concentration on 
nitrate production from rat pancreatic islets in the presence of increasing glucose 
concentrations (0, 2.8, 11.1, 16.7, 25 mM). The levels of total nitrite were recorded which 
reflects the amount of nitric oxide (NO) in samples. Data is presented as ± SEM of 7 
independent experiments and were analysed by two-way ANOVA followed by Tukey’s test. 
* p < 0.05, ** p < 0.01, **** p < 0.0001 relative to 0 mM glucose alone. † p < 0.05, †††† p < 
0.0001 relative to stimulatory glucose (11.1 mM), p > 0.05 relative to respective control (no 
extract). 
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3.3.9. Concentration dependent effects of G. tessmannii (1 µg/mL to 10 mg/mL) aqueous 
extract on low and high glucose induced insulin secretion from isolated rat pancreatic 
islets 
Figure 3.13 below shows the effect of the aqueous plant extract from 1 µg/mL to 10 mg/mL 
on insulin secretion in presence of increasing glucose concentrations. Islets were incubated 
over 90 min at 37oC with increasing glucose concentrations (0, 2.8, 11.1, 16.7 and 25 mM) 
and in presence of G. tessmannii, as described previously. The data shows that in the absence 
of glucose (Figure 3.13 a) G. tessmannii aqueous extract do not influence insulin release. 
However, at non-stimulatory and stimulatory glucose concentrations (from 2.8 to 25 mM), a 
bell shape of the effects of G. tessmannii is shown. At 2.8 mM of glucose, the aqueous 
extract triggered significant increase of glucose-induced insulin release compared to control 
at 50 µg/mL and 70 µg/mL (2.38 vs 0.90 ng/mL/10 islets p < 0.05 and 4.23 vs 0.90 ng/ml/10 
islets p < 0.0001, respectively) (Figure 3.13 a). Moreover, the effect of G. tessmannii aqueous 
extract was increased in a glucose concentration-dependant manner. At 11.1 mM glucose, G. 
tessmannii showed a marked increase in glucose-induced insulin release at 70 µg/mL (6.66 vs 
2.94 ng/mL/10 islets, p < 0.0001) (Figure 3.13 b). At 16.7 mM of glucose, G. tessmannii 
potentiation of glucose-induced insulin secretion was also seen at 70 µg/mL with 7.12 vs 4.67 
ng/mL/10 islets, p < 0.0001 (Figure 3.13 c). However, at 25 mM glucose, the effect of G. 
tessmannii at 70 µg/mL was not significant comparing to control. At non-stimulatory glucose 
concentration (2.8 mM), G. tessmannii concentrations lower than 50 µg/mL and higher than 
70 µg/mL failed to potentiate glucose-induced insulin release comparing to controls (Figure 
3.13 a). Furthermore, a significant inhibition was observed at 16.7 and 25 mM of glucose at 
G. tessmannii low (1 to 50 µg/mL) and high (1 and 10 mg/mL) concentrations (Figure 3.13 c, 
d). At 11.1 mM of glucose, G. tessmannii at 30 and 50 µg/mL did not potentiate insulin 
secretion. At low (2.8 mM) and high (11.1, 16.7 and 25 mM) glucose concentrations, G. 
tessmannii extract at 70 µg/mL was the concentration optimal compared to control (no 
extract). 
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Figure 3.13. Effects of the aqueous extract of G. tessmannii (1 µg/mL to 10 mg/mL) on insulin release from rat pancreatic islets. Dose-response 
effect of G. tessmannii on insulin release in the presence of both non-stimulatory (0, 2.8 mM) and stimulatory concentrations (>11.1 mM) of 
glucose. Values are means of 15 observations. Data were analysed by two-way ANOVA followed by Dunnett’s test, effect of G. tessmannii and 
effect of panel a) 2.8 mM b) 11.1 mM c) 16.7 mM d) 25 mM * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 relative to respective 
glucose alone (no extract). † p < 0.05, ††† p < 0.001 and †††† p < 0.001, compared with incubations at 0 mM glucose and at same 
concentrations of G. tessmannii extract. 
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3.3.10. Effects of G. tessmannii (70 µg/mL) on insulin release from isolated rat 
pancreatic islets in the presence of increasing glucose concentrations 
Following the assessment of the effects of G. tessmannii in the presence of increasing glucose 
concentrations, we compared the effects of optimal G. tessmannii concentration (70 µg/mL) 
to those of glucose in isolated pancreatic islets. The figure 3.14 below shows a concentration-
dependent increased of insulin levels when cells are incubated with increasing glucose 
concentrations (2.8 to 25 mM). At non-stimulatory and stimulatory glucose concentrations 
(2.8 to 16.7 mM), glucose-induced insulin secretion was significantly higher in presence of 
G. tessmannii at 70 µg/mL compared to controls. Indeed, G. tessmannii (70 µg/mL) 
significantly potentiated insulin release from 0.93 to 4.23 ng/ml/10 islets at 2.8 mM (p < 
0.001), from 3 to 6.66 ng/ml/10 islets at 11.1 mM (p < 0.0001) and from 4.67 to 7.12 
ng/ml/10 islets at 16.7 mM (p < 0.05). However, at 25 mM glucose there was no potentiation 
by the plant extract compared to the control. 
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Figure 3.14. Dose-response effect of glucose upon insulin release in the presence and 
absence of G. tessmannii extract (70 µg/mL). Values are means ± SEM for groups of 15 
observations and were analysed by two-way ANOVA followed by Tukey’s test. * p < 0.05, 
**** p < 0.0001, compared with incubations at the same glucose concentration without G. 
tessmannii extract. 
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3.3.11. Effects of G. tessmannii (70 µg/mL) on insulin release from isolated rat 
pancreatic islets in the presence of Tolbutamide 
The effect of optimal G. tessmannii (70 µg/mL) concentration in presence of tolbutamide 
(200 µM) is presented in Figure 3.15 below. The data shows that both tolbutamide and G. 
tessmannii aqueous extract stimulated insulin secretion at glucose non-stimulatory and 
stimulatory concentrations (2.8, 11.1, 16.7 and 25 mM). Indeed, tolbutamide increased 
significantly glucose-induced insulin secretion at concentrations greater than 2 mM glucose 
in a dose-dependent manner. Similarly, G. tessmannii at 70 µg/mL potentiated glucose-
induced insulin secretion in a glucose concentration dependent manner. Indeed, at glucose 
concentrations from 2.8 to 16.7 mM glucose G. tessmannii aqueous extract induced a higher 
but not significant potentiation of glucose-induced insulin release compared to tolbutamide at 
the same glucose concentrations (4.23 vs 2.73, 6.66 vs 6.07 ng/ml/10 islets and 7.12 vs 7.02 
ng/ml/10 islets, respectively at 2.8, 11.1 and 16.7 mM glucose), except at 25 mM glucose 
(8.26 vs 8.79 ng/ml/10 islets). The effects of both tolbutamide and G. tessmannii were 
significantly enhanced compared to the effects of tolbutamide alone at 2.8, 11.1 and 16.7 mM 
glucose (5.31 vs 2.73, 7.93 ng/ml/10 islets vs 6.07, and 8.59 vs 7.02 ng/ml/10 islets, 
respectively, p < 0.001). A combination effect of the plant extract to the anti-diabetic drug at 
these concentrations was suggested. However, the effect of tolbutamide was unchanged at 25 
mM glucose in presence of G. tessmannii.
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Figure 3.15. Effect of G. tessmannii (70 µg/mL) on insulin release from rat pancreatic islets in the presence of Tolbutamide (200 µM) in the 
presence of 2.8 mM, 11.1 mM, 16.7 mM and 25 mM glucose. Data is presented as ± SEM of 10-22 independent experiments and were analysed 
by two-way ANOVA followed by Tukey’s test. ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to control without extract or drug, #### p 
< 0.0001 compared with Tolbutamide
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3.3.12. Effects of G. tessmannii (70 µg/mL) optimal concentration and increasing glucose 
concentrations on nitrite production from rat isolated pancreatic islets 
Griess assay was also performed on cells that were incubated with G. tessmannii optimal 
concentration (70 µg/mL) and at increasing glucose concentrations (0, 2.8, 11.1, 16.7 and 25 
mM). Levels of total nitrite are shown on Figure 3.16 below, and reflects the amount of nitric 
oxide (NO), an oxidative stress major marker. Data shows that total nitrite productions are 
low at 0, 2.8 and 11.1 mM glucose (0.01, 0.01 and 0.02 µM respectively, p > 0.05 versus 0 
mM) and increased significantly at 16.7 and 25 mM glucose (0.14 and 0.25 µM respectively, 
p < 0.05). Similarly, total nitrite productions in presence of G. tessmannii (70 µg/mL) are low 
at 0, 2.8 and 11.1 mM glucose (0.03, 0.06 and 0.07 µM respectively, p > 0.05 versus 0 mM) 
and significantly increased at 16.7 and 25 mM glucose up to 0.21 µM, p < 0.001 for both 
concentrations. However, nitrite levels in the presence of G. tessmannii were not altered 
when compared to controls (no extract). 
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Figure 3.16. Effect of the aqueous extract of G. tessmannii (70 µg/mL) optimal concentration 
on nitrate production from rat pancreatic islets in the presence of increasing glucose 
concentrations (0, 2.8, 11.1, 16.7, 25 mM). The levels of total nitrite were recorded which 
reflects the amount of nitric oxide (NO) in samples. Data is presented as ± SEM of 7 
independent experiments and were analysed by two-way ANOVA followed by Tukey’s test. 
* p < 0.05, *** p < 0.001 relative to 0 mM glucose alone. † p < 0.05, †† p < 0.01 relative to 
stimulatory glucose (11.1 mM), p > 0.05 relative to respective control (no extract). 
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3.4. Discussion 
 
In this chapter, we explored the mechanism of actions of T. iboga and G. tessmannii for their 
anti-diabetic potential activity in vitro. We used the same method of extraction for T. iboga 
and G. tessmannii as the one used by traditional practitioner’s (Bading-Taika et al., 2018). 
The yield obtained for 75 g of T. iboga root barks powder was 2.11 g of aqueous extract, 
which was consistent to previous data, 2.2 g dry material was obtained for 75 g of T. iboga 
(Souza et al., 2011). In parallel, the yield obtained for 100 g of G. tessmannii stem barks 
powder was 12.49 g of aqueous extract, which was twice more than the yield obtained in 
previous studies. The discrepancy might be due to technical skills during filtration process 
(Koumba Madingou et al., 2016). Moreover, this method was chosen in order to deal in our 
experiments, with the similar compounds given to Gabonese population by traditional 
therapists for the management of diabetes (Bading-Taika et al., 2018).  
Following the aqueous extraction of the medicinal plants, we investigated for in vitro activity 
of the aqueous extracts of T. iboga and G. tessmannii. Firstly, as the main organ involved 
with diabetes is pancreas and the pancreatic islets of Langerhans, the isolation of the 
glandular organ was fundamental. Several techniques have been developed over the years to 
enable isolation of viable and functional pancreatic islets (Szot et al., 2007; Qader et al., 
2007; Carter et al., 2009). The procedure of islets of Langerhans isolation is a well-
established series of successive mechanical and enzymatic separations of connected cells, 
followed by a gradient dissociation for islets purification (Neuman et al., 2014; Miceli et al., 
2018). Among the method used in this chapter, histopaque provided better yield of rat islets 
comparing to Ficoll 400, as it enhanced islets purity (Szot et al., 2007; Carter et al., 2009; 
Miceli et al., 2018). Also, mechanical damage to the islets was reduced as inflated pancreas 
was excised and digested without been cut or mechanically digested (Carter et al., 2009). The 
isolated islets yielded 1887 ± 428, which is close to previous results suggesting a number 
between 2000 to 5000 isolated islets per pancreas for young rats, this number increases with 
age and is influenced by the expertise of the technician (Carter et al., 2009). Although, an 
ultimate expected islets yield is hard to quantify as numerous parameters must be taken into 
account such as the strain and age of rodent (Qader et al., 2007; Carter et al., 2009). The 
isolated islets obtained were selected after visual inspection under a light microscope and 
were similar to previous isolated islets pictures (Carter et al., 2009). The use of primary 
isolated rat islets in this project allowed a more precise comprehension of how islets respond 
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to certain stimuli comparing to insulinoma-derived cell lines such as INS-1 and MIN6 ß-cell 
lines (Neuman et al., 2014, Carter et al., 2009). Indeed, in vitro tissue culture models are 
useful tools for studying specific ß-cells functions. However, the interactions between 
different cell types within islets including the paracrine and somatostatin which may regulate 
ß-cells functions, and gap junction between ß-cells that potentiates insulin release may be 
altered in cell line purified cultures. Thus, the response of these immortalised ß-cell lines to 
stimuli can consistently differ from fresh cells (Carter et al., 2009; Neuman et al., 2014). 
Furthermore, using pancreas in whole animal models could be an alternative option than the 
use of primary isolated islets, however, this method presents its own set of issues including 
the accurate measure of insulin as liver plays also an important role in the metabolism of 
insulin (Neuman et al., 2014).  
The function of isolated rat pancreatic islets was then tested in presence of increasing glucose 
concentrations and insulin release measured using ELISA kits. As pancreatic rat islets contain 
insulin-secreting ß-cells, the ultimate method to confirm the type of cells isolated in this 
chapter, was by testing their capability to secrete insulin in presence of stimulatory glucose 
concentrations. Figure 3.7 shows a glucose-induced insulin release in a concentration-
dependent manner at 2.8, 11.1, 16.7 and 25 mM glucose. These results were consistent with 
other results obtained in the same conditions (Souza et al., 2011; Vilches-Flores et al., 2010) 
and confirmed the isolation of pancreatic islets containing ß-cells by the method selected in 
this chapter. At this point, glucose-induced insulin release was then assessed in the presence 
of increasing concentrations of T. iboga and G. tessmannii aqueous extracts, insulin 
secretagogue tolbutamide and σ2 receptor antagonist SM-21. 
 In the same glucose environment than previously, T. iboga increasing concentrations (0.001 
to 100 µg/mL) exhibited a bell-shape effect on glucose-induced insulin secretion at all 
glucose concentrations (Figure 3.8). Indeed, at high concentrations of T. iboga (10 and 100 
µg/mL) no potentiation of insulin secretion was seen at low glucose concentrations (0 and 2.8 
mM). However, at high glucose concentrations, T. iboga aqueous extract high concentrations 
(10 and 100 µg/mL) inhibited significantly insulin secretion at 11.1, 16.7 mM glucose and 25 
mM compared to control at same glucose concentrations with no extract (1.23 vs 3 ng/mL/10 
islets for 100 µg/mL at 11.1 mM glucose, 2.11 vs 4.67 and 0.94 vs 4.67 ng/mL/10 islets for 
10 and 100 µg/mL at 16.7 mM glucose and 1.58 vs 6.99 and 0.86 vs 6.99 ng/mL/10 islets for 
10 and 100 µg/mL at 25 mM glucose p < 0.0001). This negative effect of the σ2 ligand (T. 
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iboga) was already seen in previous data with σ2 receptor agonist PB28 in Cassano et al. 
2006 experiment. Indeed, in this experiment, high concentrations of T. iboga inhibited insulin 
release and this is thought to be an abolition of the increase of cytosolic Ca2+ triggered by the 
stimulation of high glucose concentrations. Thus, after 60 min incubation of T. iboga (10 and 
100 µg/mL), high extract concentrations may saturate σ2 receptors of endoplasmic reticulum 
(ER), mitochondria and other organelles where occur σ2 receptors, resulting in high 
concentrations of Ca2+ intracellular that may lead to cell depletion and decrease of insulin 
release (Cassano et al., 2006). This could easily be checked using fura-2 test and Griess assay 
at high T. iboga concentrations in further experiments. T. iboga (>1 µg/mL) is specifically 
inhibiting glucose stimulated insulin release at 16.7 and 25mM (no extract) which is in 
contrast with previous data at 16.7 mM glucose concentration (Souza et al., 2011) but support 
other observations by Cassano et al. (2006).  
Interestingly, at the lowest T. iboga extract concentrations tested (0.001 to 0.1 µg/mL) and at 
stimulatory glucose concentrations (11.1, 16.7 and 25 mM), a marked inhibition of insulin 
secretion was observed compared to controls at the same glucose concentrations. These 
observations suggested that T. iboga aqueous extract may contain antagonistic molecules 
which have an opposite effect to those that potentiate insulin secretion and inhibit glucose-
induced insulin secretion. These molecules at stimulatory glucose concentrations seem more 
efficient at low concentrations of T. iboga, efficacy which is gradually reduced with 
increasing concentrations of the plant extract (0.01, 0.1 and 1 µg/mL). However, at higher 
concentrations of T. iboga (from 10 µg/mL) there is an antagonism effect of insulin 
potentiation and secretion at stimulatory glucose concentrations, which was already seen at 
high concentrations of plant extracts in contrast with low concentrations effects (Djomeni 
Dzeufiet et al., 2006).  
At non-stimulatory and stimulatory glucose concentrations (2.8 and 11.1 mM), T. iboga 
aqueous extract potentiated glucose-induced insulin release with an optimal effect at 1 µg/mL 
which was significantly increased at 11.1 mM glucose (p < 0.0001) compared to the effect at 
2.8 mM glucose (Figure 3.8, panel a-b). This effect was in agreement with previous study 
(Souza et al., 2011). Interestingly, at higher glucose concentrations (16.7 and 25 mM), the 
effect of T. iboga (1 µg/mL) on glucose-induced insulin secretion decreased significantly 
compared to controls (no extract) (p < 0.01 and p < 0.01, respectively) and compared to the 
effect at 11.1 mM (p < 0.0001). This drop on the plant potentiation of glucose-induced 
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insulin release was not seen in Souza et al. (2011) at 16.7 mM. However, this discrepancy 
cannot be discussed as in Souza paper the highest glucose concentration used was 16.7 mM, 
thus we cannot predict the effect at glucose concentration above than 16.7 mM from their 
results and compare with our results which could have helped to construct a hypothesis on the 
contradictory results observed.    
The effect of the optimal concentration of T. iboga aqueous extract (1 µg/mL) was then 
compared to tolbutamide, a sulfonylurea commonly used for type 2 diabetes treatment. 
Sulfonylureas lower blood glucose through a direct insulin secretion stimulation from 
pancreatic ß-cells. Our data show that T. iboga (1 µg/mL) at non-stimulatory and stimulatory 
glucose concentrations (2.8 and 11.1 mM) potentiated glucose-induced insulin secretion in a 
glucose-dependent manner. These effects are similar to well-known insulin secretagogue 
including sulfonylurea, such as tolbutamide (Ball et al., 2004). Moreover, these results are in 
accordance with previous findings (Souza et al., 2011). In our data, T. iboga aqueous extract 
has shown to be more efficient at glucose stimulatory concentrations (11.1 mM) than 
tolbutamide and failed to potentiate glucose-induced insulin release at high glucose 
concentrations (16.7 and 25 mM). Sulfonylureas are known to stimulate insulin secretion 
from islets of Langerhans by direct binding to the sulfonylurea receptor SUR1, one subunit of 
KATP channel in ß-cell plasma membrane. This binding leads to the inactivation of KATP 
channel, promoting the membrane potential depolarisation and electrical activity with rise in 
intracellular Ca2+ and insulin secretion (Ball et al., 2004; Souza et al., 2011). However, T. 
iboga aqueous extract has been reported to exhibit an insulinotropic action in a different way. 
Indeed, previous data have demonstrated that KATP channels were involved in the effects of T. 
iboga aqueous extract, as those were suppressed in the presence of diazoxide (KATP channel 
blocker) which also inhibited, glucose and sulfonylurea-induced insulin release by preventing 
KATP channels closure (Souza et al., 2011). Our data shows that T. iboga at 1 µg/mL 
significantly potentiated the effects of Tolbutamide (200 µM) at non-stimulatory and 
stimulatory glucose concentrations (2.8 and 11.1 mM), this result is in agreement with 
previous data (Souza et al., 2011). Thus, as mentioned previously, T. iboga aqueous extract 
insulin potentiation is not purely mediated by the same binding sites as sulfonylurea (Souza 
et al., 2011). In parallel, it has been also shown that T. iboga aqueous extract insulinotropic 
effects were Ca2+-dependent. Indeed, the Ca2+dependency was evidenced by the inhibition of 
insulin release potentiation by the plant in a Ca2+-free medium and in presence of 
Ca2+channels blocker (Souza et al., 2011). Moreover, additional evidence of Ca2+ 
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involvement in T. iboga glucose-induced insulin potentiation was demonstrated when the 
plant extract exhibited enhanced Ca2+uptake in islets in the presence of increasing glucose 
concentrations in Fura-2 test (Souza et al., 2011). It has been previously suggested that T. 
iboga active principles may interact with σ2 receptors (Bowen et al., 1995; Souza et al, 
2011), which are present in endocrine tissues and have a putative role in modulating the 
synthesis of enzymes/hormones such as insulin, cytotoxicity and cell death (Bowen, 2001; 
Ahn et al., 2015).  
As T. iboga has been suggested to be σ2 receptors agonist (Bowen, 2001; Souza et al., 2011), 
we assessed T. iboga effects at a concentration of 1 µg/mL, that significantly potentiated 
glucose-induced insulin release in presence of SM-21 at low and high concentrations, along 
with the involvement of σ2 receptors in insulin secretion. SM-21 or the 3 alpha-tropanyl-2-
(4-chorophenoxy)- butyrate have been reported to possess high and preferentially affinity to 
σ2 receptors and act as functional antagonist at σ2 receptors (Matsumoto and Mack, 2002). 
Our data show that, there is significant reversal of glucose stimulating insulin release at 2.8 
mM, 11.1 mM, 16.7 mM and 25 mM glucose at high concentration of SM-21 (Figure 3.11). 
Indeed, at 11.1 and 16.7 mM glucose, glucose-induced insulin secretion was inhibited by 
more than 2-fold, while the insulin secretion was almost totally inhibited at 25 mM glucose at 
both SM-21concentrations (1 and 10 µM) compared to controls. At low concentration of SM-
21 (1 µM) glucose-induced insulin secretion was significantly partially inhibited at 
stimulatory and high glucose concentrations (11.1, 16.7 and 25 mM) by more than 2-fold at 
11.1 mM and 16.7 mM glucose and by 11-fold at 25 mM glucose concentrations, p < 0.0001, 
Figure 3.11. However, at low glucose concentration (2.8 mM), SM-21 (1 µM) inhibition of 
glucose-induced insulin secretion was not significant but inhibited significantly T. iboga 
effects at the same glucose concentration, indicating a functional antagonism. In the presence 
of 1 µg/mL T. iboga, insulin secretion potentiation was partially inhibited by 3-fold in the 
presence of SM-21 at 10 µM, Figure 3.11. At 11.1 mM glucose, the effect of both SM-21 
concentrations on insulin secretion was inhibited up to 3 ng/ml/10 islets compared to control 
at same glucose concentration, with no extract (~8 ng/ml/10 islets), while the insulin levels 
were not altered at 16.7 mM and slightly inhibited at 25 mM glucose. The σ2 receptors 
involvement in the effect of T. iboga aqueous extract was evidenced by the action of SM-21. 
There are few data in the literature on σ2 receptors mediated insulin secretion 
experimentations and no known endogenous ligand has been firmly identified yet (Souza et 
al., 2011; Nicholson et al., 2016; Zeng et al., 2014). However, the inhibition of glucose-
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induced insulin secretion by the antagonist SM-21 might be partly explained by the 
involvement of σ2 receptors in the modulation of intracellular Ca2+ flux, which is major in 
insulin secretion, as mentioned previously (Vilner and Bowen, 2000; Ashcroft and Rorsman, 
2012). Furthermore, previous experiments have revealed that σ ligands produce a dual 
modulation of intracellular Ca2+ via the release of Ca2+ from intracellular stores and the 
prevention of depolarisation-dependent Ca2+ influx (Vilner and Bowen, 2000). Indeed, in the 
absence of T. iboga, σ2 antagonist SM-21 may alter Ca2+ influx in ß-cells and decrease 
insulin secretion induced by glucose stimulatory concentrations (Ahn et al., 2015). However, 
in the presence of T. iboga aqueous extract, there is a partial inhibition by SM-21 compared 
to controls with no extract. σ2 receptors were already suggested to block all Ca2+ channel 
subtypes in the body cells (N-, L-, P/G- R-type) and modulate cell-to-cell signalling in 
sympathetic and parasympathetic neurons, since in neonatal rat intracardiac and superior 
cervical ganglia, σ2 receptors rapidly depress peak of Ca2+ channel currents (by more than 
95%) in a reversible manner (Cassano et al., 2006). Hence, taken together, the effects shown 
at high concentration of SM-21 (10 µM) and with T. iboga aqueous extract in our study 
support the hypothesis that σ2 receptors may negatively modulate an increase in cytosolic 
Ca2+, which could counterbalance the positive effect on intracellular Ca2+ observed after σ2 
receptors activation (Cassano et al., 2006). 
The indication of oxidative stress on isolated islets from increased glucose and T. iboga 
extract was assessed via Griess assay, a colorimetric assay which detects total nitrite 
reflecting the amount of nitric oxide (NO) produced, to ensure that the insulin secretion 
measured was due to treatment-induced insulin secretion and not cell death because of 
oxidative stress. Indeed, it has been mentioned that pancreatic islets isolation may induce an 
oxidative stress (Carter et al., 2009; Miceli et al., 2018). Oxidative stress is also a common 
characteristic of both type 1 and type 2 diabetes mellitus as biomarkers of oxidative stress are 
strongly elevated in pancreas of diabetics (Miceli et al., 2018). Numerous in vitro and in vivo 
studies have shown that mechanical and enzymatic separations of pancreatic islets during 
isolation, as well as elevated glucose exhibition, may lead to oxidative stress and affecting ß-
cells survival and function (Miceli et al., 2018). This issue is due to the imbalance between 
the production of reactive species (ROS) and the weak antioxidant capacity in ß-cells. As 
mentioned previously, pancreatic ß-cells are extremely sensitive to oxidative stress due to 
their frail antioxidant system, caused by a low expression and activity of the hydrogen 
peroxide (H2O2)- inactivating enzymes in insulin-producing cells comparing to other tissues 
(Miceli et al., 2018). Figure 3.12, showed that at high glucose concentrations (16.7 and 25 
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mM), levels of total nitrite, thus NO production were significantly (p < 0.0001) elevated 
compared to no glucose or stimulatory glucose concentration of 11.1 mM. These results were 
already observed in other studies when isolated islets were exposed to high glucose 
concentrations. Indeed, glucose concentrations of 16.7 and 28 mM are physiological 
stimulatory concentrations of ROS production, thus elevated NO production compared to 
controls (2.8 and 11.1 mM), which is consistent to our results (Armann et al., 2007; Zhao et 
al., 2018). Further the evidence for oxidative stress (elevated nitrates) of islets at 
concentrations >16 mM glucose may explain the reduction in insulin secretion in the 
presence of T. iboga concentrations > 10 µg/mL insulin secretagogue. High concentrations of 
T. iboga which enhance Ca2+ levels via σ2 receptor activation may induce cytotoxicity in 
cells already sensitive to oxidative stress.  
The effects of G. tessmannii aqueous extract were assessed under the same conditions as T. 
iboga. At increasing glucose concentrations (0 to 25 mM glucose), data show that the optimal 
concentration of the aqueous extract of G. tessmannii is 70 µg/mL with insulin levels 
reaching 6.66 ng/ml/10 islets at 11.1 mM glucose and 7.12 ng/ml/10 islets at 16.7 mM 
glucose compared to controls. The bell-shape effect was also observed in the data and suggest 
that at stimulatory glucose concentrations (11.1, 16.7 and 25 mM), G. tessmannii aqueous 
extract at low concentrations (1 µg/mL and 10 µg/mL for 11.1 mM glucose, 1 µg/mL to 50 
µg/mL for 16.7 and 25 mM glucose) may contain antagonistic molecules which inhibited 
glucose-induced insulin secretion, as seen with T. iboga, exhibiting a dual effect of the plant 
extract. In addition, at high concentrations of G. tessmannii (1 mg/mL and 10 mg/mL at 11.1 
and 16.7 mM glucose and from 100 µg/mL to 10 mg/mL at 25 mM glucose) the insulin 
potentiation effect was also inhibited indicating an opposite effect of the plant extract at these 
concentrations as seen with T. iboga high concentrations (10 and 100 µg/mL) and other plant 
extracts (Djomeni Dzeufiet et al., 2006).  
Interestingly, G. tessmannii optimal concentration (70 µg/mL) effects on insulin secretion 
were increasing with glucose concentrations, compared to T. iboga optimal concentration (1 
µg/mL). These effects were similar to those produced by insulin secretagogue tolbutamide at 
same glucose concentrations and those produced by T. iboga aqueous extract at 1 µg/mL at 
stimulatory glucose concentration (7.31 ng/ml/10 islets at 11.1 mM). G. tessmannii aqueous 
extract at 70 µg/mL potentiated glucose-induced insulin secretion in presence of insulin 
secretagogue tolbutamide at 200 µM, however, the effects were less amplified than those 
with T. iboga (1 µg/mL) under the same conditions, except at glucose concentrations 16.7 
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and 25 mM. Indeed, at 11.1 mM and 16.7 mM G. tessmannii aqueous extract (70 µg/mL) in 
presence of tolbutamide (200 µM) induced insulin levels to reach 7.93 and 8.59 ng/ml/10 
islets respectively compared to 8.04 and 5.24 ng/ml/10 islets for the effects with T. iboga at 1 
µg/mL, a relatively low concentration compared to G. tessmannii optimal concentration of 70 
µg/mL. G. tessmannii observed effects in presence of tolbutamide suggest that the plant 
extract may bind at the same receptor of the insulin secretagogue, but not at the same site.  
This is the first evidence that G. tessmannii has insulin secretagogue activity. G. tessmannii 
phytochemical analyses has revealed bioactive compounds such as flavonoids, alkaloids and 
triterpenes saponins (Madingou et al., 2012). These molecules have been investigated for 
several activities including antimicrobial, antioxidant, cytotoxicity, anti-inflammatory, 
immune-stimulatory and hypoglycaemia (Keller et al., 2011; Cui et al., 2015; Nyangono 
Beyegue et al., 2013; Hameed et al., 2018). Moreover, saponin-rich fraction from 
Momordica charantia, compound also present in G. tessmannii, (Madingou et al., 2012) has 
shown in vitro insulin secretion stimulation in pancreatic ß-cells (MIN6) in a concentration 
dependent-manner which may support the insulinotropic effect observed with G. tessmannii 
in primary isolated ß-cells (Keller et al., 2011). Furthermore, a previous study has shown that 
triterpenoid saponins from Aralia taibaiensis a Chinese traditional medicine, have potently 
stimulated the release of insulin from BTC3 cells at stimulatory glucose concentrations (Cui 
et al., 2015), supporting the effect of G. tessmannii aqueous extract (rich in triterpenoid) 
(Madingou et al., 2012) in pancreatic ß-cells. However, the mechanisms of action of those 
bioactive compounds are only beginning to be explored, and some of their effects are 
suggested to be mediated via GPR40 mediated Ca2+ and PKC pathways, while PKA pathway 
has also been suggested to mediate insulin secretion enhancement by flavonoids (Hameed et 
al., 2018).  
As with T. iboga, indications of G. tessmannii inducing oxidative stress was assessed. (Figure 
3.16) shows little or no effect on primary isolated rat islets after treatment with various 
concentrations of the plant extract. 
In this chapter, I demonstrated that T. iboga aqueous extract at 1 µg/mL potentiated insulin 
release at non-stimulatory and stimulatory glucose concentrations (2.8 and 11.1 mM), this 
effect was more potent than those of insulin secretagogue, tolbutamide (200 µM). Unlike 
sulfonylureas, T. iboga aqueous extract mediated the increase of insulin release through σ2 
receptors via rise of intracellular Ca2+. This mechanism was confirmed by the inhibition of T. 
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iboga effects by SM-21, a potent and selective σ2 receptor antagonist, at low and high 
glucose concentrations. Also, it was demonstrated for the first time, that G. tessmannii 
aqueous extract at 70 µg/mL potentiated insulin release at non-stimulatory and stimulatory 
glucose concentrations (from 2.8 to 16.7 mM) and these effects were similar to those of 
tolbutamide. Both plant extracts have additional effect on insulin release when incubated with 
tolbutamide at 11.1 mM glucose. Moreover, optimal concentrations of T. iboga (1 µg/mL) 
and G. tessmannii (70 µg/mL) did not induce oxidative stress at non-stimulatory and 
stimulatory glucose concentrations (2.8 and 11.1 mM). 
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C h a p t e r  4 :  I n  v i v o  i nves t i ga t ion  o f  aqueous  ex trac t s  o f  T.  i boga  i n    
                Typ e  2  f ruc tose - f ed  h y p e r g l y c a e m i c  d i a b e t i c  r a t s   
 
4.1. Introduction 
DM as described in chapter 1, is a disease mainly characterised by elevated levels of blood 
glucose as a result of defects in insulin secretion and/ or insulin action (Motala and Ramaiya, 
2010). T2DM is the most prevalent form of diabetes which and results largely from the 
body’s ineffective use of insulin, insulin resistance, excess of body weight and physical 
inactivity (Motala and Ramaiya, 2010) leading to glucose intolerance, hyperglycaemia and 
overt diabetes causing blindness, end-stage renal disease as a consequence of microvascular 
pathology, numerous debilitating neuropathies increasing morbidity and mortality in 
diabetics (Tripathy et al., 2006; Domingueti et al., 2016).  
The root bark of T. iboga is widely used in Gabonese traditional medicine for the 
management of T2DM, as mentioned previously (Bading Taika et al., 2018). Previous in 
vitro studies have demonstrated that the aqueous extract of T. iboga has sulfonylureas-like 
action on insulin release (Souza et al., 2011). T. iboga aqueous extracts (1 µg/ml) potentiated 
the stimulation of insulin secretion at glucose stimulatory concentrations (11.1 and 16.7 mM) 
in vitro via the closure of K+-ATP channels and the increase of Ca2+ influx in isolated 
pancreatic islets triggering glucose-induced insulin release, in the same way as the medicine 
tolbutamide (200 µM) (Souza et al., 2011). Furthermore, as shown in chapter 3, we confirm 
that T. iboga aqueous extract (1 µg/ml) potentiates the insulin secretion at glucose non-
stimulatory and stimulatory concentrations (2.8 and 11.1 mM) from isolated rat pancreatic 
cells via a novel interaction with σ2 receptors. 
T. iboga aqueous extract is reported to be consumed for the management of T2DM among 
Gabonese population (Tjeck et al., 2016; Bading Taïka et al., 2018). Although, to date, there 
is a lack of scientific information regarding the appropriate range of concentrations for T. 
iboga extract to be used safely for diabetes management in animals and in patients (Bading 
Taïka et al., 2018). 
Animal models of diabetes are widely used to investigate in vivo efficacy, mode of action and 
side effects of anti-diabetic plants (Eddooks et al., 2012). Wilson and Islam, (2012) have 
characterised a non-genetic, cost effective, model for T2D in rats with a fast induction time 
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and a stable pathogenesis of T2D of insulin resistance and partial pancreatic ß-cell 
dysfunction over an 11 weeks’ experimental period. One goal of this chapter was to 
determine the in vivo anti-diabetic effects of a range of concentrations of T. iboga (50, 100 
and 200 mg/kg b.w.) in this rat model of T2D. That alternative non-genetic model for T2D 
has shown similar clinical pathogeneses than those seen in human especially insulin 
resistance (IR) and partial pancreatic ß-cells dysfunction and, can be developed in an easy 
way and within a shorter period of time (Wilson and Islam, 2012). Given the insulin 
potentiation effects of T. iboga in vitro (Chapter 3), here we have determined the effect of T. 
iboga on oral glucose tolerance and intraperitoneal fasting insulin tolerance in vivo using the 
STZ/Fructose T2D models, as both techniques are useful tools routinely used to evaluate the 
influence of plant extracts or drugs on insulin sensitivity in laboratory animals in vivo 
(Guarino et al., 2013). However, the neurotoxic effects of ibogaine, one major active 
principle of T. iboga, was reported to be due, in part to agonist at the same σ2 receptor 
(Bowen, 2001; Glick et al., 2001).  
Evidence has shown the main constituent in T. iboga, ibogaine, exhibits toxicity with LD50 
ranging from 145 to 175 mg/kg via i.p. and 263 to 327 mg/kg p.o. in rats (Kubiliene et al., 
2008). Despite the neurotoxic and cardiotoxic properties of ibogaine, there may be other 
compounds in T. iboga aqueous extract with hypoglycaemic properties that prevent or reduce 
the development of T2D (Gonzales-Castejon et al., 2011; Bading-Taïka et al., 2018), 
supported by in vitro studies (Chapter 3, Souza et al., 2011). 
The main criterion/ feature, characteristic/property in the selection of a medicinal plants for 
use in health purposes is safety, as plant extracts should not only be considered efficacious 
but also safe for consumption (Bulus et al., 2011). To determine a safe non-toxic range of 
concentrations of T. iboga aqueous extract, we first evaluated the toxicity in healthy rats 
(objective 1). These results provided information for selecting a safe pharmacological 
concentration range of 50 to 200 mg/kg for evaluating in vivo hypoglycaemic efficacy in 
healthy rats and T2D rats (objective 2 and 3) (Elufioye and Onoja, 2015). 
In this Chapter, we aimed to evaluate T. iboga toxicity (from 50 to 200 mg/kg) and optimal 
dose regimen in vivo in rats, to evaluate the in vivo hypoglycaemic effect of T. iboga (50-200 
mg/kg) in naïve control rats, to investigate the in vivo anti-diabetic effect of T. iboga (50-200 
mg/kg) in Fructose-induced STZ type diabetic animal model, to evaluate the potential 
adverse effects in Fructose-induced STZ diabetic model of long time (28 days) administration 
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of T. iboga (50-200 mg/kg). The animal doses were calculated based on the reported quantity 
of T. iboga administered daily by traditional healers to their patients. This dose was 
considered as the equivalent human dose (HED) (100 ml of the aqueous extract of T. iboga 
per day) which was used to calculate back the range of doses for toxicological and in vivo 
studies (Hosseini et al., 2018). 
4.2. Materials and methods 
	
4.2.1. Animals and environment 
Wistar rats (180-250 g) from the Animal Unit of the Institute of Pharmacopoeia and 
Traditional Medicine (IPHAMETRA), were used for toxicological and pharmacodynamics 
studies. Wistar rats (9 weeks age) were housed in Group of same genders (3 each) and similar 
weight in standard cages (Techniplast 2000P) with sawdust and shredded paper wool bedding 
with free access to water and food (Labdiet 5001). All study protocols were approved by the 
National Committee of Ethics in Scientific Research of Gabon 
(0013/2019/MESRSTT/USTM/VR). 
 
4.2.2. Preparation of T. iboga aqueous extract 
The root barks of T. iboga were collected in Gabonese forest during harvest time by botanists 
from IPHAMETRA (the institute of pharmacopoeia and traditional medicine) and were 
authenticated (Gabon National Herbarium). Voucher specimens were deposited in the 
National Herbarium of Gabon as sample no. (20358). The air-dried root barks were grinded 
using a traditional mortar and pestle, and the fine powder was macerated as described in 
Chapter 3 (materials and methods- Plant material and preparation of T. iboga and G. 
tessmannii aqueous extracts). 
 
4.2.3. Toxicological studies – Acute and sub-acute toxicities (dosing schedule) of T. iboga 
aqueous extract in Wistar rats 
 
Acute toxicity in Wistar rats over 24 hours 
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Toxicity studies were conducted in accordance to the method recommended by 
UNICEF/UNDP/World Bank/ WHO special program for research guidance on non-clinical 
testing strategies, 2002 for the assessment of toxicity of medicinal plants, with slight 
modifications for T. iboga. Acute oral toxicity and toxicity by intraperitoneal route were 
carried out according to modified Lorke’s method (Lorke, 1983). This method was simple, 
reproducible and used minimum number of animals. 
• Lorke’s modified method for oral toxicity consists of two phases 1 and 2 respectively 
The phase 1 requires nine animals, divided into three Groups of three animals each. Each 
Group of animals is administered a single different dose of the plant extract tested (10, 100, 
1000 mg/kg body weight) (Table 4.1). The animals are placed under observation for their 
gross behavioural, neurologic (such as tremors, seizures), autonomic and toxic effects up to 
24 hr, as well as mortally. 
Table 4.1. Doses ranges in animal models and equivalence to human dose (Muhammad 
Ahmed, 2015) 
No Dose Ratio 
1 10 mg/kg Less than human dose 
2 100 mg/kg App similar to human dose 
3 200 mg/kg 2 times greater than human dose 
4 500 mg/kg 4 times greater than human dose 
5 1000 mg/kg 7 times greater than human dose 
6 5000 mg/kg 35 times greater than human dose 
7 10000 mg/kg 70 times greater than human dose 
8 Saline (10 ml/kg) control Group 
 
In the phase 2, further specific doses of the extract were administered once to determine the 
correct LD50 value. The phase 2 consisted of three animals divided into three Groups of one 
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animal each. The animals received higher doses 1600, 2900, and 5000 mg/kg b.w. of tested 
plant extract and then observed for 24 hr. Animals were observed frequently on the day of 
treatment and surviving animals were monitored for signs of acute toxicity - the gross 
behavioural, neurologic, autonomic and toxic effects, as well as mortality. Food 
consumption, faeces and urine were also examined at 2 hr and then at 6 hr intervals for 24 hr. 
For the surviving animals, food consumption and body weight were monitored for up to three 
weeks to established recovery from any toxicity.  
Then the medium Lethal Dose (LD50: the dose that kills 50% of test population) was 
calculated using the following formula: 
LD50 = √	($0	&	$100) 
D0 = Highest dose that gave no mortality 
D100 = Lowest dose that lead to mortality 
Hodge and Sterner scale (Table 4.2, below) was used for the evaluation of toxicity associated 
with the LD50. 
Table 4.2. Toxicity scale (Hodge and Sterner, 2005) 
No Term LD50 (rat, oral) 
1  Extremely toxic Less than 1mg/kg 
2  Highly toxic 1-50 mg/kg 
3  Moderately Toxic 50-500 mg/kg 
4  Slightly Toxic 500-5000 mg/kg 
5  Practically Non-toxic 5000-15,000 mg/kg 
 
Subacute oral toxicity in Wistar rats over 28 days 
The subacute oral toxicity was conducted on rats of both gender, divided into eight Groups of 
three animals each (three females and three males). The doses were selected regarding the 
acute toxicity results in rats’ dose (Table 4.4). The highest subacute dose was 1/5th of the 
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highest dose of the acute toxicity study. All animals were treated daily p.o. (Dose volume = 
Xml/kg) for twenty-eight days and animals were observed twice daily for any adverse effect 
or toxic signs and behavioral alterations, mortality and morbidity until the completion of the 
experiment (Adewale et al., 2016). Extract or distilled water were administered by oral 
gavage. Body weights (weekly), food and water consumption (daily) were recorded. The 
Groups were distributed as followed: 
 
Group 1 and 2: Female and Male Control Group (vehicle p.o. equivalent dose volume) 
Group 3 and 4: Female and male 50 mg/kg b.w. of T. iboga p.o. 
Group 5 and 6: Female and male 100 mg/kg b.w of T. iboga p.o. 
Group 7 and 8: Female and male 200 mg/kg b.w. of T. iboga p.o. 
On the 29th day, the animals were sacrificed by cervical dislocation after CO2 exposure 
following overnight fasting. Animal weight was recorded, organs such as heart, liver, 
kidneys, spleen, lungs, testis and ovaries were carefully dissected out and weighed. Serum 
biochemical parameters were measured (AST, ALP, ALT, TC, Urea, TG, Blood Glucose, 
Creatinine). 
 
4.2.4. Experimental design for the assessment of hypoglycaemic activity of T. iboga 
aqueous extract 
20 healthy Wistar rats were divided and treated in the following pattern according to Jaiswal 
et al. (2009): 5 per Group 
- Group 1: Normal control, vehicle, distilled water DV ml/kg, p.o. NC (N=5) 
- Groups 2: T. iboga 50 mg/kg p.o. 
- Group 3: T. iboga 100 mg/kg p.o. 
- Group 4: T. iboga 200 mg/kg p.o.  
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For all experiments, Fasting Blood Glucose (FBG) was checked initially (overnight fast 12 
hr), then Blood Glucose Level (BGL) was taken 90 min before treatment, which was 
considered as time “0 hr” value. An oral glucose tolerance test (OGTT) was performed to 
assess the hypoglycaemic activity of T. iboga on healthy rats. 
 
• OGTT  
After a 12 hr overnight fast, rats were weighed before taking a blood glucose measurement at 
time 0 hr (90 min before administration of the glucose solution with treatment). We returned 
rats from each Group in their respective Group cage (no food or water).  
One drop of tail vein blood was obtained by a needle prick of conscious rats and measured 
using a glucometer (Accu-check active, @Roche, Germany). Glucose meter was calibrated 
according to the manufacturer’s instructions before each experiment. 
We used gavage tube with rounded tip 20 gauge for glucose oral administration. 
Following FBG, a glucose solution of 20% D-Glucose in 0.9% NaCl (2 g/kg rat was given at 
a DV of 20 ml/kg rat), or 20 µl of 20% glucose/g rat (Table 4.3). 
Blood glucose at 1 hr, 2 hr and 3 hr after glucose injection at 30 sec intervals were measured. 
We returned rats at completion of 180-minute time point to their respective cages with food 
and water. We dissolved 10 g of D-glucose (Sigma) in 50 ml of 0.9% NaCl before use. 
0.9% NaCl: Dissolve 0.9 g NaCl (Sigma) in 100 ml of deionized water. 
Doses of T. iboga were calculated according to the subacute toxicity test results. We used 
values below the 10% of oral DL50 (1442.77 mg/kg b.w.) in rats, we obtained a value of 
144.28 mg/kg b.w. value that gives no adverse effect and good recovery after a long-term 
treatment with T. iboga aqueous extract. 
 
 
 
	 135	
 Table 4.3. Experimental treatment design for the effect of T. iboga on OGTT (FBG: Fasting 
blood glucose; dH2O: distilled water; BG: Blood glucose; BGL: Blood glucose level; T0: 
Time 0 hr; T1: Time 1 hr; T2: Time 2 hr; T3: Time 3 hr; b.w.: body weight) 
Treatment 
Group 
Group 1 
(Normal 
Control, NC) 
Group 2 
T. iboga (50 
mg/kg) 
Group 3 
T. iboga (100 
mg/kg) 
Group 4 
T. iboga (200 
mg/kg) 
Route Oral Oral Oral Oral 
Dose 10 ml of dH2O 
+ D-glucose 
(20%) 
50 mg/kg b.w. 
T. iboga + D-
glucose (20%) 
100 mg/kg b.w. 
T. iboga + D-
glucose (20 %) 
200 mg/kg b.w. 
T. iboga + D-
glucose (20 %) 
FBG Initial BG value 
after fasting 
Initial BG value 
after fasting 
Initial BG value 
after fasting 
Initial BG value 
after fasting 
BGL (T0) BGL 90 min 
before treatment 
administration 
BGL 90 min 
before treatment 
administration 
BGL 90 min 
before treatment 
administration 
BGL 90 min 
before treatment 
administration 
BGL (T1) BGL 1 hr after 
T0 
BGL 1 hr after 
T0 
BGL 1 hr after 
T0 
BGL 1hr after 
T0 
BGL (T2) BGL 2 hr after 
T0 
BGL 2 hr after 
T0 
BGL 2 hr after 
T0 
BGL 2 hr after 
T0 
BGL (T3) BGL 3 hr after 
T0 
BGL 3 hr after 
T0 
BGL 3 hr after 
T0 
BGL 3 hr after 
T0 
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4.2.5. Experimental design of the assessment of anti-diabetic activity of T. iboga aqueous 
extracts on type 2 fructose diabetes according to Wilson and Islam (2012) 
A non-genetic rat model T2D was generated in accordance with Wilson and Islam (2012). 38 
male Wistar rats weighing 180-250 g were used. Water supplemented with 10% fructose 
(FR10) for an initial 2 weeks’ period was provided followed by normal water regimen and 
Labdiet 5001 ad libitum throughout the experimental period. The normal control Group (NC, 
Group 1) was provided with normal drinking water throughout the study.  
On the day of STZ injection, STZ was dissolved in a citrate buffer (pH 4.4) at a concentration 
of 4 mg/ml and allowed to stand in the fridge for 30 min prior to injection, as this time period 
allows for the more toxic anomer of STZ to equilibrate with the less toxic anomer, thereby 
standardising the toxic quality of the preparation (De la Garza-Rodea et al. 2010). All animals 
were fasted overnight and injected intraperitoneally (i.p., DV 10 ml/kg) with a low dose of STZ 
40 mg kg b.w. except for Group 1 (normal control, NC) animals that were injected with vehicle 
citrate buffer, pH 4.4. Blood glucose was measured by using a glucometer on a droplet of blood 
collected from tail vein. Rats with Non-Fasting Blood Glucose (NFBG) level ≥ 300 mg/dl were 
considered as diabetic and selected for experimental study. 
Weekly FBG and NFBG were measured throughout the experimental period. For 48 hr 
following the STZ or vehicle injection 2% sucrose solution was provided to avoid initial 
hypoglycaemia observed following STZ treatment. All treated animals were giving a choice of 
2% sucrose or water (providing 1 bottle of water and 1 bottle of 2% sucrose per cage) during 
the 48 hr period after STZ or buffer injection and then returned to normal drinking water ad 
libitum throughout the study.  
In the experiment, a total of 42 rats, including 10% of possible non-diabetic rats (30 diabetic 
surviving rats and 5 normal rats) were used. Animals were randomly divided based upon mean 
body weight into 8 groups of 5 rats each after the confirmation of diabetes (blood glucose ≥ 
300 mg/dl) and drugs/ extracts were administered as in Figure 4.1. Doses were selected 
according to the sub-acute toxicity test results and hypoglycaemic efficacy (Figure 4.2). 
Group 1: Normal Control: no Fructose, no STZ 
Group 2: STZ control: STZ (40 mg/kg i.p.), no Fructose 
Group 3: STZ/ Fructose 10% Control STZ/FR10 (40 mg/kg i.p.)  
Group 4: T. iboga (50 mg/kg p.o.) + Fructose (10%, + STZ (40 mg/kg i.p.) 
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Group 5: T. iboga (100 mg/kg p.o.) + Fructose (10% + STZ (40 mg/kg i.p.) 
Group 6: T. iboga (200 mg/kg p.o.) + Fructose (10% + STZ (40 mg/kg i.p.) 
Group 7: Glibenclamide 5 mg/kg b.w. + Fructose (10%), + STZ (40 mg/kg i.p.) 
Group 8: Fructose control: Fructose (10%), no STZ 
Treatments (T. iboga, Glibenclamide, Vehicle) were orally administered once daily (8 am 
every day) for four weeks (28 days).  
Blood glucose was measured at 0, 30, 60 min then 120 min after first treatment 
administration and then daily (NFBG) during the treatment period. A droplet of blood was 
withdrawn from the tail vain each time and blood glucose measured with a glucometer 
(Accu-Check active, @Roche, Germany) 
Oral glucose tolerance test (OGTT) and intraperitoneal insulin tolerance test (i.p.ITT) were 
performed at the 2nd and 4th weeks of treatment.  
• OGTT procedure was detailed in section 4.2.4. 
• ipITT 
Intraperitoneal insulin tolerance test or i.p.ITT is designed to determine the sensitivity of 
insulin-responsive tissues in the rodent. This is determined by the measurement of glucose 
remaining in the circulation over time after a bolus i.p. insulin injection. 
Stock of Humulin R solution (100 U/ml) was diluted with saline to 0.5 U/ml (1/200 dilution) 
by adding 10 µl stock (100 U/ml) to 1990 µl 0.9% (w/v) sterile saline. 
Working insulin solution (0.075 U/ml) of 12 ml was prepared by adding 1.8 ml of 0.5 U/ml 
insulin solution to 10.2 ml of sterile physiological saline (0.9% NaCl) in a sterile 15-ml 
centrifuge tube. 
Rats fasted overnight before the day of experiment. We measured blood glucose prior insulin 
treatment. Then, administered the rat an intraperitoneal injection of 10 µl of 0.075 U/ml 
insulin solution per gram body weight (dose of 0.75 U/kg, 10 mL/kg) with a 28 G x ½” 
needle. 
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Blood samples were taken from the tail vein by a needle prick of conscious rats and measured 
using a glucometer before the insulin injection and at 30, 60, 90 and 120 min. Between each 
of these time points, we returned the rat to its cage with no food and water. 
Food and water intake, and body weights were recorded on a daily basis (morning) during the 
28 days’ experiment. At the end of 4 weeks’ experiment, rats were anaesthetised by CO2 
asphyxiation and opened at the abdomen. Blood was withdrawn from the abdominal aorta 
and centrifuged at 3000 rpm for 10 min to obtain serum. 
Organs (heart, lungs, liver, kidneys, testis) were weighed and serum biochemical parameters 
measured (HDL, LDL, Hba1c, AST, ALP, ALT, TC, Urea, TG, Blood Glucose, Creatinin) 
and also insulin resistance (HOMA-IR, HOMA-b scores). 
 
 
Figure 4.1. Experimental schedule for the induction and development of STZ/FR10 T2D 
model and T. iboga treatment. D: day, BGL: blood glucose levels, OGTT: oral glucose 
tolerance test, ITT: insulin tolerance test, W: weight, FI: fluid intake 
 
 
 
 
 
         Fructose treatment (10%)                            T. iboga treatment                          Study end 
D-14                    D-7                  D 0          D 3           D 10        D 17     D 24    D 31 D 32 
BGL                    BGL    (STZ injection)   BGL          BGL       BGL      BGL   BGL 
W+FI                 W+FI     + 2% sucrose     W+FI       W+FI     (OGTT  W+FI   (OGTT  
                                               W+FI                                        + i.p.ITT)           + i.p. ITT) 
                                                                                                    W+FI                W+FI 
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4.2.6. Biochemical analyses 
Biochemical analyses in Gabon were performed following blood samples collection from the 
heart of the animal using the heart puncture technique. Blood was collected in EDTA tubes 
which contain the anticoagulant heparin. The blood samples were rapidly centrifuged at 3000 
rpm for 10 min using a bench-top centrifuge (CYAN CL008, Cypress Diagnostics, Belgium) 
to obtain plasma. The plasma obtained was used for biochemical analyses using the 
biochemistry analyzer, CYANsmart (Cypress Diagnostics, Belgium), which is an easy-to-
operate semi-automatic biochemistry analyzer.  
Analyses carried out included the measurement of the activity of the serum alanine 
aminotransferase (ALT), the aspartate aminotransferase (AST) and the alkaline phosphatase 
(ALP), along with the serum Total Protein (TP), urea, and creatinine concentrations which 
are indicators of kidney function. Besides, the serum Triglyceride (TG) (fat carried in the 
blood), High-Density Lipoprotein (HDL) also called “good” cholesterol, Low-Density 
Lipoprotein (LDL) also called “bad” cholesterol, and Total Cholesterol (TC) concentrations 
were assessed to obtain an indication of the extract/drug effects on lipid profile. Also, serum 
glucose and glycated hemoglobin (for long period blood sugar level involved in diabetes 
conditions) concentrations gave indications and monitoring of diabetes. All these parameters 
were assessed using commercially available test kits (Biomed-Gabon, Cypress Diagnostics, 
Belgium). Glucose was measured using a glucometer (Accu-Check active, @Roche, 
Germany). 
 
4.2.7. Data analysis  
All experimental data are presented as mean ± standard error mean SEM. Data analysis was 
performed with GraphPad Prism 7.0 software to determine the level of statistical 
significance. When the level of probability (p) was less than 0.05 (*), 0.01 (**), 0.001 (***), 
or 0.0001 (****) the effect of the difference was considered statistically significant, very 
significant or extremely significant compared to an independent variable. One-way ANOVA 
was conducted to examine the effect of a single independent variable (e.g. blood glucose) on 
more than two Groups (e.g. extract concentrations, vehicle) followed by Dunnett’s test for 
comparison between treatment Groups.  
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Two-way ANOVA was conducted to evaluate the effect of two independent variables in 
specific experiments followed by Tukey’s tests, in terms of the effect of treatment (e.g., STZ) 
in addition to the effect of the tested drug concentration (T. iboga or Glibenclamide). Body 
weight, food intake, OGTT, and i.p.ITT data were analysed using a repeated-measures-in-
time design ANOVA. Repeated measures within animals were modelled using a first-order 
autoregressive variance-covariance structure (body weight and food intake over time) or an 
unstructured variance-covariance structure (OGTT and i.p.ITT data over time). Baseline 
values were used as linear covariate for body weight and food intake data.  
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4.3. Results 
4.3.1. Toxicological studies - Acute and sub-acute toxicities  
4.3.1.1. Acute toxicity of T. iboga in rats 
Table 4.4. Acute toxicity of T. iboga aqueous extract administered by oral route to Wistar rats 
(b.w.: body weight) 
Experiment Dose (mg/kg 
b.w.) 
Mortality after 
24 hr 
Symptoms after 2 
hr 
Mortality after 
14 days 
Phase 1  10 0/3 Nil 0/3 
 100 0/3 Light abdominal 
cramps 
0/3 
 1000 0/3 Light abdominal 
cramps and lost 
balance 
0/3 
Phase 2 1600 0/1 Light abdominal 
cramps and lost 
balance 
0/1 
 2900 1/1 Abdominal cramps, 
turning around, lost 
balance 
1/1 
 5000 1/1 Strong abdominal 
cramps, respiratory 
distress, trembling 
1/1 
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We obtained by oral route a maximum dose of the extract that kills 0% of the Group (LD0) of 
784.71 mg/kg b.w. and the minimum dose of the extract that kills 100 % of the population 
(LD100) of 2000 mg/kg b.w. 
LD50 by oral route was 1442.77 mg/kg b.w. 
T. iboga aqueous extract was found to be slightly toxic by oral route, according to Hodge and 
Sterner scale (Table 4.2). 
A maximum dose of the extract that kills 0% of the population by intraperitoneal (i.p.) route 
was (LD0) of 350 mg/kg b.w. and the minimum dose of the extract that kills almost 100 % of 
the Group (LD100) of 375 mg/kg b.w. 
LD50 by i.p. route was 362.28 mg/kg b.w. 
T. iboga aqueous extract was found to be moderately toxic by i.p. route, according to Hodge 
and Sterner scale (Table 4.2). 
4.3.1.2.  Sub-acute toxicity study in rats 
4.3.1.2.1.  Mortality and general behaviour 
Table 4.5. Sub-chronic toxicity of T. iboga administered by oral route to rats for 28 days (dw: 
distilled water; +: level of irritability) 
Doses (mg/kg) Toxic symptoms 
0 (1 ml/ 100 g of dw) None 
50 None 
100 None 
200 Irritability (+) 
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Oral ingestion of the aqueous extract of T. iboga at 50, 100 and 200 mg/kg b.w. once daily 
for 28 days did not induce any mortality in rats of both genders. No significant difference in 
food and water consumption was recorded in treated and control Groups.   
Body weight was recorded once a week during the 28 days’ treatment, as shown on Table 4.6 
and organs weight were measured on the 29th day (Table 4.7). 
Table 4.6. Effect of T. iboga root barks during 28 day’s treatment on healthy rats’ body gain 
weights % (Values are mean ± SEM (n=5). Two-way repeated measures ANOVA followed 
by Dunnett’s multiple comparisons test. Statistical difference between groups are indicated 
with different letters (* p < 0.05 compared to respective control group)                                                                  
Day/ T. iboga 
doses (mg/kg) 
0 50 100 200 
  7        Male 
            Female 
+ 7.16 + 17.24* + 12.55* + 18.6* 
- 12.6 + 1.48* + 12.74* - 4.16 
  14       Male 
             Female 
+ 0 + 8.23* + 2.55* + 6.96* 
- 2.42 + 5.65* + 2.54* + 1.91 
  21      Male 
            Female 
+ 0.07 + 10.58* + 20.92* + 4.62 
+ 0 + 2.75* + 5.70* - 0.52 
  28      Male 
            Female 
+ 6.15 + 4.99* + 13.20* + 0.8 
- 0.08 - 2.11* - 9.38* - 0.17 
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Male rats in control Group gained weight throughout the study. However, female rats in 
control Group lost weight during the first two weeks and then did not gain or lost weight 
(Table 4.6). In Group 1, treated with 50 mg/kg b.w. of T. iboga, male rats gained significantly 
more weight from the first week until the end of the study compared to control (p < 0.05) 
Group (Table 4.6). Similarly, female rats of the same Group gained weight throughout the 
study (Table 4.6). In Groups treated with 100 and 200 mg/kg b.w., male and female rats 
gained weight throughout the experimental period (table 4.6). The data in Table 4.6 shows 
weight gain in all experimental Groups throughout the study. 
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Table 4.7. Organ weights of healthy rats (male and female) after 28 days of oral treatment with T. iboga (Values are mean ± SEM (n=5). Two-
way ANOVA followed by Dunnett’s multiple comparisons test. Statistical difference between Groups are indicated as follow: ** p < 0.01; *** p < 
0.001; **** p < 0.0001 compared with control Group)   
Organs Control (no extract)  T. iboga 50 mg/kg b.w. T. iboga 100 mg/kg b.w. T. iboga 200 mg/kg b.w. 
Heart        Male 
                  Female 
1000.6 ± 69.1 1285.6 ±21.6 978.4 ± 14.2 1045.4 ± 22.8 
866.2 ± 33.2 745.6 ± 2.1 681 ± 8.3 999.2 ± 12.5 
Lungs        Male 
                  Female 
1817.2 ± 153.2 2407.6 ± 235.7 1685.6 ± 82.7*** 2996.2 ± 499.7**** 
1128 ± 150.6 1305.2 ± 2.5 1682 ± 18.5** 1484.4 ± 311.4 
Liver         Male 
                  Female 
7501.4 ± 118.2 7285.8 ± 46.4 6844 ± 92.6*** 7993.2 ± 86.8** 
5637.2 ± 255.1 5694.2 ± 37.5 5492.4 ± 39.7 7331 ± 175.1**** 
Kidney      Male 
(L)              
Female 
896 ± 44.3 1043.8 ± 33.1 811 ± 17.1 899 ± 6.1 
712.2 ± 46.3 584.6 ± 4.8 648.6 ± 4.4 900.8 ± 12.1 
Kidney      Male  946.2 ± 68.0 1054.8 ± 43.2 799 ± 22.7 917.8 ± 26.0 
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(R)              
Female 
722.2 ± 39.2 639.6 ± 14.0 653.6 ± 9.4 928.8 ± 13.2 
Spleen       Male 
                  Female 
627.2 ± 19.2 764.4 ± 6.0 479.8 ± 11.1 819.2 ± 78.3 
428.2 ± 22.0 383.4 ± 5.7 533 ± 9.0 504.8 ± 9.4 
Testis 3152.8 ± 201.0 3288.6 ± 11.1 3171.4 ± 100.6 3094.8 ± 61.5 
Ovaries and 
Uterus 
1239.8 ± 27.3 1382.2 ± 7.3 1733.4 ± 32.0** 1444.4 ± 50.0 
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The table 4.7 shows that male lungs weights in Groups treated with 100 mg/kg and 200 
mg/kg of T. iboga aqueous extract were significantly higher than control after 28 days (p < 
0.001 and p <0.0001, respectively). Male liver weights in Group treated with 200 mg/kg were 
significantly higher than control, however, in Group treated with 100 mg/kg of T. iboga, liver 
weights significantly decreased compared to control (p <0.01 and p <0.001, respectively). 
Similarly, female lungs weights in Group treated with 100 mg/kg of T. iboga were 
significantly higher than control (p <0.01) and female liver weights in Group treated with 200 
mg/kg of T. iboga were significantly increased compared to control (p <0.0001). Ovaries and 
uterus weights were also significantly increased in female rats Group treated with 100 mg/kg 
of T. iboga aqueous extract compared to control (p <0.01).  No change in tissue weights were 
seen in Groups treated at 50 mg/kg (p > 0.05) in both males and females. 
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Table 4.8. Biochemical parameters of healthy rats treated with T. iboga for 28 days (Values 
are mean ± SEM (n=6, male or female). One-way ANOVA followed by Dunnett’s multiple 
comparisons test. Statistical difference between groups are indicated **** p < 0.0001, ** p < 
0.01 and   * p < 0.05 vs control) 
Parameters Control (no 
extract)  
T. iboga 50 
mg/kg b.w. 
T. iboga 100 
mg/kg b.w. 
T. iboga 200 
mg/kg b.w. 
AST (IU/L)         
             Male 
            Female 
205.6 ± 3.7 
 
201.0 ± 5.1 169.200 ± 7.2 **** 203.6 ± 3.6 
199.0 ± 0.7 195.6 ± 2.3 118.8 ± 0.6*** 194.2 ± 1.6 
ALT (IU/L)  
             Male 
            Female 
53.2 ± 0.8 
 
49.0 ± 2.0 53.0 ± 0.7 53.2 ± 0.6 
61.5 ± 0.5 63.000 ± 1.356 39.080 ± 0.037**** 58.400 ± 0.510 
ALP (IU/L)      
            Male 
            Female 
484.6 ± 2.6 
 
483.4 ± 2.0 473.6 ± 3.5 **** 486.8 ± 2.1 
258.4 ± 1.2 253.8 ± 1.4 239.6 ± 1.5**** 253.6 ± 0.7 
TC (mmol/L) 
            Male  
            Female 
2.1 ± 0.0 
 
2.1 ± 0.0 2.2 ± 0.0 2.4 ± 0.0 
2.0 ± 0.0 2.0 ± 0.0 2.1 ± 0.0 2.3 ± 0.1 
Urea (mmol/L)  
            Male 
            Female 
9.5 ± 0.1 
 
9.9 ± 0.1 9.1 ± 0.6 8.7 ± 0.0 
9.3 ± 0.0 15.1 ± 0.0* 9.7 ± 0.1 9.0 ± 0.0 
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Glycemia 
(mmol/L)  
            Male 
            Female 
2.6 ± 0.4 
 
1.6 ± 0.2 1.0 ± 0.0 1.1 ± 0.1 
2.2 ± 0.1 1.3 ± 0.0 0.9 ± 0.1 0.7 ± 0.1 
Blood glucose 
(mmol/L)  
            Male 
            Female 
4.5 ± 0.5 2.3 ± 0.1 7.0 ± 0.3 5.0 ± 0.1 
 
3.4 ± 0.2 3.1 ± 0.0 3.1 ± 0.0 8.3 ± 0.1 
Creatinine 
(µmol/L)  
            Male 
            Female 
56.6 ± 3.0 51.2 ± 1.2* 58.2 ± 2.6 50.4 ± 2.3* 
 
83.0 ± 0.7 70.6 ± 0.4**** 61.8 ± 0.4**** 63.4 ± 0.5**** 
Hb (g/dL)  
            Male 
            Female 
15.1 ± 0.3 
 
15.4 ± 0.1 13.2 ± 0.2 13.5 ± 0.1 
12.2 ± 0.2 12.1 ± 0.0 15.1 ± 0.0 15.4 ± 0.1 
TC: Total cholesterol, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: 
alkaline phosphatase, Hb: Haemoglobin  
The table 4.9 indicates a significant drop of AST and ALP levels in male and female Groups 
treated with T. iboga at 100 mg/kg (p <0.0001) and ALT levels only in females Group. 
Creatinine levels in male and female Groups treated with T. iboga at 50 and 200 mg/kg were 
significantly lowered compared to control Groups, and at the 100 mg/kg dose in females only 
(p< 0.0001). 
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4.3.2. Hypoglycaemic effect of T. iboga doses (50, 100 and 200 mg/kg b.w.) during a 3 hr 
glucose tolerance test in healthy rat 
Figure 4.2 illustrates the effect of daily oral administration for 28 days with variable doses of 
aqueous extract of T. iboga (50, 100 and 200 mg/kg) on OGTT of normal rats. There is a 
significant increase in blood glucose at 50 mg/kg of T. iboga up to 2 hr after glucose load, 
followed by a significant fall in blood glucose by 3 hr. At higher doses of T. iboga (100 and 
200 mg/kg), blood glucose is elevated at 2 hr after glucose load and drop at 3 hr. All doses 
show same temporal hypoglycaemic effect after 3 hr post dose, dose of 50 mg/kg showed a 
maximum fall of 48.2% at 3hr after glucose load, whereas fall of 44.4% and 38.5% was 
observed with dose of 100 and 200 mg/kg respectively at the corresponding time. 
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Figure 4.2. Hypoglycaemic effect of graded doses of aqueous extract of T. iboga on blood 
glucose of normal rat during OGTT. Data is presented as mean ± SEM (n=5) and were 
analysed by two-way ANOVA repeated measures followed by Dunnett’s multiple 
comparison test. Statistical significance is represented as *** p < 0.001 and **** p < 0.0001 
compared with NC (no control, no extract). 
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4.3.3. Effect of T. iboga doses (50, 100 and 200 mg/kg) on STZ/FR10 type 2 diabetic rats 
- body weight, food and fluid intake, and blood glucose  
Figure 4.3 a, b below shows that all experimental Groups gained weight during the 2 first 
weeks of the experiment. However, from 2 weeks onward, weight gain significantly 
decreased in Group 3 (STZ/FR10) compared to normal control (p < 0.05) and to STZ control 
Group (p < 0.05).  Group 2 treated with STZ control significantly gained weight compared to 
Group 3 (STZ/FR10) and Group 8 (FR10, no STZ) (p < 0.05) from week 3. Group 8 (FR10, 
no STZ) gained weight significantly from week 3 onward compared to Group 2 (STZ 
control), Group 3 (STZ/FR10) and normal control (p < 0.05). Groups treated with STZ/FR10 
and T. iboga at 50, 100 and 200 mg/kg gained significantly less weight than normal control, 
while Groups treated glibenclamide gained significantly more weight than Group 3 
(STZ/FR10 control) Figure 4.3 b.  
Food intake did not fluctuate throughout the experimental period Figure 4.4, however, the 
fluid intake increased significantly in Group 3 (STZ/FR10 control) compared to normal 
control and Group 2 (STZ control) (p < 0.05). Also, fluid intake increased significantly in 
Group 2 (STZ control) and Group 8 (FR10, no STZ) compared to normal control (p < 0.05). 
FBG in all Groups did not fluctuate during the 2 first weeks of the experimental period 
(Fructose treatment period). However, from week 4, after STZ injection, NFBG increased 
significantly in all groups compared to normal control. In Group 3 (STZ/FR10) NFBG levels 
increased steadily during the remaining experimental period compared to normal control 
Group and Group 2 (STZ control) Group (p < 0.05) (Figure 4.5 a). However, in Group 2 
(STZ control) NFBG decreased significantly compared to Group 3 (STZ/FR10) and remained 
low until the end of experimental period (p < 0.05) Group 8 (FR10, no STZ) NFBG remained 
low throughout the experimental period (Figure 4.5 a). Also, NFBG significantly increased in 
Groups treated with T. iboga (50 to 200 mg/kg) and Group 7 (Glibenclamide) compared to 
NC (normal control). From week 3, in Group 4 (T. iboga 50 mg/kg) NFBG levels decreased 
significantly during the remaining experimental period compared to Group 3 (STZ/FR10 
control) and Group 2 (STZ control) (p < 0.05) to reach levels comparable to those of NC 
Group (Figure 4.5 b). Also, in Group 6 (T. iboga 200 mg/kg), NFBG levels followed the 
same pattern as Group 4 (T. iboga 50 mg/kg), although NFBG levels remained significantly 
higher than those of NC (p < 0.05) in a similar way of Group 3 (STZ/FR10) (Figure 4.5 b). In 
Group 5 (T. iboga 100 mg/kg), NFBG levels remained significantly higher than NC, 
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(STZ/FR10 control) and (FR10, no STZ) Groups from week 4 up to week 6 after STZ 
injection at week 2 (p < 0.05) (Figure 4.5 b). In Group 7 (Gli), NFBG levels increased 
significantly after STZ injection (at week 2) compared to NC (p < 0.05) and decreased 
gradually from week 3 up to the end of experimental period, however, NFBG levels remained 
significantly higher than those of NC (p < 0.05) (Figure 4.5 b). 
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Figure 4.3. Mean body gain weight over 6 weeks of experimental period. (a) Control Groups  
N=4 and (b) Treated Groups N=6- Fructose 10% treatment from week 0 to week 2, STZ 
injection at week 2, T. iboga treatment from week 2 to week 6. Data are presented as mean ± 
SEM (n=5 per group), and were analysed by two-way ANOVA with post-hoc Tukey’s 
multiple comparison test. Statistical significance is represented as * p < 0.05 vs NC, # p 
<0.05 vs STZ/FR10 control, † p < 0.05 vs STZ control, + p < 0.05 vs FR10, no STZ 
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Figure 4.4.  Mean food intake and fluid intake over 6 weeks of experimental period. Data are 
presented as mean ± SEM (n=5 per group), and were analysed by two-way ANOVA with 
post-hoc Tukey’s multiple comparison test. Statistical significance is represented as* p < 0.05 
vs NC, # p <0.05 vs STZ/FR10 control, † p < 0.05 vs STZ control 
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Figure 4.5. Mean blood glucose over 6 weeks of experimental period. (a) Control Groups 
N=4 and (b) Treated Groups N=6 - (FR10) Fructose 10% treatment was indicated from week 
0 to week 2 with FBG (Fasting Blood Glucose), STZ injection was indicated at week 2 with 
NFBG (Non-Fasting Blood Glucose) levels, T. iboga treatment from week 2 to week 6.  Data 
are presented as mean ± SEM (n=5 per group), and were analysed by two-way ANOVA with 
post-hoc Tukey’s multiple comparison test. Statistical significance is represented as * p < 
0.05 vs NC, # p <0.05 vs STZ/FR10 control, † p < 0.05 vs STZ control, + p < 0.05 vs Gli (5 
mg/kg) 
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4.3.4. Effect of T. iboga (50 to 200 mg/kg p.o.) and Glibenclamide on glucose tolerance 
and insulin sensitivity on STZ/FR10 type 2 diabetic rats 
One of the major aims of this study was to determine whether ingestion of T. iboga extract 
has any beneficial effect on T2D induced by STZ/FR10. The results of the glucose tolerance 
tests conducted at 2 weeks of treatment with T. iboga showed that Groups treated with the 
plant aqueous extract cleared glucose slower after glucose bolus dose compared to the 
negative control Group (Figure 4.6 a, b). At week 2, Group 3 (STZ/FR10 control) showed 
significantly higher levels of blood glucose compared to NC and Group 2 (STZ control) (p < 
0.05) (Figure 4.6. a, b). Similarly, in Group 7 (Gli), blood glucose levels were significantly 
higher than NC and STZ control Group 2 up to 60 min after glucose load and decreased 
significantly after 120 min compared to Group 3 (STZ/FR10 control) (p < 0.05) (Figure 4.6 a, 
b). The area under the curve (AUC) of Groups 3 (STZ/FR10 control), 2 (STZ, control) and 8 
(FR10, no STZ) showed marked glucose intolerance compared to NC (p < 0.0001). The area 
under the curves (AUC) show marked glucose intolerance in Group 3 (STZ/FR10 control), 2 
(STZ, control) and 8 (FR10, no STZ) compared to NC (p < 0.0001) (Figure 4.6 b).  
 At 4 weeks of T. iboga treatment, the glucose tolerance tests showed that Group treated with 
50 mg/kg of T. iboga cleared glucose in the same manner of NC Group. However, Groups 
treated with 100 and 200 mg/kg of T. iboga cleared slower glucose compared to the NC 
Group (Figure 4.6 c, d). Group 5 (T. iboga 100 mg/kg), exerted significantly higher blood 
glucose than NC and Group 2 (STZ control) at 30 min (p < 0.05) in the same pattern than 
Group treated with Glibenclamide (Figure 4.6 c, d). However, Group 4 exhibited significant 
lower blood glucose levels compared to Group 3 after 60 min (p < 0.05) but these levels 
remained significantly higher than those of NC (p < 0.05) (Figure 4.6 c, d). Also, Group 6 (T. 
iboga 200 mg/kg) exerted significantly lower levels of blood glucose compared to Group 3 
(STZ/FR10 control) from 30 min to 120 min after glucose load (p < 0.05) (Figure 4.6 c, d). 
The AUC results show marked glucose intolerance in Groups 3 (STZ/FR10, control), 5 (T. 
iboga 100 mg/kg, STZ/FR10) and 7 (Gli) (p < 0.0001) compared to NC (Figure 4.6 d). 
The results of the insulin sensitivity tests conducted at 2 weeks of treatment with T. iboga 
showed that the plant extract did not improve insulin sensitivity compared to negative control 
Group (Figure 4.6 a, b) at 2 weeks and 4 weeks of plant extract treatment.  Also, Group 
treated with glibenclamide did not either improve insulin sensitivity during this experiment 
(Figure 4.7 a, b, c, d). At 2 weeks, Group 5 (T. iboga 100 mg/kg) at 30 min after insulin 
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injection exerted significantly higher levels of blood glucose compared to NC, Group 2 (STZ 
control) and Group 3 (STZ/FR10 control) (p < 0.05) (Figure 4.7 a, b). Similarly, at week 4, 
blood glucose levels in Group 5 (T. iboga 100 mg/kg) significantly increased at 30 min after 
insulin injection compared to NC and Group 2 (STZ control) (p < 0.05) and decreased rapidly 
to reach levels close to those of NC at 120 min (Figure 4.7 c, d). In Group 7, at 60 min after 
insulin injection, blood glucose levels remained significantly higher than those of Group 2 
(STZ control) and NC (p < 0.05), to increase again after 60 min to levels significantly higher 
than those of Group 3 (STZ/FR10 control), Group 2 (STZ control) and NC (p < 0.05) (Figure 
4.7 c, d). Groups 4 and 6 exhibited blood glucose significantly lower than Group 3 
throughout the insulin tolerance time (p < 0.05) (Figure 4.7 c, d). 
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Figure 4.6. Effect of T. iboga aqueous extract on glucose tolerance in T2D rats at 2 weeks (a, b) and 4 weeks (c, d). Data are presented as mean 
± SEM (n=5 per group), and were analysed by two-way ANOVA with post-hoc Tukey’s multiple comparison test. Statistical significance is 
represented as **** p < 0.0001, * p < 0.05 vs NC, # p <0.05 vs STZ control, †††† p < 0.0001, † p < 0.05 vs STZ/FR10 control and + p < 0.001 
vs Gli (5 mg/kg)  
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Figure 4.7. Effect of T. iboga aqueous extract on insulin tolerance at 2 weeks (a, b) and 4 weeks (c, d). Data are presented as mean ± SEM (n=5 
per group), and were analysed by two-way ANOVA with post-hoc Tukey’s multiple comparison test. Statistical significance is represented **** 
p < 0.0001, * p < 0.05 vs NC, # p < 0.05 vs STZ control, †††† p < 0.0001, † p < 0.05 vs STZ/FR10 control and + p < 0.001 vs Gli (5 mg/kg)
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4.3.5. Effect of T. iboga doses (50, 100 and 200 mg/kg b.w.) on organs weights and 
biochemical parameters of STZ/FR10 T2D rats 
As shown on Table 4.10, T. iboga (50 to 200 mg/kg) did not influence tissue weight during 
the 4 weeks’ experimental period except for Group 6 at 200 mg/kg in which liver weight was 
significantly increased compared to Group 3 (STZ/FR10 control) (p < 0.05). However, in 
Group 3 (STZ/FR10 control), liver weight was significantly decreased compared to NC (p < 
0.05) and increased in Group 8 (FR10, no STZ) compared to NC, Group 2 (STZ control) and 
Group 3 (STZ/FR10 control) (p < 0.05). 
The Table 4.11 shows the Group 3 (FR10/STZ control) and Group 5 (T. iboga 100 mg/kg) 
have significantly higher plasma levels of glucose compared to NC (p < 0.05). Also, Group 3 
(STZ/FR10) and Group 2 (STZ control) have significant higher levels of creatinine compared 
to NC (p < 0.05), HbA1c compared to NC and Group 7 (Gli) (p < 0.05) and ALT compared 
to NC and Group 2 (STZ control) (p < 0.05). However, AST levels was significantly lower 
compared to NC (p < 0.05) in the same Group (STZ/FR10 control). Glucose levels were 
significantly lower in Groups 4 (T. iboga 50 mg/kg), 6 (T. iboga 200 mg/kg) and 8 (FR10, no 
STZ) (p < 0.05). Creatinine levels decreased significantly in Groups treated with T. iboga (50 
to 200 mg/kg), Group 7 (Gli) and Group 8 (FR10, no STZ) compared to Group 3 (STZ/FR10 
control) and Group 2 (STZ control) (p < 0.05). HbA1c levels were significantly increased in 
Group 3 (STZ/FR10 control) compared to NC and Group 7 (Gli) (p < 0.05) and in Group 8 
(FR10, no STZ) compared to NC and Group 2 (STZ control) (p < 0.05). Whereas, AST levels 
were significantly lower in Groups treated with T. iboga (50 to 200 mg/kg) and Group 7 (Gli) 
compared to NC, Group 2 (STZ control) and Group 3 (STZ/FR10 control) (p < 0.05). 
As shown on Table 4.12, T. iboga treatment in T2D rats for a period of 4 weeks did not 
influence lipid profile, except for the Group 6 (T. iboga 200 mg/kg) which exhibited 
significant increase in HDL-c levels compared to Group 3 (STZ/FR10 control) (p < 0.05). 
However, triglycerides levels were significantly increased in Group 3 (STZ/FR10 control) 
compared to NC (p < 0.05). 
 
 
 
	 162	
Table 4.9. Tissue weights in different animal groups at the end of experimental period (All values are mean ± SEM of 5 animals. NC: normal 
control, Group 2: STZ treatment, Group 3: STZ/FR10 treatment, Group 4: T. iboga 50 mg/kg treatment, Group 5: T. iboga 100 mg/kg treatment, 
Group 6: T. iboga 200 mg/kg treatment, Group 7: Gli 5 mg/kg treatment, Group 8: FR10, no STZ treatment. * p < 0.05 vs NC. † p < 0.05 vs STZ 
control. # p < 0.05 vs STZ/FR10 control) 
Parameter 
(g) 
NC Group 2 
(STZ) 
Group 3 
(STZ/FR10) 
Group 4 (T. 
iboga 50 
mg/kg 
Group 5 (T. 
iboga 100 
mg/kg) 
Group 6 (T. 
iboga 200 
mg/kg) 
Group 7 (Gli) Group 8 (FR10, 
no STZ) 
Heart  0.9 ± 0.0 0.9 ± 0.0 0.9 ± 0.1 0.9 ± 0.0 0.9 ± 0.0 1.0 ± 0.0 0.9 ± 0.0 1.2 ± 0.0 
Liver  10.3 ± 
0.2 
10.0 ± 0.5 9.2 ± 0.7* 9.7 ± 0.4 9.7 ± 0.2 10.7 ± 0.6# 10.0 ± 0.0 12.3 ± 0.5*†# 
Kidneys  2.1 ± 0.0 2.2 ± 0.1 2.3 ± 0.1 2.1 ± 0.0 2.2 ± 0.0 2.3 ± 0.2 2.8 ± 0.1 3.0 ± 0.1 
Testis  2.7 ± 0.1 2.7 ± 0.1 2.7 ± 0.1 2.3 ± 0.1 2.6 ± 0.1 3.0 ± 0.2 3.0 ± 0.0 3.7 ± 0.1*†# 
Lungs  .3 ± 0.1 1.2 ± 0.0 1.3 ± 0.0 1.6 ± 0.1 1.3 ± 0.0 1.4 ± 0.1 1.7 ± 0.1 2.0 ± 0.1 
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Table 4.10. Plasma glucose, urea, creatinine, HbA1c, AST, ALT and ALP in different animal groups at the end of experimental period  
Parameter 
(mM) 
NC Group 2 
(STZ 
control) 
Group 3 
(STZ/FR10 
control) 
Group 4 (T. 
iboga 50 
mg/kg) 
Group 5 (T. 
iboga 100 
mg/kg) 
Group 6 (T. 
iboga 200 
mg/kg) 
Group 7 (Gli) Group 8 
(FR10, no 
STZ) 
Glucose  5.0 ± 0.3 6.1 ± 1.6 16.5 ± 1.2* 4.6 ± 0.6# 15.6 ± 2.8* 6.9 ± 2.4#  11.0 ± 2.7* 3.3 ± 0.5# 
Urea  3.3 ± 0.1 3.5 ± 0.2 4.0 ± 0.4 3.6 ± 0.1 3.5 ± 0.1 3.3 ± 0.2 3.4 ± 0.3 3.1 ± 0.1 
Creatinine  58.3 ± 2.4 79.1 ± 2.3* 82.9 ± 4.3** 62.0 ± 2.5†# 63.4 ± 4.0†# 57.9 ± 3.8†# 62.3 ± 4.7† 54.8 ± 1.9†# 
HbA1c  2.0 ± 0.0 2.2 ± 0.2 4.2 ± 0.7*†  2.9 ± 0.5 4.3 ± 0.7 3.0 ± 0.4 3.3 ± 0.4 2.0 ± 0.0 
AST (U/L) 96.2 ± 4.4 72.0 ± 7.2* 114.0 ± 
1.9*† 
17.9 ± 2.6*†# 21.2 ± 4.4*†# 15.4 ± 1.4*†# 19.5 ± 0.4*†# 116.6 ± 2.0* 
ALT (U/L) 31.0 ± 3.3 37.6 ± 4.6 44.2 ± 0.9*† 17.0 ± 1.8*†# 20.1 ± 4.4 14.2 ± 1.4*†# 16.5 ± 0.8*†# 42.9 ± 3.1*† 
ALP (U/L) 123.9 ± 4.3 112.7 ± 6.7 121.5 ± 5.7 102.8 ± 6.4*# 118.2 ± 10.1 107.1 ± 5.9*# 102.0 ± 11.1*# 71.8 ± 5.2*†/# 
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Table 4.11. Plasma lipid profile in different animal groups at the end of the experimental period 
Parameter 
(mM) 
NC Group 2 
(STZ 
control) 
Group 3 
(STZ/FR10 
control) 
Group 4 (T. 
iboga 50 
mg/kg) 
Group 5 (T. 
iboga 100 
mg/kg) 
Group 6 (T. 
iboga 200 
mg/kg) 
Group 7 
(Gli) 
Group 8 
(FR10, no 
STZ) 
Cholesterol  1.4 ± 0.1 1.4 ± 0.1 1.8 ± 0.1  1.5 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.0 1.6 ± 0.0 
HDL-C  0.4 ± 0.0 0.4 ± 0.0 0.2 ± 0.0 0.4 ± 0.0 0.3 ± 0.0 0.4 ± 0.0# 0.4 ± 0.0 0.5 ± 0.0 
LDL-C  0.7 ± 0.1 0.9 ± 0.1 1.1 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.2 ± 0.0 1.2 ± 0.1 
Triglycerides  4.3 ± 0.2 3.7 ± 0.1 7.4 ± 0.6* 0.7 ± 0.1 0.7 ± 0.2 0.9 ± 0.2 0.5 ± 0.1 0.4 ± 0.0 
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4.4. Discussion 
In vivo investigations were performed in this Chapter only with T. iboga aqueous extract in 
healthy and T2D animal models, since fewer mechanistic data were available for G. 
tessmannii. Although, toxicity results of G. Tessmannii aqueous extract gave some 
indications of the dose range that could be used to conduct in vivo investigations in T2D 
animal models (Koumba Madingou et al., 2016). 
In this chapter, we first investigated the range of safe concentrations of T. iboga aqueous 
extract to be used for in vivo studies using toxicological approaches. We then investigated the 
hypoglycaemic effects of T. iboga in healthy rats using these selected concentrations from 
sub-acute toxicity study results. Lastly, the anti-diabetic potential of these selected 
concentrations of aqueous extract of T. iboga were investigated in T2D models.  
The acute toxicity study showed that oral administration of T. iboga root barks aqueous 
extracts induced mild toxicity by oral route in Wistar rats according to Hodge and Sterner 
scale (Table 4.4) with the LD50 dose of 1442.77 mg/kg b.w. Thus, after a 28 days’ subacute 
toxicity study in rats, doses lower than the acute dose of 10% of the oral LD50, which is an 
equivalent to the no-observable adverse effect level (NOAEL), were used (Bulgheroni et al., 
2009).  
In the subacute toxicity study, we observed no-significant differences in food and water 
consumption at doses of 50 mg/kg, 100 mg/kg and 200 mg/kg of T. iboga and the control 
Group in both male and female rats and in control Group during 28-day oral administration of 
T. iboga aqueous extract administration may indicate that the animals were having healthy 
growth based on their food and intake consumption. Also, rats in all experimental Group 
gained body weight over the course of this study, except for female rats in group treated with 
200 mg/kg of T. iboga (Table 4.7). Thus, it can be suggested that growth inhibition did not 
occur during this course of repeated administration of T. iboga aqueous extract root barks. 
Likewise, alteration in organ weights is an indication of toxicity in animals which are easily 
determined by toxicity tests (Adewale et al., 2016). There is a very high possibility that 
ingested plant extract into the body may be toxic to major organs, such as the kidney, liver, 
spleen, heart and brain since it has diverse roles in the body depending on its bioavailability. 
Here in this study, there is no major change in the organ weights of all experimental Groups 
(Table 4.8). 
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Biochemical analyses performed on blood samples give an important index for general 
physiological and pathological status in animals and humans (Adewale et al., 2016). Since 
blood is the major means of transport for a large number of nutrients and foreign elements 
within the body, blood constituents such as red blood cells, white blood counts, platelets and 
haemoglobin are first exposed to concentrations of toxic compounds (Adewale et al., 2016). 
T. iboga aqueous extract of root barks did not induce any damage to the blood cells of 
healthy Wistar rats since haemoglobin levels in all Groups were not altered after the plant 
administration (Table 4.8). Furthermore, aspartate and alanine transaminases (AST and ALT) 
which are good indicators of liver damage, alkaline phosphatase (ALP), that indicates bile 
ducts obstruction or liver and gallbladder inflammation, creatinine and urea which are known 
to be good indicators of renal function (Adewale et al., 2016) were measured (Table 4.8 and 
Table 4.11). In healthy male and female Groups treated with T. iboga at 100 mg/kg 
transaminases levels were significantly decreased (p < 0.0001), as well as ALP in female 
Groups (Table 4.8) indicating a non-toxicity of the plant extract to the liver. Moreover, 
creatinine levels also significantly decreased (p <0.0001) in male Groups treated with T. 
iboga at 100 and 200 mg/kg and female Groups treated with T. iboga at 50, 100 and 200 
mg/kg. This may probably be an indication that the extract did not interfere with the capacity 
of the liver and the kidney to excrete these plant metabolites and may potentiate/stimulate 
these organs functions. Also, T. iboga may improve insulin resistance as creatinine levels 
were significantly decreased at selected doses (50, 100 and 200 mg/kg) (Wilson and Islam, 
2012). Thus, these results suggest that T. iboga aqueous extract does not have negative effect 
on liver and kidney, but rather seems to have a protective effect on these organs.  
Our study revealed an in vivo hypoglycaemic effect of T. iboga aqueous extract (50 to 200 
mg/kg p.o.) on healthy rats after 3 hours. Indeed, a glucose dose of 2 g/kg administered to 
healthy rats considerably increased blood glucose levels of all experimental Groups, which 
were significantly decreased by a single oral dose of T. iboga aqueous extract compared to 
control Group (p < 0.0001), with a maximum effect in Groups treated with T. iboga at 50 
mg/kg for 180 min following glucose load (Figure 4.2). T. iboga aqueous extract did not 
show a dose-dependent hypoglycaemic effect; however, the hypoglycaemic effect was 
delayed and was shown after 3 hr, which indicates an intracellular action of T. iboga aqueous 
extract evidenced in Chapter 3, in isolated pancreatic ß-cells. Indeed, T. iboga aqueous 
extract (1 µg/ml) potentiated insulin secretion from isolated pancreatic islets Chapter 3, 
Figure 3.9). 
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Furthermore, we investigated the anti-diabetic effect of T. iboga aqueous extract (50 to 200 
mg/kg p.o.) in a non-genetic fructose/STZ rat model of T2D (Wilson and Islam, 2012). The 
combination of 10% fructose (FR10) treatment with a low dose of STZ (40 mg/kg) in our 
Wistar rats, resulted in a rapid, stable hyperglycaemia, insulin resistance and sensitivity to 
type 2 anti-diabetic drugs such as glibenclamide. Common symptoms of T2D include 
polydipsia and weight loss, which is sometimes accompanied by polyphagia (Nagata et al., 
2006). Significant polydipsia was present in diabetic control Groups in our experiment. The 
significantly higher fluid intake and significantly lower b.w. gain in the T2D compared to the 
control Groups might be due to the severity of diabetic conditions as well as higher energy 
expenditure via urinary glucose excretion in our experiment (Figure 4.4). In our experiment, 
the T2D (Group 3) did not exhibit actual weight loss as seen in T1D patients and animal 
models (King, 2012; Eddooks et al., 2012) but rather decreased weight gain as compared to 
the control Groups. Furthermore, it has been reported in previous work that animals treated 
with STZ/FR10 exhibited less body weight gain compared to NC and STZ Groups, which is 
in agreement with our results (Wilson and Islam, 2012).  
The ADA report that the FBG > 100 mg/dl but < 126 mg/dl, blood glucose at 2h post-glucose 
load > 140 mg/dl but < 200 mg/dl and fasting plasma glucose (FPG) > 140 mg/dl and/or 2 hr 
post-glucose load > 200 mg/dl are, respectively, considered as impaired fasting glucose 
(IFG), impaired glucose tolerance (IGT) and diabetes (Wilson and Islam, 2012). The NFBG 
of T1 and T2 Groups were significantly higher than NC Group 1 (Figure 4.5 a). However, the 
NFBG range of T2D Group 3 was significantly higher than the T1D Group 2 (504.8 vs 367.6 
mg/dl, Figure 4.5 a) similar to the Wilson and Islam (2012) study. Similar to other studies, 
(Mawa et al., 2019), the NFBG > 300 mg/dl has been used as cut-off point for T2D, which 
has been maintained by fructose/STZ (Group 3) but not by STZ T1 Group 2 in our 
experiment, which was also seen in Wilson and Islam (2012) study. Additionally, our T2D 
rats demonstrated sensitivity to anti-diabetic drug glibenclamide, by significantly reducing 
blood glucose levels over a 3 hr period (Figure 4.6 a, b). 
In the present study, animals treated with fructose alone and T1D rats treated with 
glibenclamide gained significantly more weight than negative control (NC) animals (p < 
0.0001), while animals in Groups treated with T2D model (STZ/FR10) and T. iboga at 50, 
100 and 200 mg/kg gained less weight than NC Group (Figure 4.3). These results are in 
agreement with the effects already reported of this T2 anti-diabetic drug and the negative 
impact of excessive fructose consumption within the body, including weight gain, fat 
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accumulation and circulating levels of triglycerides (Köseler et al., 2018). Furthermore, in 
previous work using animals treated with STZ/FR10, less body weight gain was exhibited 
compared to NC and STZ groups, which is in agreement with our results (Wilson and Islam, 
2012). A significant higher fluid intake (p < 0.0001) was observed in Groups treated with T. 
iboga at 200 mg/kg, STZ and STZ/FR10 compared to NC Group (Figure 4.4) and not lower 
doses of T. iboga. Thus, T. iboga aqueous extract at 50 and 100 mg/kg may exert some 
activity that prevent diabetic features such as polydipsia and avoid weight gain, which is a 
common side effect of T2 anti-diabetic drugs such as glibenclamide (Skliros et al., 2016). 
Hence, T. iboga may prevent excess of energy loss via urinary glucose excretion, commonly 
seen in diabetic condition (Wilson and Islam 2012). 
The OGTT performed at 2 weeks showed significantly elevated blood glucose levels for T2D 
(STZ/FR10) Group (p < 0.0001), almost during the 2 hr period of the test (> 500 mg/dl) 
compared to NC, T1D STZ Group and Groups treated with T. iboga significant differences 
between glucose tolerance in T1 STZ diabetes and T2 fructose/STZ diabetes is also seen in 
previous work of Wilson and Islam, (2012). In Groups treated with T. iboga at 50 and 100 
mg/kg, the peak of glucose level was reached only at 60 min after glucose load and decreased 
slowly after 1 hr period and was brought to levels nearly those of NC Group (Figure 4.7 a-b). 
These results suggest a rapid metabolism of glucose that may be potentiated by T. iboga at 
these doses (50 and 100 mg/kg) compared to T2D control rats. Moreover, the OGTT 
performed after 4 weeks’ period treatment of T. iboga showed a more rapid peak of glucose 
level (after 30 min) and a sharp fall of glucose levels from 30 min to decrease slowly after 60 
min and reached levels close to those of NC Group. The significant hypoglycaemic response 
of T. iboga aqueous extract was clearly shown at 50 mg/kg while, at higher doses (100 and 
200 mg/kg), less hypoglycaemic responses were evidenced. The area under the curves (AUC) 
at the OGTT test at 2 weeks plant extract treatment showed significant glucose intolerance in 
T2D, in Group treated with T. iboga at 100 mg/kg and also Group treated with 
Glibenclamide, which suggest a contradictory effect of the anti-diabetic drug on 
Fructose/STZ-induced T2D rats after 2 weeks of T. iboga treatment. Indeed, in Groups 
treated with T. iboga at 100 mg/kg, blood glucose levels were significantly elevated after 120 
min test compared to those of NC Group and Groups treated with T. iboga at 50 and 200 
mg/kg (Figure 4.7 c, d). This reduced hypoglycaemic response at higher doses of plant 
extract has already been observed with numerous indigenous plants (Singh et al., 2007; 
Jaiswal et al., 2009).  
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Similarly, ITT performed at 2 weeks showed a marked insulin resistance during the first 30 
min of the test, in Groups treated with T. iboga at 50 and 100 mg/kg, while, in other 
experimental Groups glucose levels patterns showed moderate sign of insulin resistance 
(Figure 4.7 c-d). However, when ITT was performed at 4 weeks’ period of T. iboga 
treatment, insulin resistance was increased in Groups treated with STZ/FR10, which was 
already shown in previous work and is a characteristic of T2D insulin resistance (Wilson and 
Islam, 2012), and in T. iboga at 100 mg/kg Group, while insulin resistance improvement was 
observed in Groups treated with T. iboga at 50 mg/kg and 200 mg/kg better than the anti-
diabetic drug glibenclamide (Figure 4.8 c, d). These results support the hypoglycaemic effect 
of T. iboga at 50 and 200 mg/kg, however, there are in contradiction with those seen in 
Wilson and Islam (2012) work. The contradictory effect of anti-diabetic drug glibenclamide 
seen in our study, may be related to the length difference between our works, here 4 weeks 
while > 7 weeks in Wilson and Islam (2012). Moreover, in our study, plasma insulin could 
not be measured and HOMA-ß and HOMA-IR could not be calculated which would 
emphasis pancreatic ß-cells function and the state of insulin resistance in treated Groups.    
Biochemical analyses results in Table 4.10 showed significant increase of liver weights in 
STZ/FR10 and FR10 Groups compared to control (p < 0.05) while testis weights of FR10 
Group lowered significantly compared to control (p < 0.05). These organs weight alterations 
reflect the negative effect of FR10 treatment on liver and hepatic functions, already reported 
(Wilson and Islam, 2012; Köseler et al., 2018) and suggest possible deleterious influence on 
sexual organs of high fructose diets. Plasma glucose was also significantly lower in FR10 
Group compared to STZ/FR10 Group (p < 0.05), which support the well-known STZ 
consequences on glucose levels supplemented by fructose effects (Wilson and Islam, 2012). 
Furthermore, creatinine levels in STZ and STZ/FR10 Groups were significantly increased 
compared to NC Group (p < 0.01), while significant decreased in groups treated with T. 
iboga and glibenclamide was observed compared to STZ Group (p < 0.01) and in FR10 
Group compared to STZ and STZ/FR10 Groups (p < 0.01). However, plasma urea levels in 
all Groups were not altered compared to control Group. Our results demonstrated kidney 
damage in STZ and STZ/FR10 Groups evidenced by elevated plasma creatinine levels, which 
is in agreement with previous data (Maya et al., 2019; Al Hroob et al., 2018; Wilson and 
Islam, 2012). Additionally, plasma AST levels were significantly increased in Groups treated 
with STZ and FR10 compared to NC Groups (p < 0.0001), and STZ/FR10 compared to NC 
and STZ Groups. Whilst, Groups treated with T. iboga at 50, 100 and 200 mg/kg and 
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glibenclamide showed significantly lowered plasma AST levels compared to NC, STZ and 
STZ/FR10 Groups (p < 0.05 and p < 0.0001). In a similar way, plasma ALT levels were 
increased in Groups treated with STZ/FR10 compared to NC and STZ Groups (p < 0.05), 
while in Groups treated T. iboga at 50 and 200 mg/kg and glibenclamide a significant 
decrease of ALT levels was observed compared to NC, STZ and STZ/FR10 Groups (p < 0.05 
and 0.0001). Plasma ALP levels were also decreased in Groups treated with T. iboga at 50 
and 200 mg/kg, glibenclamide and FR10 compared to NC and STZ/FR10 Groups (p < 0.05). 
Hence, T. iboga aqueous extract at 50, 100 and mg/kg may ameliorate diabetes induced liver 
damage in a similar way of glibenclamide (Chukwunonso Obi et al., 2015) and may exert a 
protective effect of liver and kidney organs by preventing deleterious change in 
transaminases and creatinine, as well as urea levels. These results are in agreement with 
previous data which demonstrated increased levels of AST, ALT and ALP parameters 
following STZ, STZ/FR10 or FR10 treatments (Köseler et al., 2018; Saeed et al., 2008). 
Overall, T2D models was developed in this chapter over 7 weeks using fructose treatment 
and low dose STZ, which allowed T2D features to be assessed by T. iboga aqueous extract 
(50 to 200 mg/kg). Hypoglycaemic effects on healthy rats and anti-hyperglycaemic effects on 
fructose-fed T2D model were demonstrated. T. iboga aqueous extract at 50 mg/kg and 
mitigated effect at 100 and 200 mg/kg. The plant extract at these selected doses (50, 100 and 
200 mg/kg), is moderately toxic and do not influence body and major organs weight or 
parameters reflecting any side effects after 28 days administration. Insulin resistance markers 
were not calculated and would have helped to understand the effect of T. iboga (50 to 200 
mg/kg|) on insulin resistance after 4 weeks’ treatment. This is the first in vivo study to 
demonstrated T. iboga aqueous extract hypoglycaemic and anti-hyperglycaemic effects 
which support the effect already shown in pancreatic ß-cells in Chapter 3. Taking into 
account the hypoglycaemic and anti-hyperglycaemic effects of T. iboga aqueous extract in 
T2D rat model, we wanted to evaluate the plant extract effect in another model of metabolic 
disorder, diet induced obesity (DIO) which exhibit features of multiple factor including 
obesity, dysglycaemia and dyslipidemia which characterise the metabolic syndrome (MetS).     
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C h a p t e r  5 :  I n  v i v o  i nves t i ga t ion  o f  the  aqueous  e x trac t  o f  T.  i boga   
                on  d ys fu nc t iona l  m etabo l i sm (g lucos e  and  l i p id   
                me tab o l i sm)  in  h igh - fa t - f ed  C 57BL/6J  mice   
 
5.1. Introduction 
Metabolic syndrome is an emerging world-wide public health issue characterised by the 
occurrence of three or more of these conditions: abdominal obesity, insulin resistance, 
impaired glucose tolerance, hypertension, and inflammatory and thrombotic state. Some of 
these features are also seen in T2DM, as mentioned in previous Chapters. An estimated 11% 
of Gabonese population meet the criteria for people with metabolic syndrome which puts 
them at high risk for developing cardiovascular disease and T2DM (Siawaya et al., 2015; 
Grundy et al., 2004; Kaur, 2014). 
Since T. iboga aqueous extract (50, 100 and 200 mg/kg) has shown in vivo hypoglycaemic 
potential and reduction in metabolic markers sur as insulin resistance (Chapter 4) and is used 
in Gabonese traditional medicine for the management of diabetes (Tjeck et al., 2016), the 
hypothesis that this medicinal plant can mitigate metabolic syndrome in male C57BL/6J 
mice, a mice model that develops obesity, hyperglycaemia and glucose intolerance/ insulin 
resistance when fed a high-fat-diet was considered. 
Unfortunately, there are limited data available on the toxicity of T. iboga, hence, information 
on ibogaine toxicity, the most abundant indole alkaloid present in the root bark, have been 
used for doses selection in this study. Indeed, the (NOAEL) is defined as the highest dose of 
a chemical which does not cause an observable adverse effect on a test animal was 25 mg/kg 
body weight for ibogaine by i.p. (Kubiliene et al., 2008), NOAEL for ibogaine has not been 
demonstrated for the oral route. Thus, the lowest dose that can cause lethality in animals 
remains 263 mg/kg body weight, which lead to a theoretical accepted dose of 0.87 mg/kg in 
humans after application of factors such as intra-species variability (division by 10), inter-
species variability (division by 10) and people susceptibility (division by 3). Nevertheless, 
higher doses ranged from 6 to 30 mg/kg b.w. (within doses that have shown evidence of 
toxicity in animal models) have also been tested in humans and exhibited good results (Schep 
et al., 2016). 
A diet-induced obesity mouse model, which more accurately displays metabolic syndrome in 
humans was selected (Miranda et al., 2016). The C57BL/6J mouse develops a metabolic 
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syndrome-like phenotype when fed a high fat diet. They develop hyperglycaemia, obesity, 
hypertension and hyperinsulinemia on a high-fat diet but remain lean when fed a low-fat diet 
(Miranda et al., 2016). 
The goal of this study was to determine the effects of T. iboga on various endpoints of 
metabolic syndrome in male C57BL/6J mice fed a high fat diet. This study advances the 
knowledge on the in vivo anti-diabetic effects of T. iboga (Chapter 4) in a non-genetic, diet-
induced rodent model of metabolic syndrome. This study has been recently published in the 
Journal of Food Biosciences (Bading-Taika et al., 2018) 
 
5.2. Materials and Methods 
5.2.1. T. iboga extraction 
Root bark of T. iboga was provided by the Institute of Pharmacopoeia and Traditional 
Medicine (IPHAMETRA) in Libreville, Gabon. T. iboga extract for the mouse feeding study 
was prepared following the method by of Sadoon et al. (2014). The method was detailed in 
Chapter 2, section 2.2.1.  
 
5.2.2. Animals and environment 
Male C57/6J mice, 8 weeks of age, weighing 20-25 g were purchased from The Jackson 
Laboratory, Bar Harbor, ME, USA. Animals were maintained on a 12h dark/light cycle and 
fed a regular mouse chow diet and individually housed in labeled standard cages with bottled 
tap water in plastic containers and fed their respective diets ad libitum (Techniplast 2000P) 
with sawdust (Datesand grade 7 substrate) and shredded paper wool bedding with free access 
to bottled tap water and lab food (Labdiet 5001). All animal studies were conducted with the 
approval from the Institutional Animal Care and Use Committee of Oregon State University, 
Corvallis, USA. At the end of 10 week’s experiment, all mice, after an overnight fast, were 
euthanized via CO2 inhalation and blood was collected for endpoint markers of metabolic 
syndrome, including diabetes 
	 173	
5.2.3. Experimental design of the assessment of the effects of bioactive compounds from 
T. iboga for the improvement of dysfunctional metabolism in DIO mouse  
After one week of acclimation, the mice were randomly assigned into 4 Groups of 12 
animals, namely:  
Each mouse was housed individually in labeled plastic cages with bottled tap water in plastic 
containers and fed their respective diets ad libitum. 
- Group 1: normal control (LFD) 
- Group 2: High-fat diet control (HFD) 
- Group 3: High-fat diet + T. iboga aqueous extract at low dose (HFD + T. iboga 0.83 mg/kg) 
- Group 4: High-fat diet + T. iboga aqueous extract at high dose (HFD + T. iboga 2.07 
mg/kg) 
Group 1 control mice were fed a regular chow diet. Group 2 mice were given HFD as control. 
The diet fed to mice was as powder) 3 mice were given HFD containing 0.83 mg of ibogaine 
as T. iboga extract/kg body weight/day (low-dose T. iboga aqueous extract). Group 4 mice 
were given HFD containing 2.08 mg of ibogaine as T. iboga extract/kg body weight/day 
(high-dose T. iboga aqueous extract). 
The HFD contained 60 %, 20% and 20 % total calories from fat, carbohydrate and protein, 
respectively. This HFD diet has been used to induce obesity and metabolic syndrome in male 
C57BL/6J mice (Miranda et al., 2016). The LFD contained 10%, 70% and 20 % total calories 
from fat, carbohydrate and protein, respectively. Both diets were obtained from Dyets Inc, 
Bethlehem, PA, USA. The HFD was fortified with T. iboga extract on a weekly basis by 
dissolving a calculated amount of extract in a very small volume of ethanol for incorporation 
into the diet, so that it would provide an ibogaine dose of 0.83 (low dose) or 2.08 mg/kg b.w. 
per day. To obtain a daily dose of 49.5 µg of ibogaine. The amount of T. iboga extract 
containing 49.5 ibogaine was dissolved in ethanol and mixed with 2.5 g of Diet that the 
mouse would consume per day. The ethanol in the pellets of diet was allowed to evaporate in 
the fume hood. The fortified amount of T. iboga extract was adjusted each week based on the 
previous week’s body weight and food intake. 
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The dose of 2.08 mg/kg body weight was 126 times lower than the LD50 (263 mg/kg body 
weight) of ibogaine in mice (Kubiliene et al., 2008). As a treatment for opioid dependence in 
humans, ibogaine is used at doses between 15 and 20mg/kg body weight. Mouse doses of 
0.83 mg/kg/day (Group 3) and 2.08 mg/kg/day (Group 4) were equivalent to human doses of 
10 mg/kg/day and 25 mg/kg/day, calculations obtained from the FDA formula for 
interspecies scaling dose (Bading-Taika et al., 2018).  
Table 5.1 Allometric scaling dose of ibogaine and T. iboga extract (total alkaloids) (for a 
person of 70 kg)  
Ibogaine  T. iboga extract (total 
alkaloids) 
Human equivalent dose (for a 
person of 70 kg) 
mg/kg/day 
0.83  19.6  0.28 
2.07  49  0.70  
0.21 50  0.70 
0.42 100  1.4 
0.84 200  2.8 
 
 
Body weights were recorded weekly and food intake was monitored every two days during 
10-week feeding study in order to reach the target dose regimes. All animals were fed their 
respective diets for 10 weeks, before the study was terminated. 
All animal studies were conducted with the approval from the Institutional Animal Care and 
Use Committee of Oregon State University, Corvallis, Oregon, USA. 
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5.2.4. Intraperitoneal glucose tolerance test (i.p. GTT) 
During the 4th and 9th week of study, a glucose tolerance test (GTT) was performed. Five 
C57BL/6J mice in each treatment Group were fasted for 4 hr and given an intraperitoneal 
(i.p.) injection of D-glucose (2 g/kg body weight). A drop of blood was collected from a tail 
prick at 30, 60, 90 and 120 min after the glucose bolus injection for measuring glucose using 
a Johnson and Johnson One Touch® Ultra Blood Glucose Monitoring System. 
After the 6-hr fast, mice were weighed before taking glucose measurement at time 0 (before 
injection of the glucose solution). We prepared mice by labelling tails (1-5 lines across tail) 
for easy order identification using marker, in the same manner as in chapter 4. We placed five 
mice from each group in one cage (no food or water) properly labelled with the group ID 
after weighing. We prepared syringe for each mouse before doing the glucose measurement 
at time 0. We calculated appropriate glucose dosage per mouse according to the following 
formula: dose in µl = weight in grams x 10. We measured blood glucose level at time 0. 
Wiped the tail first with 70% ethanol and then using a 23-gauge syringe needle, pricked the 
skin near the end of the tail. Stroke base of tail to encourage blood flow. We measured 
glucose with a glucose test strip on a drop of blood coming out from the pricked tail. Then, 
we recorded readings. After finishing the glucose time 0 measurements, we injected a glucose 
solution to the selected mice from each group at 30-sec intervals. Record starting time.  
We injected mouse with 10 µl of 10% glucose per gram body weight (equivalent to 1 g 
glucose/kg body weight). Sampled blood glucose at 15, 30, 60 and 120 minutes after glucose 
injection at 30-sec intervals. Returned mice at completion of 120 min time point to their 
respective cages with food and water. 
 
5.2.5. Intraperitoneal insulin tolerance test (i.p. ITT) 
Intraperitoneal insulin tolerance test or i.p.ITT is designed to determine the sensitivity of 
insulin-responsive tissues in the rodent. This is determined by measurement of glucose 
remaining in the circulation over time after a bolus (i.p.) insulin injection. 
An insulin tolerance test (ITT) was also conducted at 9th weeks of the feeding study. Another 
set of five mice in each treatment Group were fasted for 4 hr before giving them an i.p. dose 
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of insulin (0.75 U/kg b.w.). Blood glucose was determined using the same protocol as the 
glucose tolerance test. 
Food and water intake, and body weights were recorded on a daily basis during the 28 days’ 
experiment.  
At the end of the 10-week feeding mice were anaesthetised by CO2 asphyxiation and opened 
at the abdomen. Blood was withdrawn from the abdominal aorta and centrifuged at 3000 rpm 
for 10 min to obtain serum. 
Organs (heart, lungs, liver, kidneys, testis) were weighed and serum biochemical parameters 
measured (HDL, LDL, Hba1c, AST, ALP, ALT, TC, Urea, TG, Blood Glucose, Creatinin) 
also including markers of insulin resistance (HOMA-IR, HOMA-b scores). 
 
5.2.6. Biochemical measurement of metabolic markers 
Biochemical analyses were performed after blood samples collection in EDTA/heparinized- 
treated tubes from the heart of the animal using also the heart puncture technique. Cells were 
removed from plasma by centrifugation for 10 minutes at 2000 rpm and the supernatant were 
directly use for analysis. Blood plasma was analysed for insulin using a mouse insulin ELISA 
kit (Alpco Diagnostics, Salem, NH). Plasma Monocyte Chemoattractant Protein-1 (MCP-1) 
and Interleukin (IL)-6 were analysed by ELISA kits from Life Technologies Corporation 
(Carlsbad, CA). Plasma leptin levels and PCSK9 (Proprotein convertase 9) were estimated by 
ELISA kits obtained from Life Technologies Corporation (Carlsbad, CA) and R&D Systems, 
Inc. MN, USA, respectively; and inflammatory markers MMP-9 and ICAM-1 were 
determined using ELISA kits (ALPCO, Salem, USA; Thermo Fisher Scientific, USA, 
respectively). Total plasma cholesterol (TC) and triglycerides (TG) were determined 
following the same method of Savoldi et al., 1976 using modified Trinder method, InfinityTM 
Cholesterol and InfinityTM Triglycerides reagents kits, respectively (Thermo Scientific, 
Middletown, USA). Plasma glucose was analysed by enzymatic method (Mutarotase-GOD) 
using Autokit Glucose (Wako Chemicals USA, Inc, Richmond, VA). Plasma low-density 
lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c) levels were 
measured using microplate-based (Bioo Scientific Corporation, Austin, TX) method. ALT 
and AST were analysed using manual enzymatic assay (Bioo Scientific Corporation, Austin, 
TX). 
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5.2.7. Data analysis  
Data were analysed using SAS 9.2 software (SAS Institute Inc., Cary, NC) and GraphPad 
Prism 7.0 (San Diego, CA). Body weight, food intake, GTT, and ITT data were analysed 
using a repeated-measures-in-time design ANOVA. Repeated measures within animals were 
modelled using a first- order autoregressive variance-covariance structure (body weight and 
food intake) or an unstructured variance-covariance structure (GTT and ITT) data. Baseline 
values were used as linear covariate for body weight and feed intake data. The AUC data 
presented in Figure 5.1 were analysed using a one-way ANOVA and a post-hoc Tukey’s 
multiple comparison test. A p <0.05 was considered statistically significant.  
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5.3. Results 
5.3.1. Rationale for the selection of T. iboga doses 
We used the calculated ibogaine content of 1.93% in the bark to fortify the diets with iboga 
extract (Chapter 2, Table 2.1). The fortified diets delivered a daily ibogaine dose of 0.83 and 
2.07 mg/kg body weight.  
 
5.3.2. Effect of diet and T. iboga extract on body weight, food intake and liver weight  
The LFD-fed mice gained significantly less weight than the mice fed the HFD with or 
without T. iboga extract (Figure 5.1 a) after 1 week up to 10 weeks. The LFD mice lost 
weight during the first week and then slowly gained weight until the end of the study. The 
LFD mice actually were eating significantly more food than the mice fed the HFD within the 
first week (Figure 5.1 b) but their feed efficiency was lower compared to the mice on the 
HFD (Table 5.2). The HFD mice treated with the low dose of T. iboga extract gained 
significantly more weight than the HFD mice and the HFD mice treated with the high dose T. 
iboga. Liver weights were much higher in the HFD-fed mice than the LFD-fed mice (Table 
5.2).  
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Figure 5.1. Effect of the HFD and iboga extract feeding on body weight (a) and food intake (b) of 
mice. LFD, low-fat diet; HFD, high-fat diet; Ib, Ibogaine. Data were analysed using a repeated-
measures-in-time design ANOVA in PROC MIXED for repeated measures within animals (n = 12 per 
group). Statistical differences between Groups are indicated with different letters (*p < 0.05, ** p 
<0.01, *** p < 0.001**** p < 0.0001 vs LFD).  
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Table 5.2. Body weight gain, food intake, liver weight of mice fed experimental diets after 10 
weeks (All values are means ± SEM of 11-12 animals. * p < 0.05 vs LFD. ** p < 0.05 vs 
HFD). 
Parameter LFD HFD HFD + T. iboga 
0.83 mg/kg 
HFD + T. iboga 
2.07 mg/kg  
Body weight 
gain(g) 
0.33 ± 0.00 8.96 ± 0.72* 11.6 ± 0.71* 8.86 ± 0.67* 
Food intake 
(g/day) 
2.74 ± 0.04 2.45 ± 0.04* 2.48 ± 0.04* 2.48 ± 0.04* 
Feed efficiency 
(g weight 
gain/food 
intake) 
0.002 ± 0.000 0.052 ± 0.003* 0.067 ± 0.003* 0.051 ± 0.003* 
Liver weight 
(g) 
0.834 ± 0.0042 1.31 ± 0.196* 1.23 ± 0.044* 1.09 ± 0.042* 
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5.3.3. Effect of diet and T. iboga extract on glucose tolerance and insulin sensitivity  
One of the major aims of this study was to determine whether ingestion of T. iboga extract 
has any beneficial effect on T2D induced by feeding a HFD. The results of the glucose 
tolerance tests conducted at 4 and 9 weeks of feeding showed that mice fed the HFD cleared 
glucose slower after the glucose bolus dose compared to the LFD group (Figure 5.2). Oral T. 
iboga administration did not improve the glucose tolerance of the HFD mice. In fact, the 
HFD mice treated with the low or high T. iboga dose were slightly less glucose tolerant than 
the HFD controls at 4 weeks of treatment (Figure 5.2 a). Similar results were obtained in the 
insulin tolerance test (Figure 5.2 e, f) in that the HFD-fed mice had higher blood glucose 
levels after insulin injection while T. iboga exposure did not improve the insulin sensitivity of 
the mice fed a HFD.  
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Figure 5.2. Influence of diet and T. iboga extract on glucose tolerance in mice at 4 weeks (a, b) and 9 
weeks (c, d) and on insulin tolerance at 9 weeks (e, f) of the feeding study. The mice were fasted for 6 
h before i.p. injection of glucose, 2 g/kg body weight, or of insulin, 0.75 U/kg body weight, before 
blood glucose was analysed at designated times. LFD, low-fat diet; HFD, high-fat diet; Ib, ibogaine. 
Data presented in panels a, c, and e were analysed using a repeated-measures-in-time design ANOVA 
in PROC MIXED for repeated measures within animals (n = 5 per group). Data presented in panels B, 
D, and F were analysed using a one-way ANOVA and a post-hoc Tukey’s multiple comparison test. 
Statistical differences between groups are indicated with different letters (*p < 0.05 and *** vs LFD).  
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5.3.4. Effect of diet and T. iboga extract on other metabolic parameters  
As shown in Table 5.2, no significant difference was observed in ALT and AST between 
LFD-fed mice and HFD-fed mice. Also, the results showed that mice fed a HFD had 
significantly higher plasma levels of glucose, triglycerides, LDL- cholesterol, HDL-
cholesterol, leptin IL-6, ICAM-1, and MCP-1 compared to the group fed LFD (Table 5.2 and 
5.3). The addition of T. iboga extract to the HFD did not have a significant effect on any of 
these metabolic parameters, except for the reduction of plasma levels of MCP-1 by low-dose 
T. iboga treatment (Table 5.3).  
Table 5.3. Plasma lipids profile in mice fed experimental diets (All values are means ± SEM 
of 11-12 animals. * p < 0.05 vs LFD. # p < 0.05 vs HFD) 
Mice groups/ 
Plasma lipids 
LFD HFD HFD + T. iboga 
0.83 mg/kg 
HFD + T. iboga 
2.07 mg/kg 
(mg/dl) 
Total cholesterol 170 ± 8.96 256 ± 8.18* 258 ± 8.96* 231 ± 14.0* 
HDL cholesterol 54.7 ± 7.29 72.4 ± 3.36* 72.9 ± 1.99* 74.1 ± 3.37* 
LDL cholesterol 43.9 ± 6.95 88.7 ± 13.6* 80.8 ± 7.82* 80.6 ± 7.17* 
Triglycerides 48.8 ± 1.89 60.6 ± 4.56* 64.9 ± 4.57* 66.6 ± 5.17* 
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Table 5.4. Metabolic parameters of mice fed experimental diets (All values are means ± SEM 
of 11-12 animals. * p < 0.05 vs LFD. # p < 0.05 vs HFD) 
Mice groups/ 
plasma 
parameters 
LFD HFD HFD + T. iboga 
0.83 mg/kg 
HFD + T. iboga 
2.07 mg/kg  
Glucose (mg/dL) 243 ± 24.9 310 ± 24.4* 343 ± 12.4* 284 ± 24.1* 
Insulin (ng/mL) ND 1.35 ± 0.23 1.21 ± 0.16 1.33 ± 0.33 
Leptin (ng/mL) 6.18 ± 1.67 26.1 ± 2.26* 30.8 ± 1.31* 26.8 ± 1.81* 
IL-6 (pg/mL) 6.98 ± 0.46 9.96 ± 1.17* 8.55 ± 0.65* 8.75 ± 0.05* 
ICAM-1 (ng/mL) 17.7 ± 3.48 34.3 ± 2.34* 33.8 ± 1.87* 34.1 ± 1.97* 
MCP-1 (pg/mL) 134 ± 8.09 810 ± 284.2* 81.5 ± 23.6## 337 ± 119# 
MMP-9 (ng/mL) 30.9 ± 8.09 45.6 ± 13.8 57.8 ± 14.3 30.6 ± 5.72 
ALT (U/L) 50.2 ± 3.92 48.2 ± 1.92 54.7 ± 7.0 45.2 ± 3.79 
AST (U/I) 156 ± 12.9 147 ± 8.81 118 ± 13.8 131 ± 21.2 
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5.4. Discussion 
In this study, the mouse doses of 0.83 and 2.07 mg/kg body weight are equivalent to human 
doses of 4.7 mg/day and 12 mg/day for a 70 kg person by allometric scaling of dose (Sharma 
and McNeill, 2009). Thus, assuming that the total alkaloid content of the root bark is 7.8% 
(Chapter 2, Table 2.2), the human equivalent dose of 12 mg ibogaine per day would represent 
a total alkaloid dose of 49 mg per day (0.70 mg/kg/day for a 70 kg person) when given in the 
form of T. iboga bark extract. Moreover, the selected high dose in this study approaches the 
recently recommended human dose of 0.87 mg ibogaine/kg that is considered safe and 
appropriate for treatment of opioid addiction in humans (Schep et al., 2016). Forsyth et al., 
2016 team investigated the effects of a single oral dose of 20 mg ibogaine in humans on a 
number of psychological variables. A pharmaceutical preparation of T. manii (Lambarène), 
containing 8 mg ibogaine per tablet, was marketed in France as a neuromuscular stimulant, 
promotor of cell combustion, and anti-fatigue agent. The recommended dose was 16–32 mg 
ibogaine per day (2–4 tablets daily) (Goutarel et al., 1993). Assuming that other iboga 
alkaloids exert pharmacological activity, these doses are comparable to our low dose in mice 
(human equivalent dose for a 70 kg person: 20 mg total T. iboga alkaloids). However, these 
doses are more than twice lower than the lowest dose tested in healthy and T2D animals in 
Chapter 4 (50 mg/kg for T. iboga). As this is the first study designed to investigate the effects 
of T. iboga aqueous extract in an in vivo mouse model of metabolic syndrome induced 
glucose tolerance, we were unable to predict efficacious dose levels for ameliorating glucose 
intolerance. The data in this chapter, do not support the conclusions reached by Souza et al. 
(2011) that aqueous extracts of T. iboga root bark showed anti-hyperglycaemic activity. 
Using isolated islets of Langerhans from the pancreas of non-fasting female Wistar rats, these 
authors found that bioactives in the aqueous extract of T. iboga exerted an insulinotropic 
effect ex vivo, similar but not identical in mechanism compared to tolbutamide, a 
representative of the sulfonylurea class of T2 diabetic drugs. Similarly, we report the same 
concentration of aqueous extract of T. iboga exerted an acute insulinotropic effect ex vivo 
(Chapter 3). However, a daily consumption for 10 weeks of the plant extract incorporated in 
mice chow might induced an increased concentrations of T. iboga active constituents which 
might activate other pathways than the one leading to lowering blood glucose levels as seen 
in Chapter 4. With chronic administration of sulfonylureas, insulin levels do not change with 
treatment, consistent with our observations, but fasting plasma glucose levels decrease due to 
lowering of insulin resistance (Davis, 2006), which we did not observe with T. iboga 
treatment in this study. One explanation for the discrepancy is that the doses used in this 
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study were not optimal. In addition, we cannot exclude the possibility that T. iboga bioactives 
are converted into inactive metabolites by gut microbial or hepatic metabolism. For instance, 
ibogaine undergoes O- demethylation by the hepatic cytochrome P450 enzyme CYP2D9 
(Obach et al., 1998). It is possible that the metabolite, 12-hydroxyibogamine (syn. 
noribogaine), lacks insulinotropic activity or might be in concentrations (after chronic 
administration) too high which would induced an antagonism to the hypoglycaemic effect of 
the metabolite, as suggested in Chapter 3. 
One major concern of the use of herbal or dietary supplements such as kava-kava (Stickel and 
Shouval, 2015) is liver damage. Plasma levels of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) are generally used as indicators of liver injury (Ozer et al., 
2008). As shown on Table 5.2, supplementation of the HFD with T. iboga extract did not 
cause a significant increase in ALT or AST suggesting that the extract is not hepatotoxic. 
Furthermore, other important parameters in MetS are pro-inflammatory cytokines including 
interleukin 6 (IL-6) and adhesion molecules including intercellular adhesion molecule 1 
(ICAM-1) which are involved in the progression and development of MetS complications 
such as cardiovascular diseases (Colina-Coca et al., 2017). These parameters were increased 
in HFD, HFD + Low and High T. iboga Groups compared to LFD Group, thus T. iboga 
extract did not improve inflammatory disease processes (Colina-Cola et al., 2017). Also, 
plasma leptin levels, which are well associated with body fat mass, fat accumulation and 
insulin resistance, were elevated in HFD, HFD + Low and High T. iboga (Table 5.2). Leptin 
is mainly expressed by adipocytes and promotes vascular inflammation and calcification, 
increased levels has been reported in subjects with high levels of TC and TG, as shown in our 
results, and are associated with endothelial derived inflammation (Parka et al., 2017). In 
contrast, results in Table 5.1 showed in HFD + Low T. iboga Group, significantly lowered 
plasma levels of MCP-1 or CCL2 which is a chemokine that may contribute to low-grade 
inflammation in obesity by recruiting monocytes to adipose tissues (O’Connor et al., 2015). 
Therefore, T. iboga aqueous extract may be beneficial in ameliorating low-grade 
inflammation in obesity when dosed prophylactically in DIO models. However, the extract 
did not improve lipid plasma profile as TC, LDL and HDL remained elevated in treated 
Groups compared to HFD Group. 
Overall, feeding a HFD to male mice for 10 weeks resulted in obesity and high plasma levels 
of circulating glucose and insulin, which were not attenuated by treatment with T. iboga 
	 187	
extract at dose levels of 0.83 and 2.07 mg/kg/ day. However, plasma levels of MCP-1, a 
chemokine involved in inflammation in obesity, was significantly attenuated by low-dose T. 
iboga extract (0.83 mg/kg/day) suggesting an anti-inflammatory effect of the extract and 
suggesting a prophylactic activity of T. iboga extract on DIO models. 
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C h a p t e r  6 :  Genera l  d i s cu s s ion  
 
Since preliminary in vitro investigations of the root barks of T. iboga aqueous extract have 
shown potentiation of insulin secretion (Souza et al., 2011) and this plant has been reported 
to be used in Gabonese traditional medicine for the management of DM and its 
complications, along with the stem barks of G. tessmannii aqueous extract (Bading Taika et 
al., 2018), the aim of this thesis was to (i) characterise the phytochemical composition of T. 
iboga root barks and identify potential insulinotropic agents in the plant, (ii) to investigate for 
the first time the effects of the aqueous extracts of G. tessmannii on glucose-induced insulin 
release from rat isolated pancreatic cells, (iii) to investigate the role of σ2 receptors in 
mediating T. iboga aqueous extract effects on glucose-induced insulin release from rat 
pancreatic cells, and  (iv) to investigate for the first time the effects of T. iboga aqueous 
extract in naïve rats, in fructose-fed/STZ T2D animal model and in DIO animal model of 
dysfunctional metabolism in C57BL/6J mice. 
 
6.1. Identification of five phenolic phytochemicals, and thirty alkaloid phytochemicals 
from T. iboga root bark 
Phytochemical characterisation of the aqueous extract of T. iboga root barks was performed 
using LC-MS/MS technique in positive ionisation mode due to the presence of alkaloids 
which contain nitrogen atoms with high proton affinity. Several unknown and known 
compounds of the aqueous extract of T. iboga were revealed using a mass defect filtering 
approach specifically designed for screening of indole alkaloids. 30 alkaloids were detected, 
of which only 7 were previously reported in T. iboga including ibogaine, iboxygaine, 
ibogaline, alloibogamine, catharanthine, ibogamine, noribogaine (Chapter 2, Table 2.5) 
(Taylor, 1968; Alper, 2001; Gaignault and Delourme-Houdé, 1977; Bowen, 2001). This 
useful post acquisition data processing based on mass defect (difference between the nominal 
mass and the monoisotopic mass of a molecule) detected group of molecules with similar 
elemental compositions, including indole alkaloids. Previous studies have already revealed 
presence of indole alkaloids in T. iboga root barks (Gaignault and Delourme-Houdé, 1977), 
with ibogaine as its major constituent (Bartlett et al., 1958). The principal alkaloid of T. 
iboga, ibogaine, has attracted attention in many countries around the world for providing 
relief of opioid craving in drug addicts (Glick et al., 1996). The anti-addictive property of 
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ibogaine has been cited in Gabonese religious community ‘Bwiti’, who use the plant root 
barks as  in traditional ritual to enter in trance and reach an in between state, to be able to 
contact ancestors (Mazoyer et al., 2013) Among the unknown compounds revealed for the 
first time in this thesis, several have previously been identified in other plants also belonging 
to the Apocynaceae family including Yohimbine from Rauwolfia root bark (Funk et al., 
2019; Stavrinides et al., 2015), Quinidine (Halperin et al., 2018; Yang et al., 2009; 
Stavrinides et al., 2015), Coronaridine  (Arias et al., 2011; Arias et al., 2017), Affinine 
(Rosales et al., 2019; Yang et al., 2010), Jerantinine B isolated from Tabernaemontana 
corymbosa  (Qazzaz et al., 2016). Among the 23 known alkaloids listed in Chapter 2 (Table 
2.5), only yohimbine, an alpha2-adrenoceptor antagonist, has been reported to exhibit in vivo 
anti-diabetic property (Abdel-Zaher et al., 2001). This study revealed that yohimbine at 20 
mg/kg b.w. potentiated glucose-induced insulin release in non-diabetic control rats and 
improved oral glucose tolerance, potentiated glucose-induced insulin release in T2D, but not 
in T1D rats. Moreover, pre-treatment of yohimbine enhanced the hypoglycaemic and 
insulinotropic effects of glibenclamide in an additive manner and antagonised 
hyperglycaemia and hyperinsulinemia effects induced by diazoxide in control and T2D rats 
(Abdel-Zaher et al., 2001). The presence of the alkaloid, yomhibine in T. iboga aqueous 
extract may contribute to the antidiabetic activity we report in chapters 3 and 4. The 
investigation of potential additive antidiabetic effects of T. iboga and glibenclamide in vitro 
and in vivo will be of interest in future studies. 48 unknown alkaloids could not be 
characterised as these constituents were not listed in any libraries (Chapter 2, Table 2.5).  
For the first time, phenolic compounds were revealed in significant quantity in T. iboga and 
the most prevalent was 3-O-caffeyolquinic acid (Chapter 2, Table 2.5). The amount of 3-O-
caffeoylquinic acid in T. iboga root bark, extracted with 70% aqueous methanol, was 
determined to be 0.97 mg/g of plant powder (Table 2.5, figure 2.8). 3-O-caffeoylquinic acid 
is a phenolic compound naturally found in food which has exhibited numerous 
pharmacological properties including antioxidant, free radical scavenging, anti-inflammatory, 
radio protective, anti-tumour, antioxidant, analgesic and anti ulcerogenic activities (Bagdas et 
al., 2015; Jabeur et al., 2016). The amount of chlorogenic acid found in T. iboga aqueous 
extract, in this study was estimated at 0.97 mg/g in 100 mg of plant root barks (Chapter 2, 
section 2.3.2). A previous study has shown that 3-O-caffeyolquinic acid at 100 mg/kg b.w. 
orally administered to DIO model HFD-fed C57BL/6J mice increased insulin resistance and 
hepatic lipid accumulation compared to control HFD mice (Mubarak et al., 2013). However, 
another study demonstrated that 3CQA at a lower dose of 20 mg/kg b.w administered orally 
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to HFD-fed ICR mice decreased their insulin levels, thus exhibiting improvement of insulin 
resistance (Cho et al., 2010). The amount of 3-CQA in T. iboga doses used the in vivo anti-
diabetic study in healthy, fructose/STZ T2D rats (Chapter 4), and DIO models C57BL/6J 
mice (Chapter 5), would give 0.05 mg in 50 mg/kg, 0.1 mg in 100 mg/kg, 0.2 mg in 200 
mg/kg, 0.10 mg/kg in 107 mg/kg (dose containing 2.07 mg of ibogaine) of T. iboga by 
extrapolation, if the extraction yield were quantitative. These very low T. iboga extract 
amounts of chlorogenic acid are unlikely to have contributed to the effects of T. iboga seen in 
the in vivo studies in chapters 4 and 5. Furthermore, to test the hypothesis that alkaloids in T. 
iboga root barks and not 3-O- caffeoylquinic acids are responsible for the reported biological 
effects, alkaloid extracts devoid of phenolic acids were prepared for testing in vivo chapters 4 
and 5. Thus, other compounds in T. iboga aqueous extract may in part, play a role in the anti-
diabetic action of the plant. As all active compounds in T. iboga root barks aqueous extract 
have not been fully characterised, further investigations are needed to correlate the active 
principles contributing to the anti-diabetic effects of T. iboga.  
 
6.2. T. iboga aqueous extract (1 µg/ml) stimulated glucose-induced insulin release from 
isolated rat pancreatic islets 
In order to assess the effects of G. tessmannii and T. iboga aqueous extracts on glucose-
induced insulin release in isolated rat pancreatic islets, a reproducible method of isolation 
was developed in Chapter 3 adapted from Carter et al. (2009) and Szot et al. (2007). The 
isolated rat pancreatic islets were responsive to glucose and functional throughout the 
experimental period of 90 min, in a similar manner reported in previous studies (Szot et al., 
2007; Carter et al., 2009 and Souza et al., 2011).  
The finding that aqueous extract of T. iboga (1µg/ml) stimulates glucose-induced (2.8 to 11.1 
mM) insulin release is in line with previous published work, in isolated rat pancreatic islets at 
stimulatory glucose concentrations (2.8 to 16.7 mM) (Souza et al., 2011). These aqueous 
extract effects were more effective than the insulin secretagogue, tolbutamide (Souza et al., 
2011; Chapter 3). However, the bell-shape effects seen at glucose stimulatory concentrations 
(11.1 to 25 mM) suggested that certain T. iboga active constituents might have an antagonism 
activity to insulin secretion and those are efficient at low concentrations (0.001 to 0.1 µg/ml). 
Indeed, as crude plant extracts are complex mixtures with multiple pharmacological 
activities, the different constituents may exert antagonistic, allosteric and/ or synergistic 
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effects (Kennedy and Wightman, 2011; Rasoanaivo et al., 2011). Depending on the 
concentration, an active constituent could have blunted the activity of a second bioactive 
constituent revealing a dual effect (Djomeni Dzeufiet et al., 2006). Moreover, in certain 
instance, a potentially active constituent at higher concentration, might be stabilised by a 
second constituent, which could lead to the effects seen at high concentrations of the plant 
extract (10 to 10 µg/ml) (Rasoanaivo et al., 2011). 
 
6.2.1. T. iboga aqueous extract (1 µg/ml) stimulated glucose-induced insulin release was 
blocked by the σ2 receptor antagonist, SM-21 (1 and 10 µM) 
At high glucose concentrations (16.7 and 25 mM) T. iboga (0.01 to 100 µg/ml) inhibited 
glucose-induced insulin secretion. Furthermore, low (state concentrations 0.001 to 0.01 
µg/ml) and high (10 to 100 µg/ml) concentrations of T. iboga aqueous extract did not alter 
glucose-induced insulin secretion, except for T. iboga at 0.1 µg/ml and low glucose 
concentrations (2.8 and 11.1 mM), which is not in agreement with previous findings (Souza 
et al., 2011). The discrepancy seen with high concentrations of T. iboga (10 and 100 µg/ml) 
may be explained by its effect via σ2 receptors which are involved in apoptosis process 
(Bowen, 2001). Hence, the results support the insulinotropic effect of T. iboga aqueous 
extract (1 µg/ml), but not in the same dose- and glucose-dependent manners as stated 
previously (Souza et al., 2011).  
T. iboga insulinotropic effects have been suggested to be mediated by σ2 receptors (Souza et 
al., 2011), and its main active constituents (ibogaine and related iboga congeners) are 
selective σ2 receptors ligands (Bowen et al., 1995). In the presence of the σ2 receptor 
antagonist, SM-21 at 1 and 10 µM, the insulinotropic effects of glucose and T. iboga (1 
µg/ml) were inhibited. This confirmed for the first time the involvement of σ2 receptors in 
the action of T. iboga aqueous extract in isolated rat pancreatic islets. σ2 receptors 
antagonism may act directly or indirectly on K+-ATP channels, as diazoxide, which prevents 
K+-ATP closure inhibits glucose-induced insulin secretion and T. iboga potentiation of 
glucose-induced insulin release (Souza et al., 2011). The involvement of σ2 receptors on 
intracellular Ca2+ flux in T. iboga aqueous extract insulin release is suggested by previous 
study, where intracellular Ca2+ flux was increased in the presence of T. iboga aqueous extract 
(1 µg/ml), and T. iboga aqueous extract insulin stimulatory effects were inhibited in the 
presence of cobalt, an inorganic Ca2+ channel blocker (Souza et al., 2011). Latent and 
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sustainable rise of Ca2+ by σ2 ligands may lead to toxicity and cell death (Bowen, 2001). 
Given that σ2 receptors increase intracellular Ca2+ levels in apoptosis induced cell death 
(Bowen, 2001), this may explain, the contradictory effect of high concentrations (> 10 µg/ml) 
of T. iboga aqueous extract inhibiting glucose-stimulated insulin release from isolated rat 
pancreatic islets. T. iboga aqueous extract (1 µg/ml) did not increase the levels of nitrates 
indicating no cell toxicity at stimulatory glucoses concentrations (2.8 and 11.1 mM), however 
higher concentrations of T. iboga (> 10 µg/ml) on nitrate production from isolated rat 
pancreatic islets was not investigated. Neurotoxic effects of ibogaine, one major active 
principle of T. iboga, are reported to, in part, be due to agonist action at the same σ2 receptors 
(Bowen, 2001; Glick et al., 2001). Elevated glucose levels (> 16 mM) as seen in diabetic 
conditions, may chronically activate this pathway, leading to pancreatic islet cell 
desensitization and glucotoxicity (Hall et al., 2018). Glucose concentrations greater than 16.7 
mM significantly elevated nitrate production from isolated rat pancreatic islets, compared 
with no glucose, and although insulin secretion increased glucose dependently up to 25 mM, 
elevated nitrates may indicate these cells are under oxidative stress (akin to other reports 
Arman et al., 2007; Zhao et al., 2018). Furthermore, high concentrations of T. iboga (> 10 
µg/ml) elevating Ca2+ levels via σ2 receptors activation may induce cytotoxicity in isolated 
pancreatic islets already sensitive to oxidative stress, leading to the reduction in insulin 
production seen in Chapter 3.  
 
6.2.2. G. tessmannii aqueous extract potentiates glucose-induced insulin release from 
isolated rat pancreatic islets 
Using isolated rat pancreatic islets, this thesis has demonstrated for the first time that the 
aqueous extract of G. tessmannii (70 µg/ml) has insulinotropic effects at stimulatory glucose 
concentrations (2.8 to 25 mM), supporting its traditional medicinal use in managing diabetes 
(Chapter 3). The insulin secretion potentiation of G. tessmannii (70 µg/ml) was seen at higher 
glucose concentrations (16.7 mM) compared with T. iboga (up to 11 mM). These effects 
were similar to those of tolbutamide (200 µM) and enhanced the effect of tolbutamide when 
incubated in the same medium. At the highest glucose concentration (25 mM) G. tessmannii 
(70 µg/ml) did increase insulin secretion, which was close to statistical significance. Low (1 
to 60 µg/ml) and high (100 µg/ml to 10 mg/ml) concentrations of G. tessmannii inhibited 
insulin release at all glucose concentrations, producing a bell-shaped dose-dependency, 
similar to T. iboga. In future studies, it will be interesting to evaluate if G. tessmannii 
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aqueous extracts stimulatory and inhibitory effects on glucose-stimulated insulin release and 
additive effect with tolbutamide may be explained by an interaction with σ2 receptors and 
modulation of intracellular Ca2+. Moreover, a phytochemical characterisation of G. 
tessmannii aqueous extract might allowed the identification of other active constituents that 
may exert inhibitory activity of insulin secretion at 1 to 50 µg/ml. G. tessmannii aqueous 
extract (70 µg/ml) did not increase the levels of nitrates over cells treated with no extract, 
indicting no cell toxicity at stimulatory glucose concentrations, however lower (<60 µg/ml) 
and higher (>100 µg/ml) concentrations of G. tessmannii on nitrate production from isolated 
rat pancreatic islets was not investigated. 
G. tessmannii phytochemical analyses has revealed bioactive compounds such as flavonoids, 
alkaloids and triterpenes saponins (Madingou et al., 2012). Moreover, a saponin-rich fraction 
(present in G. tessmannii) from Momorcica charantia stimulates insulin secretion in 
pancreatic ß-cells (MIN6) (Keller et al., 2011). Furthermore, triterpenoid saponins from 
Aralia taibaiensis a Chinese traditional medicine, potently stimulate insulin release from 
BTC3 cells at stimulatory glucose concentrations (Cui et al., 2015). The insulin potentiation 
mechanism of action of G. tessmannii aqueous extract in primary isolated rat pancreatic islets 
requires further investigation. 
 
6.3. T. iboga aqueous extract (50 to 200 mg/kg b.w.) induces hypoglycaemia in healthy 
rats  
T. iboga aqueous extract concentrations (50 to 200 mg/kg) were shown to be moderately 
toxic, however, after 28 days’ daily treatment, the aqueous extract did not influence major 
organs weight and functions. T. iboga at 50 and 200 mg/kg induced hypoglycaemia activity 
over 3 hours fasted glucose tolerance.  
 
6.3.1. T. iboga aqueous extract (50 to 200 mg/kg b.w.) an anti-hyperglycaemic in 
fructose-fed/STZ T2D models 
The anti-diabetic effects of T. iboga concentrations (50, 100 and 200 mg/kg b.w.) were 
investigated in a fructose-fed/STZ T2D rat model according to Wilson and Islam (2012) 
protocol in Chapter 4. Feeding a 10% fructose solution over 2 weeks combined with a low 
intraperitoneal dose of STZ (40 mg/kg) to rats, led to the development of T2D, in agreement 
	 194	
with Wilson and Islam (2012) data. This model presented T2D features, including IR and 
glucose intolerance (significantly different from T1D group that received STZ alone) and 
allowed the assessment of the effects of T. iboga aqueous extract on T2DM. T2D rats 
exhibited significantly less body weight gain and higher blood glucose levels than T1D rats 
and normal control rats over 28 weeks, in agreement with Wilson and Islam, (2012). This is 
the first study to demonstrate in vivo anti-diabetic effects of T. iboga (50 mg/kg) comparable 
to glibenclamide (5 mg/kg), and with no side effect and normalisation of body weight. Also, 
this is the first study to demonstrate in vivo glucose tolerance improvement of T. iboga (50 
mg/kg) with decreased creatinine levels compared to control and T1 and T2D (Wilson and 
Islam, 2012). Moreover, this is the first study to assess T. iboga (50 to 200 mg/kg) on 
hyperglycaemia, blood tissue and tissue markers of IR. 
 
6.3.2. Antidiabetic effects of T. iboga on DIO model, C57BL/6J mice 
As the time of the experiments in Chapter 5, efficacious and non-toxic concentrations of T. 
iboga for ameliorating glucose tolerance in DIO mouse models was not predicted and hence 
pharmacological low (0.83 mg/kg) and high (2.07 mg/kg) doses were selected based upon 
ibogaine toxicity in mice (LD50 263 mg/kg) (Kubiliene et al., 2008). T. iboga aqueous extract 
(0.83 and 2.07 mg/kg) indicated a trend of improvement of insulin resistance in HFD with a 
possible prophylactic effect on DIO models, suggesting that the doses selected may be too 
low compared to those which have exhibited hyperinsulinemia and anti-hyperglycaemia in rat 
diabetic models.  
 
6.4. Final Conclusion 
In this thesis, T. iboga phytochemical characterisation has revealed 23 unknown alkaloids, 
never reported for T. iboga, and 7 known alkaloids. Among the unknown alkaloids, only 
yohimbine has shown in vivo anti-hyperglycaemic and hypoglycaemic activities, which has 
been demonstrated for the first time with T. iboga at 50 mg/kg in fructose-fed/STZ T2D 
model and healthy rats. However, T. iboga at 107 mg/kg (or 2.07 mg of ibogaine) failed to 
improve metabolic syndrome in DIO C57BL/6J mice. The insulinotropic effect of T. iboga at 
1 µg/ml in isolated pancreatic islets was shown for the first time to be mediated by σ2 
receptors, which could also mediate toxic effects. Significantly, T. iboga aqueous extract is 
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regularly consumed by Gabonese population and controlled toxicology study has 
demonstrated that it is moderately toxic at 50, 100 and 200 mg/kg doses.   
Overall, it has been demonstrated that T. iboga aqueous extract has hypoglycaemic and anti-
hyperglycaemic properties when administered orally to rats and these activities may be 
mediated through an interaction with σ2 receptors. Collectively these in vitro and in vivo 
experiments support the continued use of T. iboga and G. tessmannii root extracts for the 
management of diabetes.  
A key goal in managing diabetes is to improve blood glucose levels and to improve insulin 
levels in people who live with Type 2 diabetes. Further investigations are now needed to 
evaluate the 23 previously unknown alkaloids in T. iboga for insulinotropic activity and 
mechanism of action and subsequently evaluation of appropriate safe doses of active 
alkaloids in controlled long term clinical trials before validating the use of T. iboga aqueous 
extract for the management of diabetes and to have a real positive social impact by improving 
the health and wellbeing of people living with Type 2 diabetes in Gabon. Moreover, the few 
data collected so far on the mechanism of action of G. tessmannii aqueous extract are 
encouraging but not concluding for this plant extract to be used safely for the management of 
DM in Gabon. 
 
6.5. Future works 
6.5.1 Assessment of known and unknown alkaloids fractions of T. iboga at stimulatory 
concentrations (2.8 to 11.1 mM) on rat isolated pancreatic islets  
6.5.2. Ca2+ imaging and assessment of high concentrations of T. iboga (10 and 100 µg/ml) in 
isolated pancreatic ß-cells in presence of low and high glucose concentrations (2.8 to 25 mM) 
6.5.3. Ca2+ imaging in the presence of thapsigargin and T. iboga (1 µg/ml) from isolated 
pancreatic ß-cells at stimulatory glucose concentrations (2.8 and 11.1 mM) 
6.5.4. Screening of T. iboga compounds in insulin producing cells at high and low glucose 
concentrations (2.8 and 25 mM) 
6.5.5. Assessment of T. iboga optimal concentration (1 µg/ml) in σ2 receptors knockout cells  
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6.5.6. Phytochemical characterisation of G. tessmannii using LC/MS-MS and Progenesis 
software  
6.5.7. Investigation of G. tessmannii stimulatory (70 µg/ml) and inhibiting concentrations 
(<60 µg/ml and >100 µg/ml) on σ2 receptors at glucose stimulatory concentrations and in 
presence of tolbutamide (200 µM) on isolated rat pancreatic islets 
6.5.8. Investigation of G. tessmannii optimal concentration (70 µg/ml) on K+-ATP receptors in 
presence of diazoxide on isolated rat pancreatic islets 
6.5.9. Modulation of intracellular Ca2+ in presence of G. tessmannii stimulatory concentration 
(70 µg/ml) on isolated rat pancreatic islets (Ca2+ imaging) 
6.5.10. Griess assay with low (<60 µg/ml) and high (>100 µg/ml) concentrations of G. 
tessmannii on nitrate production at stimulatory glucose concentrations on isolated rat 
pancreatic islets 
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